Bone repair potential of human amniotic fluid stem cells by Ranzoni, A
 1 
 
 
 
 
 
 
Bone repair potential of human 
amniotic fluid stem cells 
 
Anna Maria Ranzoni 
 
A thesis submitted for the degree of  
Doctor of Philosophy 
 
Institute for Women’s Health 
University College London 
 
2018  
LONDON’S GLOBAL UNIVERSITY 
 2 
Declaration of authorship 
 
I, Anna Maria Ranzoni, declare that this thesis titled “Bone repair potential of human 
amniotic fluid stem cells” and the work presented in it are my own.  
 
I confirm that: 
• This work was done wholly while in candidature for a research degree at this 
university. 
• No part of this thesis has previously been submitted for a degree or any other 
qualification at this university or any other institution. 
• Where I have quoted from the work of others, the source is always given. 
• With the exception of such quotations, this thesis is entirely my own work. 
• Where the thesis is based on work done by myself jointly with others, I have 
made clear exactly what was done by others and what I have contributed 
myself. 
 
 
 
 
 
 
Signed:  _________________________ 
Date:      _________________________ 
  
 3 
Abstract 
The amniotic fluid is a rich source of fetal mesenchymal stem cells with broad 
differentiation capacity. Human amniotic fluid stem cells (AFSCs) have a high 
expansion potential, fast growth kinetics and harbour therapeutic potential to treat 
a variety of conditions. Moreover, they are easily isolated at mid-trimester or at 
delivery and can be used without ethical restrictions. Osteogenesis imperfecta (OI) is 
a genetic disease characterised by bone fragility, due to production of abnormal 
collagen type I.  
In this study, human AFSCs were transplanted into immunocompetent oim mice (OI 
mouse model, n=28) at birth. Bones were harvested after 8 weeks and analysed for 
mechanical properties, micro-structure, engraftment of donor cells and gene 
expression. Non-transplanted oim and wild-type mice were used as controls.  
Human AFSC injection decreased bone fracture rate and increased bone strength. 
Donor cells migrated to the bones, engrafted into sites of active bone formation and 
appeared to differentiate into osteoblasts, producing normal collagen. Moreover, 
transplantation improved the microarchitecture of the bones, although bone volume 
remained unaffected. Transplantation also promoted endogenous osteogenesis, with 
mouse genes involved in osteoblast differentiation and skeletal development 
significantly up-regulated, compared to non-transplanted mice.  
As a side project, a protocol for the isolation and differentiation of human fetal 
osteoblasts from the calvaria was optimised and a biobank of 24 samples, from 
gestational ages ranging from 9 to 21 weeks post-conception, was established.  
The data presented in this thesis indicate that human AFSCs are a promising source 
for cell therapy in OI. Donor cells may exert their therapeutic effects both by 
normalising the ECM and by influencing the maturation of resident osteoblasts. 
Ongoing work is focused on the further understanding of the mechanism of action of 
donor cells, using co-culture experiments with human AFSCs and human fetal 
osteoblasts.  
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1.1 Bone composition and function  
Bone is a mineralised connective tissue with structural, metabolic and synthetic 
functions. The main role of bones is to provide structural support to the body, 
allowing movement and protecting internal organs. Bone also acts as a reservoir for 
minerals, essential for the chemical homeostasis of the body. Its extracellular matrix 
(ECM) contains more than 90% of the total phosphate and calcium ions in the human 
body, in addition to numerous growth factors including transforming growth factor β 
(TGF-β), insulin-like growth factors (IGFs) and bone morphogenetic proteins (BMPs) 
(Baylink et al., 1993; Flynn, 2003). Finally, bone also exerts a synthetic function, with 
the bone marrow being the site of haematopoiesis, the process in which 
hematopoietic cells are formed and differentiate.  
1.1.1 Bone development 
During mammalian fetal development, bones are formed in two distinct ways. Most 
bones in the human skeleton, including vertebrae and long bones of the limbs, 
develop by endochondral ossification, a process which requires a cartilage 
intermediate. The flat bones of the skull, the mandible and the sternum, on the other 
hand, generate through intramembranous ossification, without the involvement of a 
cartilage intermediate.  
Endochondral ossification starts with the condensation and differentiation of 
mesenchymal stem cells (MSCs) into chondrocytes, through the local expression of 
the transcription factor SOX9 (SRY-box 9). Chondrocytes secrete cartilage-specific 
matrix and produce a cartilaginous model of the forming bone. Subsequently, 
chondrocytes become hypertrophic and undergo apoptosis, while the deposited 
cartilage starts being mineralised. The cartilaginous model is then invaded by blood 
vessels due to the local release of growth factors, including VEGF (vascular 
endothelial growth factor), while expression of RUNX2 (runt-related transcription 
factor 2) drives the differentiation of MSCs into osteoblasts. The cartilage model acts 
as a template for osteoblasts to replace chondrocytes and deposit collagen type I 
(Bruder and Caplan, 1989). The newly formed trabecular bone gradually replaces 
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completely the cartilage framework. From this primary centre of ossification, bone 
grows towards the ends of the structure, where secondary ossification centres 
develop. A small portion of cartilage remains where the primary and secondary 
centres meet and forms the growth plate of long bones, allowing the bone to grow 
further, until development ends and the growth plate is replaced by mineralised 
tissue (Mackie et al., 2008; Gilbert, 2014).  
“Intramembranous” ossification begins with the proliferation and condensation of 
MSCs into compact structures of connective tissue, where blood vessels develop as 
well. Upon expression of RUNX2, the MSCs found within the structures differentiate 
into osteoblasts and start secreting collagen and depositing osteoid. The collagenous 
matrix gradually mineralises and the osteoblasts that remain trapped inside it 
become osteocytes. As development continues, mineralised spicules form from the 
centre of ossification, while a thin layer of condensed MSCs surrounds the newly 
formed bone, forming the periosteum (Gilbert, 2014).  
1.1.2 Stromal fraction of bones  
Bones contain a rich connective compartment, comprising of many stromal cell types 
which support haematopoiesis and contribute to bone homeostasis. The bone 
marrow is a highly vascularised tissue consisting of islands of haematopoietic cells 
mixed with adipose cells (Anthony and Link, 2014). Marrow adipose tissue can make 
up to 70% of the total bone marrow volume and is thought to be one of the main 
energy storages of the body (Suchacki et al., 2016). In addition to adipocytes, the 
stromal compartment of the bone marrow also includes mesenchymal stem cells, 
pre-osteoblasts, osteoblasts and chondrocytes. The characteristics of osteoblasts, 
osteocytes and osteoclasts, the three main cell types found in bone, each exerting a 
specific function to contribute to bone homeostasis, are discussed below. 
1.1.3 Osteoblasts and bone formation 
Osteoblasts, or bone forming cells, are characterised by cuboidal/cobblestone 
morphology and have been estimated to represent the 4-6% of the total cells present 
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in human bones (Florencio-Silva et al., 2015). Osteoblasts have the function of 
depositing collagen and forming the osteoid. When osteoblasts are not actively 
secreting proteins, they are found in a quiescent state, in which they become flat-
shaped bone-lining cells and cover the bone surface (Miller et al., 1989). Osteoblasts 
derive from MSCs, through the strictly regulated and timed expression of osteogenic 
genes. The master regulator of osteogenic commitment is RUNX2, as demonstrated 
by the lack of differentiated osteoblasts in RUNX2-deficient transgenic mice (Komori 
et al., 1997). RUNX2 expression leads to the upregulation of osteoblast-specific genes 
including collagen type I (COL1A1 and COL1A2) and alkaline phosphatase (ALP), 
leading to the differentiation of early osteoblasts. Subsequently, the expression of 
genes encoding proteins of the extracellular matrix (ECM), such as osteocalcin 
(BGLAP) and bone sialoproteins, indicates the terminal differentiation of osteoblasts 
(Komori et al., 1997).  
Two steps are required for the formation of bone ECM by osteoblasts. The first stage 
concerns the secretion by osteoblasts of the organic component of the matrix, 
composed of collagen type I, non-collagenous proteins, including osteopontin, 
osteonectin, osteocalcin and bone sialoprotein, and proteoglycans, including decorin 
and biglycan. The second step is the mineralisation of the organic matrix. Initially, 
osteoblasts release vesicles containing calcium ions, which are deposited on the 
matrix by binding to proteoglycans (Anderson, 2003). Osteoblasts also produce 
alkaline phosphatase, which degrades phosphate-containing compounds releasing 
phosphate ions. Subsequently, calcium and phosphate ions nucleate inside the 
vesicles forming hydroxyapatite, which is then released to form the mineral 
component of bone matrix (Glimcher, 1987). Mineralisation depends on the 
availability of calcium and phosphate ions and is negatively regulated by 
pyrophosphate (Hajjawi et al., 2014; Orriss et al., 2016). 
1.1.4 Osteocytes and mechanosensing 
Following bone formation, a subpopulation of osteoblasts further differentiates into 
osteocytes, which are estimated to represent about 90% of the total number of bone 
cells. Located in bone lacunae and embedded into the matrix, osteocytes have a 
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remarkably long life-span and can live up to years (Franz-Odendaal et al., 2006). 
Osteocytes are characterised by numerous cytoplasmic processes elongating in the 
lacunar canaliculi, that confer the peculiar dendritic morphology (Dallas et al., 2013). 
The cytoplasmic elongations allow osteocytes to interact with other osteocytes by 
gap junctions and with osteoblasts, contributing to cell signalling and to the exchange 
of oxygen and nutrients coming from the vasculature. It is thought that, through this 
extensive network, osteocytes exert the function of sensing mechanical loading of 
the bone, thus contributing to the bone adaptation to such stimuli, although the exact 
mechanism has not been fully understood (Klein-Nulend et al., 1995; Rochefort et al., 
2010; Al-Jazzar et al., 2016). Osteocytes regulate bone mineralisation, through the 
expression of sclerostin, which inhibits osteoblast activity, and the production of 
RANK ligand (RANKL), which promotes osteoclast formation (Bonewald, 2011; Xiong 
et al., 2015). Moreover, osteocytes are a source of pyrophosphate, which inhibits 
mineralisation, and secrete signalling molecules such as nitric oxide and 
prostaglandins (Dallas et al., 2013; Orriss et al., 2016).  
1.1.5 Osteoclasts and bone resorption 
Osteoclasts, or bone resorbing cells, are large multinucleated cells deriving from 
mononuclear cells of the hematopoietic lineage. Osteoclast formation starts with the 
secretion by osteoblast progenitors and osteoblasts of M-CSF (macrophage colony-
forming factor) and RANKL (RANK ligand). M-CSF promotes cell survival and 
proliferation while RANKL, interacting with its receptor RANK located on the surface 
of osteoclast precursors, stimulates osteoclast differentiation (Teitelbaum, 2000). On 
the other hand, osteoblasts produce osteoprotegerin (OPG), which prevents RANKL 
from binding to its receptor RANK, thus inhibiting osteoclast differentiation 
(Hofbauer et al., 2000). The RANKL/RANK/OPG pathway therefore plays a key role in 
the regulation of osteoclastogenesis. The main role of osteoclasts is the degradation 
of bone matrix, a process known as bone resorption. In a physiological context, bone 
resorption is coupled with bone formation in achieving the constant renewal of the 
tissue (Figure 1).  
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Figure 1. Bone remodelling. 
Bone remodelling is a complex process involving two main steps: bone resorption by 
osteoclasts and bone formation by osteoblasts. (Kapinas and Delany, 2011). 
Bone remodelling is the life-long dynamic process resulting from the anabolic and 
catabolic activities of osteoblasts and osteoclasts. Bone resorption is a complex 
multistep process, which starts with osteoclast polarisation. The part of the 
osteoclast in contact with the bone matrix becomes characterised by a ruffled border, 
composed by numerous microvilli, and a sealing zone, to tightly attach to the bone 
matrix to be degraded. Bone resorption occurs via the release of protons across the 
ruffled border, through a H+-ATPase, which causes a local acidification and the 
consequent degradation of hydroxyapatite crystals (Arana-Chavez and Bradaschia-
Correa, 2009). Lysosomal enzymes produced by osteoclasts, such as cathepsin-K, are 
responsible for the degradation of the organic component (Troen, 2004). More 
recently, osteoclasts have been described as cytokine-secreting cells and the name 
clastokines was coined to refer to the numerous factors produced by osteoclasts, 
most of which are involved in the regulation of osteoblast activity and in the 
modulation of bone remodelling (Drissi and Sanjay, 2016). 
1.1.6 Collagen type I structure and biosynthesis 
Collagen type I accounts for 90% of total proteins found in bones, to which it provides 
mechanical strength. Collagen type I is a 300nm long heterotrimer formed by two 
α1(I) and one α2(I) chains, encoded by COL1A1 and COL1A2 genes respectively, that 
are defined by the repetition of the Gly-X-Y tri-peptide repeat. Glycine is always found 
 22 
in the first position of the triplet for steric reasons; its side chain is the only one small 
enough to fit into the coiled coil structure of the collagen triple helix. X and Y can be 
any amino acids, although hydroxyl-proline is often found in the third position to 
confer stability to the trimeric molecule, by allowing the twisting of the molecule 
(Rich and Crick, 1961; Brodsky and Persikov, 2005).  
Collagen biosynthesis is a complex process which takes place in different 
compartments of the cell and involves many proteins. COL1A1 and COL1A2 
transcripts are first translated into the pro-collagen proα1(I) and proα2(I) chains, in 
the endoplasmic reticulum. Pro-collagen is then assembled into a left-handed triple 
helix of 1,014 amino acids, starting from the C-terminus, which is characterised by 
the presence of disulphide bonds. Pro-collagen assembly is assisted by a number of 
chaperone proteins found in the endoplasmic reticulum, including serpin H1 and the 
multi-protein prolyl 3-hydroxylation complex (Marini et al., 2007).  
Before assembly is complete, pro-collagen chains are also subject to several post-
translational modifications. The prolyl 3-hydroxylation complex is responsible for the 
3-hydroxylation of proline residues, specifically α1(I)Pro986 and α2(I)Pro707, while 
P4H (L-proline trans-4-hydroxylase) and PLOD (procollagen lysyl-hydroxylase) carry 
out the 4-hydroxylation of proline residues and the hydroxylation of lysine residues, 
respectively (Myllyharju and Kivirikko, 2004). Proline hydroxylation, a reaction that 
requires ascorbic acid and iron ions as a co-factors and oxygen, is particularly 
important because it has been shown to stabilise the collagen molecule. (Hutton et 
al., 1967). Upon secretion, proteinases cleave the C- and N-terminal globular domains 
of pro-collagen, forming tropo-collagen. The removal of the C-terminus acts as a 
signal for the final assembly of mature collagen molecules into 50 μm fibrils. The 
organisation of individual fibrils into collagen fibres is achieved by covalent cross-
linking between adjacent lysine and hydroxylysine residues, catalysed by lysyl 
oxidases (Kadler et al., 1987).  
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1.2 Osteogenesis imperfecta  
Osteogenesis Imperfecta (OI), also called brittle bone disease, comprises a 
heterogeneous group of congenital diseases that overall affect 1 in every 15-20,000 
live births (Forlino and Marini, 2016). OI is manifested by thin and brittle bones that 
are more fragile and prone to frequent fractures, even as a result of mild trauma. 
Other hallmark features comprise growth deficiency, vertebral compression, bowing 
of long bones, joint hypermobility, dentinogenesis imperfecta and macrocephaly. 
Depending on disease severity, non-skeletal features may also be present, including 
degenerative hearing loss, reduced pulmonary function, blue-coloured sclerae and 
defects of cardiac valves (Kuurila et al., 2000; LoMauro et al., 2012). 
Histomorphometric analyses in OI show a generalised osteopenia with long bones 
characterised by reduced cortical and trabecular thickness (Rauch et al., 2000). OI has 
prenatal onset and its most severe forms can be detected during second and third 
trimester ultrasound scans, when fractures and bowing of long bones can be 
visualised (Figure 2).  
 
Figure 2. Prenatal diagnosis of OI. 
Prenatal ultrasound scan comparing femurs from a healthy fetus and a fetus with severe OI. 
Courtesy of Prof. Anna David (UCL Institute for Women’s Health).  
1.2.1 Genetic origin 
OI is a connective tissue disorder originating from abnormal production of collagen 
type I. OI was initially considered an autosomal dominant disorder caused only by 
mutations on genes encoding for the two types of α-chain forming collagen type I, 
Healthy	femur OI	femur
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namely COL1A1 and COL1A2. In the last decade, however, mutations in other 14 
genes have been identified as cause of recessive forms of the disease (Morello et al., 
2006; Lim et al., 2017). Now more than 1,500 mutations have been linked to OI, with 
about 85-90% of cases caused by structural mutations in the two collagen genes and 
the remaining caused by mutations on genes involved in the biosynthesis of collagen 
type I, including its post-translation modifications and folding (Rauch and Glorieux, 
2004; Forlino and Marini, 2016).  
The most frequent mutations observed are glycine substitutions in the helical 
domains of collagen type I, which cause an impaired trimer assembly. Glycine 
substitution in the α1 chains lead to more severe phenotype and even to perinatal 
lethality, while those mutations on the α2 chain are associated with milder features 
(Lim et al., 2017).  Mutations in genes encoding for the α-chains of type I collagen 
cause dominant forms of OI, with qualitative or quantitative defects. Heterozygous 
null mutations in COL1A1 lead to degradation of the abnormal transcript and, as a 
result, only half of the normal amount of collagen type I is produced. Mutations in 
COL1A2, on the other hand lead to a variety of phenotypes and severities, due to the 
accumulation in the extracellular matrix of collagen homotrimers that fail to correctly 
assemble (Forlino et al., 2011). Qualitative structural defects in the collagen chains 
have been linked with more severe phenotypes than quantitative defects in which 
less normal collagen is produced (Forlino and Marini, 2016).  
Procollagen is subject to a number of post-translational modifications that are 
necessary for its correct folding, secretion and interaction with other ECM proteins. 
Mutations in genes involved in this processing generate a variety of OI phenotypes 
with recessive inheritance, that are commonly referred to as non-classical OI 
syndromes. Most mutations causing non-classical OI are found on genes involved in 
the formation of the prolyl 3-hydroxylation complex, a multi-protein complex 
responsible for the 3-hydroxylation of specific proline residues in different types of 
collagen, necessary for its folding (Marini et al., 2007). In particular, mutations in 
CRTAP and LEPRE1 genes cause very severe OI phenotypes, characterised by 
osteochondrodystrophy, since the complex is also involved in cartilage formation 
(Barnes et al., 2006; Morello et al., 2006; Cabral et al., 2007). Other genes 
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participating in collagen crosslinking are known to harbour mutations leading to OI 
and related disorders. PLOD2 and FKBP10 encode for proteins involved in the 
conversion of lysine residues into hydroxylysine, necessary for the establishment of 
crosslinks (Gjaltema et al., 2016). Mutations on these genes results in a specific type 
of OI with joint contractures, known as Buck syndrome (Ha-Vinh et al., 2004). 
SerpinH1 is a chaperone protein which contributes to collagen translocation between 
the endoplasmic reticulum and the Golgi apparatus, through the stabilisation of the 
collagen triple-helix (Koide et al., 2006). Mutations in this gene cause severe recessive 
OI due to collagen aggregation and impaired secretion (Christiansen et al., 2010). 
Osteoblast differentiation is crucial for collagen deposition and mineralisation and 
genes of the Wnt signalling pathway have been linked to OI. WNT1 heterozygous 
mutations are associated with early-onset osteoporosis, while homozygous null 
mutations lead to OI (Pyott et al., 2013). Finally, CREB3L1 encodes a endoplasmic 
reticulum-stress transducer which translocates into the nucleus and is responsible for 
the activation of the COL1A1 promoter (Murakami et al., 2009). 
1.2.2 Pathogenesis 
As a consequence of abnormal collagen production, fibrils are unable to fold in the 
correct heterotrimeric conformation and to interact with non-collagenous proteins. 
Moreover, collagen chains that fail to assemble activate the unfolded protein 
response in the endoplasmic reticulum, leading to protein degradation (Boot-
Handford and Briggs, 2010). This causes the formation of a disorganised ECM, unable 
to support the normal apposition of minerals. The resulting disordered mineralization 
contributes to bone fragility observed in OI ( Sweeney et al., 2008).   
At a cellular level, OI manifests itself by an increased number of osteoblasts that fail 
to reach full maturity and individually produce less bone (Rauch et al., 2000). 
Osteoblasts derived from OI patients produce lower levels of osteonectin and 
proteoglycans and higher levels of fibronectin and hyaluronan (Fedarko et al., 1996). 
In addition, the ECM of OI patients is characterised by aberrant levels of 
mineralisation, which contribute to bone brittleness and fragility (Roschger et al., 
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2008; Rauch et al., 2010). Moreover, OI is characterised by high osteoclast activity 
and, overall, this results in an increased bone turnover with no bone mass gain 
(Forlino et al., 2011; Biggin and Munns, 2014). The abnormal matrix, characterised by 
lack of cross-links, has been suggested to indirectly contribute to the impairment of 
osteoblast precursor differentiation (Fernandes et al., 2009), which correlates with 
an increase of osteoclast recruitment, resulting in further imbalanced bone turnover 
(Li et al., 2010; Forlino et al., 2011).  
Recently, in a mouse model of the disease, it was demonstrated that transforming 
growth factor β (TGF-β) is present in excessive amounts in its active form in OI (Grafe 
et al., 2014a). TGF-β is secreted by osteoblasts and stored in the ECM due to its 
interaction with non-collagenous proteins such as the latency-associated peptide 
(LAP) and small leucine-rich proteoglycans (SLRPs), such as decorin (Hildebrand et al., 
1994; Lim et al., 2017). Release of TGF-β from the ECM has been reported during 
bone resorption by osteoclasts, thus locally attracting bone-forming osteoblasts 
(Oreffo et al., 1989; Dallas et al., 2002). In a physiological setting, therefore, it appears 
that TGF-β plays an essential role in bone turnover. When present in excessive 
amounts, however, TGF-β signalling has been linked to the inhibition of osteoblast 
differentiation and the promotion of osteoclast activity, resulting in low bone density 
(Hattersley and Chambers, 1991; Erlebacher and Derynck, 1996; Alliston et al., 2001). 
In the study, crtap-/- mice were characterised by excessive TGF-β signalling and had 
features of the recessive form of OI including low bone mass and impaired 
osteoblasts. Interestingly, treatment with an inhibitor of TGF-β corrected most of the 
OI phenotype. Excessive TGF-β signalling in OI might be due to the abnormal ECM 
which is unable to correctly retain TGF-β in its latent form (Grafe et al., 2014b).  
1.2.3 Classification  
In the last decade, it has become evident that OI syndromes are not separate diseases 
and that the range of severities rather lies on a continuum. Nevertheless, the 
categorisation of patients into different types has proven effective to evaluate 
prognosis and assess the therapeutic benefits of treatments (Kamoun-Goldrat and Le 
Merrer, 2007). A first classification of the disease, proposed in 1979 and based on 
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radiographic and clinical features, divided the dominant OI types into 4 groups: type 
I as a mild form, type II as a perinatally lethal form, type III as the most severe 
survivable form of the disease, characterised by progressive deformity, and type IV 
as an intermediate form (Sillence and Rimoin, 1978; Sillence et al., 1979) (Figure 3). 
This classification, however, only considers those types with an autosomal dominant 
pattern of inheritance and are caused by mutations in COL1A1 and COL1A2 genes.  
Following the discovery of different mutations leading to the disease, some of which 
following a recessive inheritance pattern, the classification was expanded to cover 
the whole spectrum and new types were added (Table 1). According to the most 
widely used classification of the disease, which categorises OI types according to the 
genetic mutation and resulting disease aetiology, there are 11 types of OI, including 
both dominant and recessive forms (Forlino et al., 2011). Type V and VI are caused by 
mutations in IFITM5 and SERPINF1 and have mineralisation defects, types VII, VIII and 
IX are very severe/lethal forms caused by mutations in genes involved in 3-
hydroxylation (CRTAP, LEPRE1 or PPIB), while types X and XI are severe forms caused 
by defects in chaperone proteins (SERPINH1 and FKBP10). This classification is being 
constantly expanded with the discovery of new mutations.  
 
Figure 3. Types of OI 
The four classic types of OI differ in 
their severity, ranging from the mild 
type I, to the intermediate type IV to 
the severe type III. Type II is perinatally 
lethal. Adapted from (Reeder and 
Orwoll, 2006). 
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Table 1. OI classification.  
Summary of the different OI types, inheritance patterns, phenotypes and underlying genetic 
mutations. Adapted from (Forlino et al., 2011). 
1.2.4 Clinical management  
Diagnosis and clinical management of OI are challenging. It is advisable for clinicians 
to run full screenings for OI-causative genes, even after a first mutation is found, in 
order to better address the complexity of each different case. However, due to the 
high cost of the test, a screening for mutations on COL1A1 and COL1A2 is usually 
performed first and full sequencing of the other genes is performed only in case of 
OI	type Mutated gene Phenotype Inheritance
I COL1A1 Mild Autosomaldominant
II COL1A1	/	COL1A2 Perinatally lethal Autosomaldominant
III COL1A1	/	COL1A2 Severe Autosomaldominant
IV COL1A1	/	COL1A2 Moderate Autosomaldominant
V IFITM5 Moderate Autosomaldominant
VI SERPINF1 Mineralisation	defects
Autosomal	
recessive
VII CRTAP Severe Autosomal	recessive
VIII LEPRE1 Severe	/	lethal Autosomal	recessive
IX PPIB Moderate	/	severe Autosomal	recessive
X SERPINH1 Severe Autosomal	recessive
XI FKBP10 Progressivelydeforming
Autosomal	
recessive
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negative results (Forlino and Marini, 2016). Clinical management is usually performed 
by a multidisciplinary team in a specialised centre with experience of OI and aims at 
promoting normal function, relieving pain and improving the quality of life.  
Physiotherapy and hydrotherapy, aimed at strengthening the muscles and increasing 
the range of motion of joints, are highly recommended to improve independence 
(Brizola et al., 2014). Decline in pulmonary functions and lung infections are the most 
common causes of mortality in OI patients (Singer et al., 2001).  
Monitoring of cardiac function is also essential, since aortic dilation and valvular 
defects, especially mitral regurgitation, are common complications in OI patients 
(Lamanna et al., 2013). Hearing assessment is also important, since early onset 
hearing loss happens in 5% of cases (Kuurila et al., 2000).   
1.2.5 Pharmacological therapy 
In terms of treatment, the use of bisphosphonates remains the gold standard 
pharmacological therapy for OI. Bisphosphonates are synthetic analogues of 
inorganic pyrophosphate that act as osteoclast inhibitors, inducing cell death (Rogers 
et al., 2000). They bind to the hydroxyapatite crystals of the bone, from which they 
are endocytosed by osteoclasts during bone resorption, causing apoptosis. 
Treatment is therefore aimed at increasing bone mass by inhibiting bone resorption. 
The rationale of this therapy is that more bone mass, even if still defective, improves 
bone strength (Forlino and Marini, 2016). Bisphosphonate treatment gives some 
therapeutic benefits to most children, with the highest results in the second and third 
year of administration. Bisphosphonates have a very long half-life and beneficial 
effects can last for years (Rauch et al., 2002). Despite being useful for many patients, 
bisphosphonates are unable to reduce the long-term incidence of fractures and to 
reduce bone pain (Ward et al., 2011). Moreover, recent meta-studies that considered 
several placebo-controlled randomised trials concluded that the data fail to 
demonstrate a statistically significant decrease in fracture rate and sustained bone 
pain relief in OI patients treated with bisphosphonates (Dwan et al., 2014; Hald et al., 
2015). The inefficiency in reducing the number of fractures despite increasing bone 
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mass is possibly explained by the consequent increase in bone brittleness due to the 
higher mineralisation, as observed in mouse models (Uveges et al., 2009). 
Denosumab, a blocking antibody to RANKL, is another osteoclast inhibitor which has 
recently shown therapeutic effect on children with type IV OI, by decreasing the rate 
of bone resorption (Semler et al., 2012).  
Other pharmacological options include the administration of growth hormone and 
human recombinant parathyroid hormone. Growth hormone shows anabolic effects 
but no data on long-term effects are available (Thomas and DiMeglio, 2016), while 
parathyroid hormone has proven promising in type I OI patients, in which bone 
mineral density was increased (Orwoll et al., 2014). Novel pharmacological therapies 
that are currently being tested on rodent models, include antibodies against 
sclerostin, a member of the Wnt pathway which inhibits bone formation (Bonewald, 
2011; Sinder et al., 2013), and TGF-β, which is present in excessive amounts in OI 
(Grafe et al., 2014b).  
1.2.6 Surgery 
Corrective surgery, particularly osteotomy of long bones with the insertion of 
intramedullary telescopic rods, is often performed in order to allow ambulation and 
manage fractures, complemented with physical rehabilitation aimed at strengthening 
of muscles. Despite the great advances of surgery techniques and technologies, non-
unions occur in about 15% of osteotomy procedures in OI and rods migration towards 
a joint has been reported (Luhmann et al., 1998). Due to the inability of these 
treatments to target the underlying molecular defect, other approaches have been 
more recently explored, particularly gene and cell therapy. 
1.2.7 Gene therapy 
Gene therapy for OI aims at correcting the causative mutation or replacing the 
defective gene, in order to achieve a long lasting therapeutic effect. In the recessive 
forms of OI, the deficiency of factors required for collagen processing and post-
translational modifications could be reverted by introducing new copies of the gene. 
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On the other hand, dominant forms with structural defects of collagen would rather 
benefit from the silencing of the mutated gene. Antisense oligonucleotides, designed 
to target a specific mutation, have been investigated to suppress the expression of 
the mutant COL1A2 gene, in vitro, in fibroblasts isolated from OI type IV patients. This 
approach was able to decrease the amount of mutant protein by 50%, however it also 
partially suppressed the normal allele (Wang and Marini, 1996). Despite the initial 
interest in this approach, in the past decades the scientific community has focused 
on other strategies. Collagen type I genes contain more than 50 exons each and more 
than 800 different OI-causing mutations have been identified on these two genes 
alone. This genetic heterogeneity makes it difficult and time consuming to design 
vectors for specific mutations (Niyibizi et al., 2004; Forlino et al., 2011). Adenoviral 
vectors have been successfully used to target mutations on the COL1A1 and COL1A2 
genes in MSCs in vitro and in vivo in animal models, restoring the production of 
correct collagen fibres (Chamberlain et al., 2004; 2008).  
1.2.8 Gene therapy with iPS and ES cells 
One of the main drawbacks in the use of MSCs for gene therapy is the limited 
replicative capacity of adult MSCs, which cannot be expanded in high numbers 
needed for therapeutic applications (Zaim et al., 2012). In order to tackle this issue, 
several groups have developed protocols for the generation of pluripotent stem cell-
derived MSCs, either from induced pluripotent stem cells (iMSCs) or from embryonic 
stem cells (eMSCs) (Frobel et al., 2014; Wang et al., 2014). To investigate the potential 
of iPS-based gene therapy for OI, iPS cells have been derived from previously gene-
corrected MSCs from OI type III and IV patients, and subsequently differentiated in 
vitro into osteoblasts, able to form bone in vivo if transplanted to mice (Deyle et al., 
2012). These promising approaches are still at an early stage and need to be further 
validated, particularly with respect to the possibility of random integration of viral 
vectors and of tumour formation in pluripotent stem cell-derived MSC 
transplantation.  
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1.3 Rationale for cell therapy with MSCs  
Much interest in the field of regenerative medicine is focused on cell therapy, which 
promises to regenerate damaged tissues by providing healthy cells as replacements. 
Cell therapy is based on few key characteristics of stem cells, such as their ability to 
engraft into the damaged tissues, self-renew and differentiate into the appropriate 
cell type, by responding to the cellular niche, and at the same time modify such niche 
by secreting soluble factors (Nitkin and Bonfield, 2017). Different types of stem cells 
have been investigated as potential candidates for cell therapy in various disorders. 
In the case of OI, the most promising and widely studied cell source is represented by 
MSCs.   
1.3.1 Mesenchymal stem/stromal cells 
MSCs have been described and officially named in the early 1990s as adult cells, 
derived from the bone marrow, able to be expanded in vitro and to differentiate into 
cells of the different mesodermal lineages (Caplan, 1991; Haynesworth et al., 1992). 
The first reports of plastic-adherent progenitor clonal cells with osteogenic potential 
from the bone marrow, however, date much earlier (Friedenstein et al., 1968; 1970; 
Owen and Friedenstein, 1988). The widely accepted criteria to describe MSCs have 
been agreed by the International Society for Cellular Therapy in 2006. They define 
MSCs as a plastic-adherent, non-hematopoietic multipotent stem cells, able to 
differentiate into bone, cartilage and adipose cells. A panel of surface markers to 
define MSCs has also been described. MSCs are currently identified as cells positive 
for the surface markers CD73 (ecto-5’-nucleotidase), CD90 (Thy-1) and CD105 
(endoglin) and lacking expression of the hematopoietic markers CD45 (protein 
tyrosine phosphatase, receptor type C pan-leukocyte marker), CD34 (hematopoietic 
progenitor cell antigen CD34) and CD14 monocyte marker (Dominici et al., 2006). 
Despite these attempts to precisely identify MSCs, the exact definition remains 
elusive, due to the high variability in the pattern of expression of MSC markers and in 
their ability to differentiate depending on the stem cell niche of the tissue of origin 
(Kuhn and Tuan, 2010).  
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It has been reported that MSCs reside in many adult and fetal tissues and protocols 
have been developed to isolate and culture MSCs from a variety of sources (Ullah et 
al., 2015; Pérez-Silos et al., 2016). In addition to the bone marrow, efficient protocols 
have been established to isolate adult MSCs from adipose tissue (Zuk et al., 2001; 
Wagner et al., 2005), dental tissue (Huang et al., 2009), menstrual blood (Allickson et 
al., 2011), skin (Bartsch et al., 2005) and synovial fluid (Morito et al., 2008). 
The increased knowledge in the biology and immune-modulation of MSCs, together 
with the bulk of information derived from pre-clinical studies, have led to a boost in 
the translation of MSC-based cell therapy strategies to the clinics. In recent years, 
there has been a steady increase in the number of registered clinical trials using MSCs 
for a variety of conditions, including skeletal diseases, heart conditions, diabetes and 
autoimmune disorders among the most addressed (Figure 4).  
 
 
 
 
 
 
 
 
 
Figure 4. MSCs in clinical trials. 
A) Diseases addressed by MSC transplantation in clinical trials (total of 352 trials). B) Clinical 
phase of MSC trials (total 315 trials). (Trounson and McDonald, 2015). 
A 
B 
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Adult bone marrow, adipose-derived MSCs and fetal MSCs of various origin are by far 
the most used cell types in clinical trials happening across the world at the moment. 
The NIH database lists more than 400 registered clinical trials involving MSCs, 
completed or ongoing, which is a 3-fold increase since 2011 (Trounson and 
McDonald, 2015). The large majority of these trials are however still in phase I or II. 
According to the Food and Drug Administration (FDA) guidelines, phase I trials aim at 
solely assessing safety and identifying the most common adverse effects of a therapy, 
while phase II trials are early investigations of therapy effectiveness. Very few trials 
involving MSCs are in the more advanced phase III, which compares the effectiveness 
and safety of the new therapy to the ones currently available, and IV, which gathers 
additional information on approved therapies (Squillaro et al., 2016).  
1.3.2 Migration to site of injury 
One of the key features of MSCs to be exploited in the development of cell therapies 
is their apparent ability to migrate towards the site of injury and engraft into the 
target tissue, where they exert therapeutic functions. MSCs have been shown to 
migrate towards specific stimuli, represented by the release of cytokines, chemokines 
and growth factors from the injured tissue (Fox et al., 2007). In a physiological 
context, the stem cell niche is a dynamic microenvironment constituted by secreted 
factors which provides cues to stem cells to maintain their stemness, proliferate or 
differentiate in response to local signals (Schofield, 1978). When injury occurs, the 
secretion of inflammatory cytokines acts as a stimulus for MSC trafficking and 
homing, by facilitating migration, adhesion and trans-endothelial movement 
(Chavakis et al., 2008).  
As stem cell therapy capitalises on this natural occurring event to deliver donor cells 
directly to the site of injury, the understanding of the composition of this dynamic 
environment as well as the interplay between donor cells and target tissue is pivotal 
for the development and translation of cell therapies (Dimmeler et al., 2014). The 
mechanism directing leukocytes across the endothelium and towards areas of 
infection or injury has been well studied and is based on the expression of chemokine 
receptors on the cell surface, which respond to the stimulus of secreted inflammatory 
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cytokines released locally by damaged tissues, leading to cell migration (Miyasaka 
and Tanaka, 2004). In a similar manner, MSCs are rich in chemokine receptors and 
similar mechanisms involved in their migration have been investigated for their 
potential application in cell therapy. Studies have shown that MSCs undergo 
extravasation following a multi-step process similar to the one of leukocytes, 
involving initial contact with the endothelium, tethering and endothelial rolling 
(Henschler et al., 2008; Nitzsche et al., 2017). 
Interestingly, it has been reported that MSCs home preferentially in cardiac and brain 
tissues following infarction or injury and into bones following fractures (Granero-
Moltó et al., 2009; Ghadge et al., 2011). Injured tissues release a variety of soluble 
factors that act as a signal to MSCs, including stromal-derived factor-1 (SDF-1) and 
hepatocyte growth factor (Kucia et al., 2004; Son et al., 2006), bone morphogenetic 
proteins BMP2 and BMP4, platelet derived growth factor (PDGF-bb) and insulin-like 
growth factors IGF-I and IGF-II (Fiedler et al., 2002; 2006). At the same time, MSCs 
express a broad range of chemokine receptors including CCR1, CCR7, CCR9, CXCR4, 
CXCR5 and CXCR6 (Honczarenko et al., 2006).  
SDF-1 is a particularly relevant chemokine for donor cell homing and has been object 
of extensive study. When SDF-1 is recognised by its receptor CXCR4, the interaction 
causes cytoskeletal reorganisations within the cell, leading to migration toward the 
SDF-1 gradient and therefore favouring trans-endothelial migration (Dar et al., 2006). 
The importance of SDF-1/CXCR4 interaction for donor cell homing is highlighted by 
studies that showed the inability of CXCR4-negative cells to home in the site of bone 
fracture and the increased homing of fetal MSCs following priming with SDF-1 
(Granero-Moltó et al., 2009; Jones et al., 2012a).   
Not all MSCs possess the same migratory ability, which strongly depends on the tissue 
of origin. In a study that compared the migratory capacity of MSCs from different 
origins, fetal MSCs derived from the lungs showed higher mobility compared to fetal 
bone marrow MSCs, which showed similar levels of migration to adult bone marrow 
MSCs. Also, within the same MSC population, only a small fraction of cells showed 
migratory abilities (Maijenburg et al., 2010). It has also been reported that prolonged 
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ex vivo culture of MSCs leads to changes in the expression of surface markers 
correlated to a diminished homing ability (Kim and Park, 2017). The careful selection 
of the appropriate MSC source and the evaluation of possible priming strategies 
appear of key importance during the design of cell therapy studies, in order to 
optimise donor stem cell homing in the target tissue. 
1.3.3 Engraftment 
One of the major challenges in cell therapy is the achievement of high numbers of 
donor stem cells in the target tissue that show long term engraftment and survival.  
Often injury and disease leave tissues highly damaged and a large number of donor 
cells are needed to replace a massive amount of dead or impaired endogenous cells. 
Poor engraftment remains one of the major hurdles in the development and 
translation of all stem cell therapies, including those with established clinical 
protocols such as hematopoietic stem cell transplantations (Dimmeler et al., 2014).  
Different studies of cell-tracking in rodent models transplanted with MSCs showed 
very low engraftment levels, ranging from 2 to 10% in the first weeks and almost none 
after 3 months (Gu et al., 2012; Dimmeler et al., 2014). On the other hand, the short 
lifespan and limited replicative capacity of MSCs may guarantee safety form 
malignant transformation following transplantation (Kim and Park, 2017). The only 
cell type that has shown long-term engraftment and survival is embryonic stem cells 
in their undifferentiated state, which however formed tumours when transplanted 
(Gu et al., 2012).  
A possible explanation for the short lifespan of transplanted cells is found in the 
hostile environment that cells encounter when reaching the damaged tissue. Injured 
tissues are characterised by high concentrations of inflammatory cytokines and low 
levels of oxygen. Another possible explanation is that often donor cells are 
transplanted into mature tissues that appear to be less permissive than developing 
tissues to donor cell integration. For this reason, more recently, in utero 
transplantation of stem cells has been investigated for a variety of conditions, 
including osteogenesis imperfecta (Guillot et al., 2008). Intervening early in 
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development, with either in utero or neonatal transplantation, would allow to 
address the defect before irreversible tissue damage occurs. This approach benefits 
from stoichiometric advantage, since fewer cells are needed to treat a fetus or a 
neonate than an adult.  
The levels of engraftment also depend on the route of administration used for the 
delivery of stem cells. The most widely used route is intravenous delivery which 
allows the infusion of large number of cells. It is however known that large numbers 
of MSCs delivered in this way are unable to reach the target tissue and remain 
trapped in the lungs, due to the larger size of cells compared to the pulmonary 
vasculature (Fischer et al., 2009). More recently, local MSC delivery through a scaffold 
has been investigated to repair bone defects, achieving lager engraftment (Nitkin and 
Bonfield, 2017).  
1.3.4 Differentiation 
The ability to differentiate into cells of different mesodermal lineages with high 
efficiency is crucial for the use of MSCs for regenerative medicine purposes. The 
classic rationale behind stem cell therapies is based on the idea that MSC 
transplantation will benefit tissue repair due to the ability of these cells to 
differentiate into specific cells of the target tissue and repopulate the damaged 
organ, by replacing deficient resident cells (Squillaro et al., 2016). MSCs of various 
origin are able to differentiate efficiently into cells of the adipogenic, chondrogenic 
and osteogenic lineages. More recently it has been reported that MSCs isolated form 
fetal tissues have a broader differentiation potential as they are able to differentiate 
into limited cell types of ectodermal and endodermal origin as well (De Coppi et al., 
2007; Abdulrazzak et al., 2010).  
In a cell therapy approach, stem cells can be transplanted either in their naïve, 
undifferentiated state, or in a partially or fully differentiated state. While naïve stem 
cells have a higher replicative life span, differentiated cells may be better able to 
respond to the niche of the target tissue and to produce the appropriate cytokines 
and growth factors that are needed to repair the injured tissue (Nitkin and Bonfield, 
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2017). Moreover, the differentiation ability of stem cells greatly depends on the 
tissue of origin and it is well reported that differentiation potential narrows with 
increasing donor age (Choudhery et al., 2014). It has for example been reported that 
MSCs shift their differentiation commitment from the osteogenic to the adipogenic 
lineages with increasing cellular senescence (Kim et al., 2012).  
1.3.5 Paracrine effect 
In addition to directly replacing damaged cells, stem cells appear to be also able to 
repair a tissue by acting in a paracrine manner. A growing body of evidence shows 
that MSCs secrete a broad variety of soluble factors, including cytokines, chemokines 
and growth factors, which is commonly referred to as “MSC secretome” (Doorn et al., 
2012). Moreover, MSCs release large numbers of extracellular vesicles, membrane-
derived bodies containing peptides, lipids and microRNAs that are involved in cell-to-
cell communication (Rani et al., 2015).  
The trophic effect of MSCs has recently become of great interest in the field of 
regenerative medicine, since it could explain why therapeutic benefits are observed 
following transplantation of MSCs, even when levels of engraftment are very low (Iso 
et al., 2007; Wang et al., 2011; Phinney et al., 2015; Prockop, 2017). It is now widely 
accepted that paracrine factors, locally secreted by MSCs, modify the 
microenvironment and indirectly promote tissue regeneration by stimulating 
endogenous cell proliferation and preventing apoptosis of resident cells (Caplan and 
Dennis, 2006). This role is exemplified also by the function that MSCs exert in a 
physiological setting. MSCs are found in a wide variety of tissues, where they act as 
stromal support to other cells of the hematopoietic and endothelial niche 
(Quesenberry et al., 1989; Spees et al., 2016). 
More recently, however, a new paradigm for the paracrine effect of MSCs has taken 
shape. MSCs appear to be able to influence the fate of cells that are very distant from 
the site of original engraftment, possibly through the release of soluble factors and 
extracellular vesicles that travel through the vasculature. This new model could 
explain the remarkable healing properties of MSCs in the numerous cases where cells 
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remain trapped in the lung microvasculature following transplantation, due to their 
size (Spees et al., 2016). Many studies describe beneficial effects of MSC-derived 
conditioned medium in a variety of pathological settings. Some of the most 
convincing evidence comes from studies on rodent models of myocardial and kidney 
injuries. Transplantation of MSCs did not result in long-term engraftment but 
therapeutic benefits were observed in both cases, which were explained by the 
secretion of trophic factors (Iso et al., 2014). The same effects were indeed obtained 
after administration of MSC-derived conditioned medium (Bi et al., 2007).  
Despite extensive research, the exact mechanisms that govern the paracrine effects 
of MSCs in the context of tissue repair remain elusive. Nevertheless, the idea of being 
able to inject cell-free factors instead of cell preparations is highly appealing, since 
this strategy would avoid any adverse effects and rule out any possibility of immune 
rejection and tumour formation.  
1.3.6 Safety 
One of the main hurdles of cell therapy strategies is the immune rejection of 
transplanted cells in an allogeneic setting. The privileged immunologic properties of 
MSCs became evident for the first time from in utero transplantation of MSCs 
conducted on sheep. Cells were not rejected and were able to engraft, even after 
immune competence of the fetus was acquired (Liechty et al., 2000). Surprisingly, no 
significant difference was observed in terms of therapeutic efficacy between 
autologous and allogeneic MSCs, indicating that MSCs are a remarkably safe source 
of cells for cell therapy. MSCs have been used as a cell source for transplantations for 
more than 15 years in thousands of patients and it is a general consensus that they 
are clinically safe (Trounson and McDonald, 2015). 
The absence of immune response against transplanted MSCs is mainly due to the lack 
of expression of human leukocyte antigen (HLA) class II and low levels of expression 
of HLA class I, which protects MSCs from being lysed by natural killer cells (Rasmusson 
et al., 2003; Giuliani et al., 2014). MSCs can only differentiate into cells of mesodermal 
lineages and there have been no reports of malignant transformation or formation of 
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teratomas in vivo (Götherström, 2016). Moreover, the transient nature of MSCs, 
which only have a limited lifespan in the host following transplantation, is a further 
guarantee of safety against malignant transformation (Trounson and McDonald, 
2015; Kim and Park, 2017). 
1.3.7 Immunomodulation 
The unique immunomodulatory properties of MSCs have been of great interest in the 
field of regenerative medicine in the last two decades. A bulk of evidence from both 
in vitro and in vivo studies have demonstrated that MSCs interact with a variety of 
immune cells.  MSCs have been shown to be able to directly inhibit the proliferation 
of natural killer and cytotoxic T cells (Le Blanc et al., 2003; Selmani et al., 2008). 
Moreover, MSCs increase regulatory T cells (Tregs), thus indirectly decreasing in the 
activity of cytotoxic T cells (Glenn and Whartenby, 2014). The immunosuppressive 
activity of MSCs has been reported to be stimulated by T-lymphocyte-produced 
cytokines such as tumour necrosis factor alpha (TNFα) and interferon gamma (IFNγ), 
which causes the production of nitric oxide, indolamine-2,3-dioxygenase (IDO) and 
prostaglandin (DelaRosa et al., 2009; Ghannam et al., 2010). On the other hand, 
reports have shown that MSCs may also stimulate the immune system and recruit 
immune cells if the level of pro-inflammatory cytokines is too low, acting as sensors 
of inflammation (Bernardo and Fibbe, 2013).  
Due to their suppressive effects on the immune system, MSCs have been investigated 
in a clinical setting as a possible treatment for acute cases of graft versus host disease 
(GVHD), a severe consequence to transplantation of allogeneic grafts in which the 
host immune system recognises and attacks the graft. Phase II clinical trials for 
steroid-resistant GVHD with repeated infusions of bone marrow MSCs have shown 
beneficial effects with half of the patients responding to the therapy and having a 
higher 2-year survival rate compared to non-responders (53% vs. 16%) (Le Blanc et 
al., 2008; Prasad et al., 2011). Due to their low immunogenic profile and immune 
modulatory properties, MSCs are widely considered a promising source of donor cells 
for cell therapy and regenerative medicine. 
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1.3.8 Limitations 
Despite the successes of the recent years, many limitations in the translation of cell 
therapy strategies remain. MSCs are very heterogeneous and vary greatly according 
to the tissue of origin, age of donor and culture conditions. Therefore, more 
standardised protocols are needed for the further development of cell therapies and 
to be able to compare results. Moreover, MSCs are usually subject to prolonged 
expansion, since high number of cells are needed for transplantation. Prolonged ex 
vivo culture has been linked to genomic variations and altered cell phenotype (Bara 
et al., 2014). MSCs only have a limited replicative life-span and MSCs derived from 
older donors might reach cellular senescence, thus impairing their homing, 
differentiation and immunomodulatory potential (Kim and Park, 2017). Due to this 
issue, different MSC sources with higher proliferative potentials have been 
investigated, including fetal MSCs of various origins.  
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1.4 Fetal sources of mesenchymal stem cells 
The use of MSCs from adult tissues for regenerative medicine purposes is limited due 
to the limited proliferation capacity of cells, which reach senescence. To overcome 
this problem, MSCs derived from perinatal and fetal tissues have attracted the 
attention of the scientific community as promising alternative to adult MSCs for cell 
therapy and tissue engineering applications. 
1.4.1 MSCs in development 
MSCs appear in the fetal blood from early gestation, before migrating to the bone 
marrow. The most widely accepted hypothesis is that MSCs provide stromal support 
to HSCs, as shown by studies in mouse models in which MSCs favoured the 
engraftment of HSCs (Anklesaria et al., 1987; Noort et al., 2002). MSCs represent 
around 0.4% of all nucleated fetal blood cells during first trimester and their number 
dramatically declines with age (Gucciardo et al., 2009). In the fetus, the ratio of MSC 
/ total nucleated cells in the bone marrow is 1:400, which is reduced to 1:10,000 in 
newborns and to 1:250,000 in adults (Caplan, 1994; Campagnoli et al., 2001; 
Götherström, 2016). 
1.4.2 Advantages and limitations of fetal MSCs 
Fetal MSCs share the same phenotype, secretory profile and low immunogenic 
properties as their adult counterparts and present additional advantages. They are 
more proliferative, having an average doubling time of 30 hours compared to the 80 
hours of adult MSCs and achieve an average of 70 population doublings without 
reaching senescence, compared to the 15-40 of adult MSCs (Guillot et al., 2007; 
Götherström, 2016). Fetal MSCs, moreover, have longer telomeres than MSCs 
derived from adult tissues, due to the presence of active telomerase (Guillot et al., 
2007; Bieback and Brinkmann, 2010). Notwithstanding their higher proliferative 
capacity, fetal MSCs are non-tumorigenic as evidenced by their inability to form 
teratomas when transplanted (Guillot et al., 2006). MSCs from fetal tissues also 
present a more primitive phenotype, expressing some pluripotency markers and 
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being able to differentiate into more cell types, such as muscle and neurons, than 
adult MSCs (Chan et al., 2007; Kennea et al., 2009). Finally, MSCs from fetal tissues 
have been reported to have a higher osteogenic potential than their adult 
counterparts (Zhang et al., 2009). Due to the favourable properties of fetal cells, 
numerous protocols have been established to isolate MSCs from a variety of fetal and 
perinatal tissues, including bone marrow, liver, blood and extra-embryonic tissues 
such as the placenta and the amniotic fluid. 
The collection of cells from tissues of the fetus implies the termination of pregnancy. 
The only exception is cardiocentesis that can be performed on live fetuses for the 
isolation of fetal blood stem cells. It however carries a high miscarriage risk and high 
morbidity for the mother and it cannot be performed routinely (Chan et al., 2008; 
Sarno and Wilson, 2008). Moreover, since most terminations are carried out in the 
early stages of gestation, it is usually only possible to isolate small number of cells, 
due to the small size of the fetus. Finally, although such fetal material would be 
discarded following a termination, ethical restrictions limit the clinical use of fetal 
MSCs (Cananzi et al., 2009). Due to these limitations, different cell sources that are 
ethically available, safe to collect and can yield a high number of cells are needed to 
further investigate and eventually translate fetal cell therapy into clinical practice. 
Figure 5. Extraembryonic tissues. 
 Fetal MSCs can be isolated from a variety of extraembryonic tissues, including placenta, 
umbilical cord and amniotic fluid (Anatomy & Physiology, 2016, Rice University).  
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1.4.3 Extra-embryonic tissues 
The extra-embryonic tissues are rich in fetal stem cells. They can be easily collected 
at delivery or during invasive prenatal diagnostic procedures that are now routinely 
used in clinics. Cells isolated from such tissues represent a valid and ethical 
alternative source of stem cells for regenerative medicine applications, including cell 
and gene therapy as well as tissue engineering (Loukogeorgakis and De Coppi, 2016). 
Figure 5 depicts the extra-embryonic tissues that surround the fetus during 
pregnancy. 
1.4.4 Placenta 
The placenta is an organ which develops during pregnancy to nourish and sustain the 
development of the fetus, by supporting the transfer of oxygen, nutrients and waste 
products between the mother and the fetus. Recently, the placenta has been 
identified as a rich source of fetal stem cells. Placental tissue can be isolated during 
chorionic villous sampling, an invasive prenatal diagnosis, from the 10th week of 
gestation (Ilancheran et al., 2009) and during delivery, when it is usually discarded 
(Antoniadou and David, 2016). Chorionic mesenchymal stem cells have been 
reported to possess a more primitive phenotype and a faster growth kinetics if 
compared to adult MSCs (Soncini et al., 2007; Barlow et al., 2008; Jones et al., 2012b). 
They express the pluripotency markers OCT4 and SSEA-3 as wells as the MSC markers 
and are able to differentiate in cells of the mesodermal lineage (Battula et al., 2007; 
Poloni et al., 2008). It has also been reported that placental MSCs can be 
differentiated into cells of the hepatic and neurogenic lineages (Portmann-Lanz et al., 
2010; Kim et al., 2011). Gestational age greatly influences the properties of placental 
MSCs; cells isolated at younger developmental ages have a higher proliferation 
potential and differentiation ability than cells isolated at the end of pregnancy (Sung 
et al., 2010; Park et al., 2013).  
As other fetal MSCs, placental stem cells have low immunogenicity, due to the low 
expression of HLA molecules and also possess immunomodulatory properties 
(Antoniadou and David, 2016). Placental MSCs are able to suppress the proliferation 
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of T-lymphocytes and have been shown to shift the macrophage phenotype from 
inflammatory to anti-inflammatory  (Poloni et al., 2012; Abumaree et al., 2013). The 
main hurdle for the isolation of placental MSCs is the contamination with decidual 
maternal cells (In 't Anker et al., 2004; Soncini et al., 2007).  
1.4.5 Umbilical cord 
The umbilical cord is a flexible structure connecting the developing fetus to the 
placenta. It contains two arteries and a vein, surrounded by mucus-rich connective 
tissue and covered by an amnion-derived epithelium. The umbilical cord is another 
rich source of fetal MSCs. They can be easily isolated at delivery from the connective 
tissue which forms the largest component of the umbilical cord, also called Wharton’s 
jelly (McElreavey et al., 1991; Wang et al., 2004). In particular, fetal MSCs have been 
isolated from the perivascular and sub-amniotic areas of the Wharton’s jelly 
(Karahuseyinoglu et al., 2007). Wharton’s jelly MSCs express mesenchymal markers 
CD73, CD90, CD105 and CD146 and have been described as more primitive than adult 
MSCs in terms of faster proliferation kinetics and broader differentiation potential  
(Joerger-Messerli et al., 2016). Wharton’s jelly MSCs can differentiate into the 
osteogenic, adipogenic and chrondrogenic lineages as well as into hepatocytes and 
neurons (Mitchell et al., 2003; Wang et al., 2004; Anzalone et al., 2010). In a 
comparative study, MSCs from the Wharton’s jelly expressed lower levels of HLA II 
than bone marrow and adipose derived MSCs and showed a strong ability to inhibit 
T cell proliferation (Li et al., 2014)  
1.4.6 Amniotic fluid  
The amniotic fluid is a liquid found in the amniotic sac, which surrounds the fetus 
during its development. While consisting for 98% of water and electrolytes, it also 
contains hormones, nutrients, growth factors and cells of fetal origin (Cananzi et al., 
2009). The main functions of the amniotic fluid are to protect the growing fetus 
against external traumas, while allowing it to move freely, and to act as a carrier of 
nutrients and water between the mother and the fetus (Underwood et al., 2005). The 
volume and content of the amniotic fluid varies greatly during fetal development. It 
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first starts developing around the 2nd week of pregnancy, when a small sac of fluid 
forms between the epiblast, which will then form the embryo, and the amnioblast, 
which will form the amnion membrane (Miki and Strom, 2006). By the 4th week of 
pregnancy, the amniotic fluid completely envelops the embryo. Initially the amniotic 
sac is entirely composed by water and solutes derived from maternal plasma, which 
pass through the fetal side due to osmotic and hydrostatic forces, following active 
transport of chlorine and sodium across the fetal membranes (Creasy et al., 2004). In 
the second half of the pregnancy, however, the fluid also contains fetal urine and 
excretions of the respiratory and digestive systems (Fauza, 2004). The volume of 
amniotic fluid increases considerably during pregnancy, starting from 20 ml at week 
7 to 600 ml at week 25 reaching 1 litre at week 34 (Brace and Wolf, 1989).  
The amniotic fluid contains fetal cells, the origin of which is still debated. The main 
hypothesis is that fetal cells from the skin, respiratory, urinary and gastrointestinal 
systems are shed into the fluid during fetal development (Fauza, 2004). The number 
of cells in the amniotic fluid increases with time during pregnancy, and it has been 
shown to further increase in case of spina bifida or anenchephaly, and abnormally 
decrease in case of urogenital atresia (Gosden and Brock, 1978). Different cell types 
have been identified in the amniotic fluid, initially according to their morphology. The 
first report describes viable adherent cells as amniocytes (61%), epithelial-like (34%) 
and fibroblast-like (5%) cells (Hoehn et al., 1975). More recently, progenitor cells with 
high proliferative and differentiation abilities were isolated from the amniotic fluid, 
both from the hematopoietic and the mesenchymal lineage (Torricelli et al., 1993; 
Streubel et al., 1996).  
Due to their potential applications in regenerative medicine, MSCs from the amniotic 
fluid have generated a great interest and many protocols have been developed for 
their isolation and characterisation. Amniotic fluid can be safely collected by 
amniocentesis during the second trimester, when performing amnioreduction during 
the third trimester, or at caesarean section (Loukogeorgakis and De Coppi, 2017). 
From amniotic fluid samples, MSCs have been initially isolated by plastic adherence 
in high serum culture medium (Tsai et al., 2004). Subsequently, C-KIT (CD117, type III 
tyrosine kinase receptor for stem cell factor) has been used to select and isolate stem 
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cells in the amniotic fluid, which represent around 1% of the total amniotic cells (De 
Coppi et al., 2007). 
Amniotic fluid stem cells have all the characteristics of fetal MSCs and also possess a 
broader differentiation potential, being able to also differentiate into cells of non-
mesodermal lineages, including endothelia, hepatic and neuronal cells (De Coppi et 
al., 2007).  The cellular characteristics of amniotic fluid MSCs vary according to the 
gestational age. Cells isolated from first trimester have a more primitive phenotype, 
sharing the majority of the transcriptome with embryonic stem cells, while second 
and third trimester cells have more mesodermal-committed phenotype (Moschidou 
et al., 2013a; Loukogeorgakis and De Coppi, 2017). Despite being able to differentiate 
into cells of the three lineages, amniotic fluid stem cells are unable to form teratomas 
in vivo when injected into immunodeficient mice (Roubelakis et al., 2007). This 
suggests that amniotic fluid stem cells are a safe cell source for regenerative medicine 
applications, although further studies with longer cultures are needed 
(Loukogeorgakis and De Coppi, 2017).  
Analysis of the secretome of amniotic fluid MSCs showed the release of numerous 
growth factors and cytokines, including vascular endothelial growth factor (VEGF), 
endothelial growth factor (EGF), interleukin 6 (IL-6), and stromal cell-derived factor 1 
(SDF-1) (Mirabella et al., 2011). Moreover, amniotic fluid MSCs possess strong 
immunomodulatory properties. Treatment of amniotic fluid stem cells with TNFα and 
INF-γ led to the inhibition of T-cells proliferation, both by direct cell contact and by 
conditioned medium, supporting the idea of a paracrine effect of MSCs (Kode et al., 
2009; Joerger-Messerli et al., 2016). 
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1.5 Pre-clinical studies of cell therapy for OI  
1.5.1 Mouse models of OI  
Several mouse models of OI have been developed, both for the dominant and for the 
recessive forms of the disease. Here are listed three of the most commonly used. 
Mov-13 mouse model of OI type I: the first model of OI was developed in the late 
1980s by retroviral insertion of the Moloney murine leukaemia virus at the 5’ end of 
the col1α1 gene encoding for the α1 chain of collagen type 1 (Harbers et al., 1984). 
This leads to the inhibition of the transcription of the gene and the absence of α1 
chains in the model. The α2 chain is normally produced, however it is subject to 
degradation due to its inability to correctly fold in trimeric fibres. Homozygous mice 
do not produce any collagen type I and are not viable, whereas heterozygous mice 
produce around half of the physiological levels of collagen type I and have a normal 
lifespan and mild phenotype. Mov-13 mice manifest reduced mechanical properties 
of the long bones, increased bone porosity and progressive loss of hearing (Bonadio 
et al., 1990). 
Oim/oim mouse model of OI type III: the most widely used model for pre-clinical 
studies on severe OI is the oim/oim mouse (osteogenesis imperfecta mouse), a model 
of human type III OI. Homozygous oim/oim mice (B6C3Fe a/a-Col1α2oim/Col1α2oim) 
are characterised by smaller size with short and thin bones, which are subject to 
multiple fractures, decreased bone strength and skeletal deformities (Figure 6). 
Heterozygous oim/+ mice display only mild skeletal features, while homozygous 
oim/oim mice have substantial deformities (Saban et al., 1996). Oim mice live a 
normal lifespan. This phenotype is caused by a naturally occurring glycine deletion at 
nucleotide 3983 on the Col1α2 gene, encoding for the α2 chain of collagen type 1. 
The mutation causes a frame shift at the 3’ end of the transcript, involving the 
sequence corresponding to the last 48 amino acids, and the subsequent production 
of altered collagen pro-peptides, that fail to assemble in the correct heterotrimeric 
COL1(α1)2(α2)1 fibre. As a consequence, abnormal homotrimeric collagen fibres, 
formed by three α1 chains, accumulate in the extracellular matrix (Chipman et al., 
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1993). In homozygous oim/oim bones, the mineral component is abnormal and 
characterised by smaller and disorganised hydroxyapatite crystals, while the collagen 
component is less resistant to tensile stress (Misof et al., 1997). Taken together, these 
abnormalities lead to brittle and fragile bones. At the cellular level, moreover, oim 
osteoblasts fail to fully differentiate and remain in an immature stage, which leads to 
an increase in osteoclastogenesis, thus contributing to the abnormal bone turnover 
(Li et al., 2010b). In addition to the skeletal systems, other organs are affected; the 
production of abnormal collagen also alters myocardial mechanics (Weis et al., 2000), 
causes structural defects of the thoracic aorta (Pfeiffer et al., 2005) and leads to 
nephropathy (Phillips et al., 2002).  
 
Figure 6. The oim model. 
 X-ray image, adapted from (Camacho et al., 2001) and MRI scan (Courtesy of Dr. Pascale 
Guillot, UCL Institute for Women’s Health) showing the skeletal deformities of oim mice 
compared to wild-type mice.  
 
Brtl IV mouse model of OI type IV: another widely used model is the Brtl IV (Brittle 
mouse), which has a glycine to cysteine knock-in mutation at position 349 of the 
Col1α2 gene, obtained by cre-lox recombination. The Brtl IV model shares the same 
features as human type IV OI and manifests in a highly variable manner, with 
phenotypes ranging from perinatal lethality to normal lifespan with mild skeletal 
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defects (Forlino et al., 1999). Interestingly, heterozygous Brtl IV mice present severe 
reduction of bone mineral density and frequent fractures, while homozygote mice 
have a milder phenotype with normal mineral density, and moderately smaller size. 
This is probably because the homozygosity leads to a more homogeneous and 
therefore less brittle organisation of the extracellular matrix. As observed in type IV 
OI patients, the number of fractures in the Brtl IV mouse decreases with age. 
Moreover, it has been reported that the distinct phenotypes observed in the Brtl IV 
model result from the same ratios of mutant and normal collagen chains, therefore 
suggesting that interactions with extra-collagenous factors are critical for the 
different manifestation of the disease (Kamoun-Goldrat and Le Merrer, 2007). 
COL1A1 minigene mouse model of OI type II-IV: the transgenic OI mouse model was 
obtained by insertion, through genome engineering techniques, of a mini-gene 
version of human proα(I) collagen gene characterised by normal promoter and 3’ end 
region but lacking the central sequence, containing 41 exons (Stacey et al., 1988). The 
phenotype of the resulting mice was highly heterogeneous, with some mice 
displaying skeletal deformities, albeit without fractures. The human shortened 
proα(I) chains assemble with the endogenous proα(I) chains, leading to their 
degradation due to structural instability. The mini-gene OI model can be modulated 
to obtain a wide range of severities, from moderate type IV OI to severe/perinatally 
lethal type II OI, by increasing the level of expression of the human proα(I) mini-gene 
(Khillan et al., 1991). This transgenic line is particularly relevant because it has been 
the first to be used as a model of OI to assess the outcome of a cell therapy studies 
for OI, in 1998 (Pereira et al., 1998). 
Several other mouse models have been developed to mimic the wide variety of 
genetic defects and resulting phenotypes that characterise the OI spectrum. Table 2 
summarises the main OI mouse models developed to date. 
 
  
 
 Table 2. Mouse models of OI. 
Summary of the mouse models developed for the study of OI. Adapted from (Jones and Guillot, 2013)
Model Mutation OI	type Reference
Mov13	 +/- - Mov13	 -/- M-MuLV insertion I	/ II Bonadio, 1990
Sp7	-/- Knock-out	Sp7 II Baek,	2009
Oim -/- Col1a2 III Chipman, 1993
Aga2	+/- Col1a1 III Lisse,	2008
Brtl +/- - Brtl -/- COL1A1	knock-in IV Forlino,	1999
Col1a1-minigene Human	COL1A1 knock-in II	/ IV Khillan,	1991
Col1a1 jrt/+ Col1a1 IV	/	Ehles-Danlos syndrome Chen,	2014
IFITM5	- transgenic IFITM5 V Lietman,	2015
Crtap -/- Knock-out	Crtap VII Morello,	2006
Lepre -/- Knock-out	Lepre VIII Vranka,	2010
Ppib -/- Knock-out Ppib IX Choi,	2009
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1.5.2 Cell therapy in OI animal models  
Cell therapy has been proposed as a promising option for OI following observation of 
natural occurring mosaicism in OI families. OI mosaic carriers have a mixture of 
mutant and normal cell populations in all tissues, due to post-zygotic events, and only 
show minimal symptoms or are unaffected at all, even when a high proportion of 
their osteoblasts harbours the mutation (Dalgleish, 1998; Cabral and Marini, 2004). 
The original rationale of cell therapy for OI was therefore to mimic the mosaic 
situation, providing healthy osteoblast precursors that would be sufficient to 
normalise the disease phenotype, even with low engraftment (Gerson, 1999). The 
most relevant studies in OI mouse models to date are summarised in Table 3. 
First studies: The first stem cell transplantation study was performed by injecting 
MSCs derived from the bone marrow of wild-type mice into a transgenic mouse 
model of OI, expressing the human minigene for COL1A1. 3-week-old transgenic mice 
where marrow-ablated by irradiation and transplanted intraperitoneally with MSCs 
(0.7 – 12 x 106 cells per animal). Donor cell DNA was detected in the bone marrow, 
cartilage and lungs after 2.5 months following transplantation, giving the first 
evidence of engraftment in an OI model. Engraftment levels varied from 4 to 19%. 
Higher levels of collagen and minerals were detected in bones following 
transplantation, however no mechanical tests were performed on bones and no in 
vivo differentiation of donor cells was reported (Pereira et al., 1998).  
Ten years later, two studies from Niyibizi’s group confirmed the results of the 
previous study and were able for the first to show in vivo differentiation of donor cells 
in an OI model. In one study, 8-week-old wild-type mouse MSCs were labelled with 
green fluorescent protein (GFP) and injected into wild-type neonate mice via the 
temporal vein. After 35 days, those donor cells that had engrafted into the bones 
were retrieved. Analyses of the GFP+ retrieved cells showed that they underwent 
partial osteogenic differentiation in vivo. These osteoprogenitors were then re-
transplanted into previously irradiated neonate oim/oim mice, again via the temporal 
vein. Four weeks later, GFP+ osteoblasts were detected in the epiphyses of long 
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bones, site of active bone formation, and in the cortex, showing further in vivo 
differentiation and contribution to bone formation (Wang et al., 2006).  
The second study from the same group transplanted 5 x 104 GFP-labeled MSCs from 
wild-type mice into previously irradiated oim/oim neonates and were able to show 
engraftment into the bones. They observed for the first time that the collagen 
synthesized following transplantation was composed by both α1 and α2 chains that 
formed normal heterotrimeric collagen. Since the oim model is unable to produce 
Col1α2 chains, this was the first evidence that transplanted cells contributed to ECM 
formation in vivo (Li et al., 2007).  
Intrauterine transplantations: The basis for in utero transplantation for the treatment 
of OI were suggested for the first time by a study performed injecting human first-
trimester blood MSCs into oim/oim fetuses. MSCs were transduced with luciferase-
expressing construct and intraperitoneally injected into the fetuses (106 cells per 
animal) following laparotomy. No bone marrow ablation or immune suppression was 
performed and human cells were not immune rejected following transplantation in 
mice. After 12 weeks, donor cells were shown to engraft at low level (5%) in bones 
and to differentiate into osteoblasts in vivo. Following transplantation, fracture rate 
was decreased by two thirds and bone mechanical properties were significantly 
improved (Guillot et al., 2008a).  
A second intrauterine transplantation study from Guillot’s group using human fetal 
blood MSCs confirmed the previous result, with an engraftment level of 5% and a 
84% decrease in fracture rate, and showed that also donor human cells were able to 
produce the normal COL1A2 chain, missing in the oim model, and to improve the 
quality and stiffness of the ECM (Vanleene et al., 2011).  
A similar experiment supporting intrauterine cell therapy was performed with the Brtl 
IV mouse model of OI. Bone marrow MSCs derived from GFP-transgenic mice were 
transplanted in utero into heterozygous Brtl IV mice (5 x106 cells per fetus). Donor 
cells were found to engraft and differentiate, contributing to 20% of the total amount 
of collagen produced. Brtl IV mice have normally a much shorter life span than wild-
type mice. Following MSCs administration, transplanted mice lived twice longer than 
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non-transplanted controls and the mechanical properties of the analysed bones were 
improved (Panaroni et al., 2009). 
Priming MSCs: In order to increase engraftment levels, Guillot’s group later 
investigated priming human fetal blood MSCs with SDF-1 before intraperitoneally 
injecting them into oim/oim and wild-type neonate mice (106 cells/animal). Primed 
cells showed overexpression of CXCR4, which was related to improved chemotaxis 
and overall better engraftment. Higher engraftment levels positively correlated with 
a decrease in long bone fractures, although bone strength remained unchanged 
(Jones et al., 2012a). 
Intra-femoral transplantation: Another study from Niyibizi’s group proposed direct 
intra-femur administration of MSCs, to avoid large number of cells being trapped into 
the lungs. Mouse GFP-labelled MSCs were infused into the femurs of irradiated 
oim/oim mice (106 cells/animal), together with a collagen gel, to improve 
engraftment. After two weeks, new bone formation and increased mechanical 
properties were demonstrated in the femurs of transplanted mice and GFP+ cells 
were detected 6 weeks after transplantation (Li et al., 2010a).  
Another group tried a similar approach and injected MSCs from GFP-transgenic mice 
into the intramedullary cavity of the femur of previously irradiated oim/oim mice (106 
cells/animal). Donor cells underwent osteogenic differentiation and new bone 
formation was observed. GFP+ cells were then retrieved from the bones and re-
transplanted into other oim/oim mice, to show the persistence of stem/progenitor 
cells in vivo (Pauley et al., 2014). 
Ethical sources of MSCs: given the robust body of evidence supporting cell therapy 
for OI, both before and after birth, systemically and locally, the interest of the 
scientific community is now focused on the identification of the best stem cell source 
for the further clinical translation. Human fetal MSCs are not easily isolated and their 
use is ethically restricted since their availability relies on terminations of pregnancy. 
Recently, extra-embryonic fetal tissues have been investigated as possible sources of 
donor cells. In a recent study from Guillot’s group, oim/oim neonate mice were 
intraperitoneally injected with human fetal early placental chorionic MSCs (106 
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cells/animal). Cells engrafted at low levels and differentiated into osteoblasts in vivo. 
Fracture rate decreased by two thirds and bone volume increased in transplanted 
mice, although bone strength was not improved. This was concomitant with an up-
regulation of endogenous chondrogenic genes, suggesting a paracrine effect of 
transplanted cells (Jones et al., 2014a). 
  
 
Table 3. Preclinical studies of cell therapy for OI.  
  Cell therapy studies in OI mouse models. i.p.: intraperitoneal, i.v.: intravenous, i.h.: intrahepatic, i.f.: intrafemur. Adapted from (Jones and Guillot, 2013).
Model Cells Age Route Irradiated Engraftment Differentiate Bones	 Reference
COL1A1
mini-gene
WT	mouse	
bone marrow	
MSC
3	weeks i.p. Yes Yes	(4-19%) Not	measured Not	assessed Pereira, 1998
Oim/oim
GFP+ WT	
mouse	osteo-
progenitors
neonatal i.v. Yes Yes Yes Not	assessed Wang, 2006
Oim/oim
GFP+ WT	
mouse	osteo-
progenitors
neonatal i.v. Yes Yes Yes Not	assessed Li,	2007
Oim/oim
Luciferase+
human	fetal
blood	MSCs
fetal i.p. No Yes	(5%) Yes < fracture	rate>	bone	quality Guillot,	2008
Heterozygous
Brtl IV	
GFP+ WT	
mouse	bone
marrow	MSC
fetal i.h. No Yes Yes >	bone	quality Panaroni,	2009
Oim/oim
GFP+ WT	
mouse	bone
marrow	MSC
Neonatal i.f.	+ collagen	gel Yes Yes Yes
New	bone	
formation	
> bone	quality
Li,	2010
Oim/oim Human	fetalblood	MSCs fetal i.p. No Yes	(5%) Yes
<	fracture	rate
>	bone	quality Vanleene,	2011
Oim/oim
SDF-primed	
human	fetal
blood	MSCs
neonatal i.p. No Yes	(5-10%) Yes < fracture	rate>	bone	quality Jones,	2012
Oim/oim
GFP+ WT	
mouse	bone
marrow	MSC
2-3	months i.f. Yes Yes Yes New	bone	formation Pauley, 2014
Oim
Human fetal
early	chorionic	
MSCs	
neonatal i.p. No Yes Yes < fracture	rate>	bone	quality Jones,	2014
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1.6 Cell therapy for OI in clinics  
Following the promising results of the preclinical studies for cell therapy in OI, which 
report engraftment and therapeutic benefits in mouse models of the disease, 
different attempts to translate this approach have been made. Since 1999, ten 
children with severe OI have been transplanted with MSCs, either before or after 
birth. The limited clinical experience reported so far and ongoing efforts are 
summarised here.    
1.6.1 Postnatal transplantations  
In 1999, three children with severe deforming type III OI were transplanted in the 
second or third year of life (13-32 months of age) with bone marrow MSCs derived 
from HLA-matching or single-antigen-mismatched siblings (5.7-6.2 x108 cells/kg), 
following ablative conditioning. Opportunistic bone biopsies were collected from two 
of the transplanted children and engraftment of donor cells was estimated around 
2%. Despite the low level of engraftment, an increase in bone mineral content was 
observed in all three children, ranging from 45% to 77% gain of total body mineral 
content in the first 6 months after transplantation. The three patients showed a 2-2.5 
cm growth in the first 3 months and two children grew in line with the normal median 
growth velocity for their age in the first 6 months. A dramatic decrease in fracture 
rate was also reported. In the year before transplantation, two children reported 
more than 20 fractures, which decreased to 2-3 in the first 6 months after the 
procedure and none were reported in the following 6 months. In terms of toxicity, 
one child experienced pulmonary insufficiency, sepsis and developed an hygroma, all 
of which were resolved (Horwitz et al., 1999a).  
Two years later, the authors reported a 36-month follow-up of two patients and an 
additional child, which also included clinical data from two non-transplanted age-
matched OI children as controls. The transplanted children showed a showed a 
median 7.5-cm growth in the first 6 months, compared to the 1.25 cm observed in 
control children in the same period of time. After this initial improvement, however, 
growth reached a plateau. The number of fractures decreased from a median of 10 
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before treatment to a median of 2 at 12 months after transplantation, while in control 
children it remained constant at 4. Six children, who had previously undergone bone 
marrow transplantation as part of previous studies, were enrolled in a study to assess 
the therapeutic effects of repeated MSC transplantations. Two infusions (1-5 x 106 
cells/kg) with the same MSC donor used for the previous study were performed 18-
34 months after the original treatment. Five children showed engraftment of donor 
cells in bones. In the six months after transplantation, growth rates showed a marked 
acceleration (60-94% of the predicted median). No adverse effects were observed 
apart from one child suffering from a skin rash (Horwitz et al., 2002).  
1.6.2 Prenatal transplantations 
OI can be diagnosed during mid-pregnancy ultrasound scan, allowing the possibility 
of stem cells transplantation before birth. Advantages of prenatal, rather than 
neonatal, transplantations are numerous, including the possibility to limit the 
damages of severe congenital disorders, the lack of requirement of ablative therapy, 
the more permissive fetal environment for donor cell homing and the stoichiometric 
advantage in terms of number of cells required, given by the small size of the fetus 
(Le Blanc et al., 2005).  
Only two cases of in utero MSC transplantation for OI have been reported so far. The 
first fetus was diagnosed with severe type III OI and was transplanted at 32 weeks of 
gestation with allogeneic mismatched MSCs derived from the liver of a 10-week 
aborted fetus (6.5 x 106 cells), via the umbilical vein under ultrasound guidance. Since 
donor cells were of male origin and the recipient fetus was a female, engraftment 
analyses were performed by assessing the karyotype of cells in a bone biopsy. A 
median of 7.4% of Y chromosome-positive cells was estimated. No immune rejection 
of donor cells was detected and the child had only three fractures in the first 24 
months of life (Le Blanc et al., 2005). The child, who also had pharmacological 
treatment with bisphosphonates, then grew according to the predicted growth rate 
until 8 years of age, despite having several complications and more long bone 
fractures. At 6 years of age, donor cells were no longer detected in an opportunistic 
bone biopsy and the child’s growth slowed down. At 8 years of age, the child 
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underwent a second transplantation (2.8 x 106 cells/kg, intravenously injected) with 
the same fetal liver MSCs used in the intrauterine setting. In the two years after the 
postnatal transplantation no new fractures were observed and the child grew 
normally and had a good quality of life. Engraftment was very low after 9 months, 
with about 0.003% Y chromosome-positive cells detected in a bone biopsy. A child 
with the same mutation of the transplanted patient, who was treated with 
bisphosphonates and did not undergo MSCs transplantation, died at 5 months of age 
(Götherström et al., 2014). 
 The second child was diagnosed with OI after detection of intrauterine bone 
fractures during an ultrasound scan at mid pregnancy. The fetus was transplanted at 
31 weeks with allogeneic fetal liver MSCs derived from a 7-week-old terminated fetus 
(30 x 106 cells/kg) via the hepatic vein. The baby was born without complications and 
grew without fractures until 1 year of age, when her growth arrested. A second MSC 
transplantation was performed at 19 months of age with the same cells used 
previously (10 x 106 cells/kg), which allowed the girl to grow just below the normal 
curve. No information on engraftment is available in this second case. A therapy with 
bisphosphonates was given in both cases (Götherström et al., 2014).  
1.6.3 Phase I/II clinical trial 
Stemming from the promising results obtained by the many preclinical studies and 
the limited clinical experience so far, the first in utero stem cell transplantation 
clinical trial will be initiated in 2017, led by the Karolinska Institute. The Boost Brittle 
Bones Before Birth (BOOSTB4) phase I/II trial is funded by the European Commission 
Horizon 2020 and the Swedish Research Council and will assess the safety and efficacy 
of prenatal and neonatal transplantation of MSCs for the treatment of severe OI 
(types III and IV). The study is a multicentre study and four clinical hubs are taking 
part: the Karolinska Institute in Sweden, UCL/Great Ormond Street Hospital in the UK, 
Leiden University in the Netherlands and Uniklinik Koln in Germany. The trial 
consortium (http://boostb4.eu) is going to compare the safety and benefits of in 
utero transplantation with postnatal transplantation at 4 months of age and absence 
of treatment in age and mutation matched controls (Chitty et al., 2016).  
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1.7 Thesis aims and research questions 
The main aim of the work presented in this thesis is the investigation of the 
therapeutic potential of human amniotic fluid stem cells (AFSCs) transplantation in 
the oim mouse model of osteogenesis imperfecta (OI).  
Moreover, this work aims at investigating the mechanisms of action of human AFSCs 
transplanted into the oim mouse model of OI, leading to therapeutic effects.  
The last aim of this work is the establishment of a protocol for the isolation and 
differentiation of human fetal osteoblasts that could be used to model human bone 
in vitro. 
Specifically, the following research questions have been addressed: 
 
• Do human AFSCs transplanted into oim mice engraft and differentiate in vivo? 
(Chapter 3) 
• Does transplantation of human AFSCs into oim mice ameliorate oim bone 
biomechanical properties and bone structure? (Chapter 4) 
• Do human AFSCs transplanted into oim mice have a paracrine effect on oim 
osteoblasts? (Chapter 5) 
• Can AFSC-conditioned medium recapitulate in vitro the effect of AFSCs seen 
in vivo? (Chapter 6) 
• Is the human fetal calvaria a source of osteoblasts that can be used to model 
human bone formation in vitro? (Chapter 6) 
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Chapter 2  
  Materials and methods 
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2.1 Cell biology and animal work 
2.1.1 Cell culture of human amniotic fluid and fetal liver MSC 
Human first and second trimester AFSCs were isolated by a previous member of the 
lab (Dr. Dafni Moschidou), following ultrasound-guided amniocentesis of normal 
pregnancies, using the isolation protocol described previously (Moschidou et al., 
2013b). Informed consent for the use of cells for research was obtained and ethical 
approval was given by the Research Ethics Committees of Hammersmith & Queen 
Charlotte’s Hospitals (08/H0714/87), in compliance with national guidelines. Briefly, 
amniotic fluid was centrifuged and pelleted cells were plated in Dulbecco’s Modified 
Eagle Medium – high glucose (DMEM, Invitrogen), supplemented with 10% fetal 
bovine serum (Biosera), 2 mM L-glutamine (Gibco), 50 IU/ml penicillin and 50 mg/ml 
streptomycin (Gibco) (From now referred to as DMEM). Cells were incubated at 37°C 
in a humidified incubator with 5% CO2. Following adhesion, cells were detached with 
TrypLE dissociation reagent (Gibco) and sorted for C-KIT expression. Selected cells 
were expanded and cryopreserved in liquid nitrogen.  
First trimester human fetal liver MSCs were isolated from aborted tissues by Dr. Dafni 
Moschidou following the protocol described previously  (Guillot et al., 2008). Briefly, 
fetal liver tissue was minced through a nylon filter and single cell suspension was 
plated in DMEM an incubated in a humidified incubator at 37°C and 5% CO2. After 72 
hours medium was changed to remove non-adherent cells and remaining cells were 
expanded and cryopreserved in liquid nitrogen until use. Cells for the experiments 
were expanded by seeding them at 10,000 cells/cm2, changing the medium every 3 
days. Cells were passaged when reaching 70% of confluence by TrypLE detachment. 
Experiments were performed using AFSCs and fetal liver MSCs at passage 5-8. When 
cryopreservation was needed, cells were detached with TrypLE, centrifuged and 
resuspended in freezing medium consisting of 50% fetal bovine serum (Biosera), 40% 
DMEM (Invitrogen) and 10% dimethyl sulfoxide (DMSO, Sigma). Cells were then 
transferred into cryo-vials and stored in liquid nitrogen.  
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2.1.2 Transplantations in the oim model 
Animal work was carried out by Dr. Dafni Moschidou and Dr. Gemma Jones. Oim 
homozygous and wild-type colonies were established after sequencing the oim 
fragment in offspring of oim heterozygous male and female mice (B6C3Fe a/a-
Col1a2oim/ Col1a2oim, Jackson Laboratory). Offspring were weaned at 30 ± 1 day. At 
3-4 days of age, homozygous oim mice were transplanted intraperitoneally with 
human AFSCs (106 cells per mouse, in 20μl of cold PBS, passage 5-8, derived from one 
donor) and were culled at 8 weeks of age, together with age-matched non-
transplanted oim and wild-type mice as controls.  
2.1.3 Conditioned medium preparation 
Conditioned medium was produced by culturing AFSCs (20,000 cells/cm2) for 48 
hours in expansion medium (expansion medium only or supplemented with 5 ng/ml 
TGF-β or TNFα for 24 hours), collecting the culture medium and concentrating it using 
Amicon Ultra filters, pore size 3kDa (Merck) to reach a concentration of 200 times. 
Briefly, 4 ml of culture medium was collected from the AFSC culture wells, transferred 
into the Amicon filters and centrifuged for 40 minutes at 4,000 x g using a swinging 
bucket rotor (Thermo Scientific). The resulting concentrated medium was collected 
from the filter and dissolved in 4ml of fresh culture medium to produce conditioned 
medium. 
2.1.4 MG-63 osteosarcoma cell line culture 
MG-63 osteosarcoma cells were obtained from the American Type Culture Collection 
(ATCC). Cells were seeded at 20,000 cells/cm2 in DMEM in a humidified incubator at 
37°C and 5% CO2 and passaged at 80% confluence by TrypLE incubation. Expansion 
medium was changed every 3 days. 
2.1.5 Mouse osteoblast isolation and culture 
Osteoblasts were isolated from calvarial bone of 3-day old oim/oim mice, using a 
previously established protocol (Taylor et al., 2014), consisting of sequential 
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enzymatic digestions (Figure 7). Briefly, after the skin, brain tissue and cartilage were 
carefully removed with a scalpel, the calvaria was cut in half, washed with PBS 
(Biosera) and incubated for 10 minutes in 0.25% trypsin-EDTA solution (Gibco) at 
37°C, in order to lyse the proteins of the outer layer. The resulting digestion was then 
discarded and the calvarial pieces were washed with FBS-containing medium in order 
to inactivate trypsin and incubated for 30 minutes in a 0.2% collagenase type II 
solution in Hank’s balanced salt solution (HBSS, Gibco) at 37°C, to loosen the collagen 
structure and release cells. The second digestion was also discarded and bone pieces 
were incubated for an additional 60 minutes in 0.2% collagenase type II solution in 
HBSS, to release the osteoblasts. The last digest was plated into a 75 cm2 flask in 
Alpha-Modified Essential Medium (αMEM, Gibco) supplemented with 10% FBS 
(Biosera), 2mM L-glutamine (Gibco) and 50 IU/ml penicillin and 50 mg/ml 
streptomycin (Gibco) (from now described as αMEM). Cells were allowed to grow 
until confluent (6 days) in a humidified incubator at 37°C and 5% CO2, replacing 
medium every 3 days. Cells were cultured by seeding them at 10,000 cells/cm2 and 
passaged by trypsin-EDTA detachment. Experiments were performed with cells at 
passages 2-3. When cryopreservation was needed, cells were detached with trypsin-
EDTA, centrifuged and resuspended in freezing medium consisting of 50% fetal 
bovine serum (Biosera), 40% αMEM (Gibco) and 10% dimethyl sulfoxide (DMSO, 
Sigma). Cells were then transferred into cryo-vials and stored in liquid nitrogen.  
2.1.6 Human fetal osteoblasts isolation and culture  
Human fetal osteoblasts were collected by fetal calvarial tissue, obtained by 
terminated pregnancies, collected by the MRC/Wellcome-Trust funded Human 
Developmental Biology Resource (HDBR) at the UCL GOS Institute of Child Health. 
Samples had gestational ages ranging between 9 and 21 weeks post conception and 
had all a normal karyotype. Upon collection, calvarial tissue was dissected and soft 
tissues discarded. In order to achieve effective isolation of human fetal osteoblasts, 
the protocol used for mouse osteoblast isolation (Taylor et al., 2014) was optimised 
by testing different cycles of trypsin and collagenase digestion (See Figure 7 for 
comparison with the original mouse protocol). Bone tissue was dissected into small 
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fragments of about 0.5 cm2 and washed thoroughly with PBS. Bone fragments were 
subsequently incubated with 0.25% trypsin-EDTA solution to digest the outmost layer 
of proteins. Different 15-minute cycles of 0.25% trypsin-EDTA solution were tested 
(See Results Chapter 6), followed by different combinations of 30-minute cycles of 
0.2% collagenase type II in HBSS incubation in a humidified incubator at 37°C and 5% 
CO2. The resulting final digestions was plated in αMEM and cultured changing 
medium every 3 days until confluency. Isolated human fetal osteoblasts were 
cultured by seeding them at 10,000 cells/cm2 in αMEM and passaged upon 
confluency. Experiments were performed with cells of passage 2-5. A biobank of 24 
human fetal osteoblast samples derived from calvarial bones was built, by freezing 
cells at early passages (1-3). Cells were detached by TrypLE (Gibco) and transferred 
to liquid nitrogen in freezing medium consisting of 50% fetal bovine serum (Biosera), 
40% αMEM (Gibco) and 10% dimethyl sulfoxide (DMSO, Sigma).  
 
     Figure 7. Mouse and 
human osteoblast 
isolation protocols. 
Diagram comparing the 
protocols used for 
mouse and human 
osteoblast isolation.    
 
Cut	calvaria in	0.5	cm2
pieces
Wash	with	PBS
1-4	cycles	0.25%	trypsin-
EDTA,	37°C,	15	mins
0.2%	collagenase	 type	II,	
37°C,	30	mins,	1h	or	2x1h
Plate	digestion
Cut	calvaria in	half
Wash	with	PBS
0.25%	trypsin-EDTA,	
37°C,	10	mins
0.2%	collagenase	 type	II,	
37°C,	30	mins
0.2%	collagenase	 type	II,	
37°C,	60	mins
Plate	digestion
Mouse osteoblast 
Isolation (Taylor et al., 2014) 
Optimisation of human 
osteoblast isolation 
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2.1.7 Osteogenic differentiation 
Human and mouse cells were seeded at 20,000 cells/cm2 in 6 or 12-well plates in 
expansion medium (DMEM or αMEM). Upon confluency, cells were cultured in 
osteogenic medium for up to 3 weeks, changing medium every 3 days. Osteogenic 
medium contained 0.2 mM ascorbic acid (Sigma), a cofactor for the biosynthesis of 
collagen, 10 nM dexamethasone (Sigma), which enhances osteogenic differentiation, 
and 2.5-10 mM β-glycerophosphate (Sigma), which acts as a substrate to alkaline 
phosphatase to provide the orthophosphate needed for mineralisation (refer to 
individual chapters for β-glycerophosphate concentrations used with the different 
cell types). Previous studies showed that finding the correct β-glycerophosphate 
concentration is crucial to obtain in vitro bone formation and to avoid non-specific 
mineral deposition (Orriss et al., 2012; Taylor et al., 2014). Terminated cultures were 
fixed with 70% ethanol for 5 minutes and then let to air-dry for 30 minutes. 
2.1.8 Alizarin red staining 
Mineralised cultures were stained with 1% w/v alizarin red in PBS (Sigma) for 5 
minutes, washed three times with 50% ethanol to remove excessive staining and let 
to air-dry for 30 minutes. Cultures were then imaged by a high-resolution flat-bed 
scanner (Epson). 
2.1.9 Adipogenic differentiation 
Cells were seeded at 10,000 cells/cm2 and cultured in DMEM until 90% confluent. 
Expansion medium was then replaced by adipogenic permissive medium (StemPro 
adipogenesis differentiation medium, Gibco), which was changed twice a week for 3 
weeks. Cultures were then fixed with 4% paraformaldehyde for 15 minutes and 
stained with Oil Red O. 
2.1.10 Oil Red O staining 
Oil Red O (Sigma-Aldrich) was prepared at 0.3% concentration in isopropanol (VWR) 
and subsequently diluted in distilled water in a ratio of 3:2 and filtered. Fixed cells 
  67 
were washed with 60% isopropanol and then incubated for 15 minutes with the Oil 
Red O solution at room temperature. Finally, cells were washed thoroughly with 
distilled water to remove excessive stain and cultures were imaged with an inverted 
phase contrast microscope (Olympus IMT-2) and a colour digital camera (Zeiss 
AxioCam). 
2.1.11 Growth rate 
Growth rate of first trimester AFSCs, fetal liver MSCs and human fetal osteoblasts of 
different gestational ages was measured by estimating their cumulative population 
doublings, following the protocol described in (Guillot et al., 2007). Briefly, cells were 
plated at low density (5,000 cells / cm2) in 12 well plates in triplicate. Every 3 days 
cells were detached, counted in a haemocytometer and subsequently seeded at the 
same density. This was repeated for 3 weeks and the number of population cell 
doublings was measured by counting the number of adherent cells before and after 
each passage. Doubling time was measured with the formula DT=t/(Log2[y/m] with t 
being time in culture, y the number of cells at the end of culture and m the number 
of cells at the beginning of culture for each passage. 
 
2.2 Molecular Biology 
2.2.1 Flow cytometry 
Surface marker expression was assessed by flow cytometry. AFSCs were detached, 
using TrypLE, blocked with 1% bovine serum albumin (BSA, Sigma-Aldrich) in PBS and 
incubated with specific conjugated primary antibodies (See Table 5) for 1 hour at 4°C. 
Cells were then washed in 1% BSA in PBS and analysed by FACScalibur flow cytometer 
(Becton Dickinson). Immunoglobulin G (IgG) primary antibody-specific isotypes were 
used as negative controls. Data were analysed with Flowjo software (Tree Star). 
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2.2.2 RNA isolation 
Total RNA was isolated from cells using the RNeasy mini kit (Qiagen) following 
manufacturer’s instructions and eluted in RNase-free water (Qiagen). RNA from 
mouse oim and wild-type bones and soft organs was extracted by grinding tissues 
using a rotor stator homogeniser with the addition of Trizol (Invitrogen), followed by 
chloroform (Sigma-Aldrich). The aqueous phase was then mixed with isopropanol to 
precipitate RNA and centrifuged. 70% ethanol was then used to wash the pellet, 
which was then resuspended in RNase-free water. In both protocols, RNA was then 
quantified by measuring absorbance at a wavelength of 260 nm using a NanoDrop 
spectrophotometer (Thermo Scientific).  
2.2.3 cDNA synthesis 
Complementary DNA (cDNA) was produced incubating RNA with random primers 
(Promega) at 70°C for 5 minutes and subsequently adding Moloney-Murine Leukemia 
Virus reverse transcriptase (M-MLV RT, Promega) and dNTPs (Promega), in presence 
of RNase inhibitor (Promega). The reaction was incubated at 37°C for 1 hour and then 
frozen to stop the reaction. cDNA synthesis for gene arrays was performed using a 
RT2 First Strand Kit (Qiagen), according to manufacturer’s instructions. 
2.2.4 Quantitative real-time PCR 
Quantitative real-time polymerase chain reaction (qPCR) was performed using SYBR 
Green PCR Master Mix (Applied Biosystems) and specific pairs of forward and reverse 
primers (See Table 4 for sequences). Amplification of cDNA was obtained using a 
StepOne Plus thermocycler (Applied Biosystems) with the following cycling 
conditions: 1 x 2 mins 94°C, 40 x (15 sec 94°C and 1 min 60°C). GAPDH or β-actin were 
used as internal controls to normalise the expression of the target genes in each 
sample. Unless specified, data were collected in triplicate and were analysed 
according to the 2-ΔΔCt method. Refer to individual figures for sample number. To 
measure AFSC engraftment level on oim bones and organs, the ratio of the expression 
of human β-actin to the expression of total human + mouse β-actin was calculated 
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and used to estimate the level of  human:mouse chimerism, as described in (Guillot 
et al., 2008; Jones et al., 2014). Areas of β-actin gene sequence (accession number: 
NM_001101) that are present in the human gene but not in the mouse gene were 
used to design the human-specific primers and specificity was verified by the lack of 
amplification in non-transplated oim cDNA (Guillot et al., 2008; Jones et al., 2014). 
Samples were considered positive with a human specific β-actin Ct value below 36 at 
a threshold of 0.13ΔRn. 
2.2.5 Gene array 
The expression of multiple genes in transplanted and non-transplanted oim bones 
was assessed by gene arrays, which allow the analysis of expression of a panels of 
mouse genes simultaneously. The arrays used were commercially available mouse-
specific osteogenesis and osteoporosis RT2 Profiler mouse PCR arrays (Qiagen). Two 
internal controls (housekeeping genes β-actin and Hsp90ab1) were used to normalise 
the level of expression to total cDNA amount in each sample. The arrays were run 
using a HT7900 Fast Real-Time PCR cycler (Applied Biosystems) at the UCL GOS 
Institute of Child Health Genomics facility. Cycling conditions were the following: 1 x 
10 mins 95°C, 40 x (15 sec 95°C and 1 min 60°C). Data were analysed using the 
GeneGlobe Data Analysis Centre web tool included in the arrays (Qiagen) and 
expression of genes following AFSC transplantation was plotted as a fold change from 
the level of expression in non-transplanted animals (2-fold change was selected as a 
threshold cut-off). 
2.2.6 Protein extraction and quantification 
Mouse femurs were ground to powder from frozen with a rotor-stator homogeniser 
and total protein was extracted using RIPA buffer, containing 1% Nonidet P-40, 0.5% 
sodium deoxycholate, 0.1% sodium dodecyl sulphate (SDS) and 0.004% sodium azide, 
supplemented with protease inhibitor cocktail (all Sigma). The concentration of 
proteins was measured using the BCA protein assay (Thermo Scientific), and reading 
absorbance at a wavelength of 560 nm, using BSA to build a standard curve. 
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2.2.7 Western blot 
Protein lysates were separated on an 8-10% SDS-PAGE gel and blotted onto a 
nitrocellulose transfer membrane (GE Healthcare) for an hour at 4°C. The membrane 
was then blocked for one hour with 5% milk PBS-T (0.1% Tween20 in PBS) and 
incubated overnight at 4°C with primary antibodies raised against the proteins of 
interest (See Table 5 for specific antibodies). Incubation with secondary antibodies 
conjugated to horseradish peroxidase (HRP) was performed at room temperature for 
one hour (See Table 6 for specific antibodies). Detection was achieved by incubation 
with the Enhanced Chemiluminescent developing solution (ECL substrate, Thermo 
Scientific). Bands were imaged with a Chemidoc detection system (Bio Rad) and 
quantified using ImageJ software, based on band densities. β-actin was used as a 
loading control (Santa Cruz). 
 
2.3 Histology and microscopy 
2.3.1 Immunohistochemistry 
Mice tibiae were dissected, decalcified for 2 weeks in 10% EDTA at pH 7.4 and 
embedded in paraffin. 4μm thick sections were cut, deparaffinised in xylene, and 
rehydrated. Heat induced antigen retrieval was performed on a hot plate with citrate 
buffer at pH 6 followed by serum-free blocking agent. Slides were subsequently 
incubated with Peroxidase Blocking Reagent (Dako) and blocked with 5% goat serum 
in PBS. Staining was performed with human-specific primary antibody (See Table 5) 
at 4°C overnight. Slides were then incubated with HRP-conjugated secondary 
antibody followed by DAB+ substrate-chromogen staining (Dako) and imaged by a 
Zeiss Axioplan2 microscope with Zeiss Axiocam HRc colour camera (UCL GOS Institute 
of Child Health microscopy facility; collaboration with Ms Mahrokh Nohadani). 
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2.3.2 Haematoxylin and eosin staining 
Mice tibiae were dissected, decalcified for 2 weeks in 10% EDTA at pH 7.4 and 
embedded in paraffin. 4μm thick sections were cut, deparaffinised in xylene, and 
rehydrated. Sections were then stained with haematoxylin (Harris modified, Thermo 
Scientific) for 5 minutes. Then they were rinsed in 1% acid alcohol (37% HCl into 70% 
ethanol) and counterstained in 1% eosin Y in distilled water (Sigma) for 3 minutes. 
Dehydration was then performed with increasing concentrations of alcohols and 
sections were incubated in xylene for 6 minutes before mounting with DPX (Sigma). 
2.3.3 Immunofluorescence  
Mice tibiae were dissected, decalcified for 2 weeks in 10% EDTA at pH 7.4 and 
embedded in paraffin. 4μm thick sections were cut, deparaffinised in xylene, and 
rehydrated. Heat induced antigen retrieval was performed on a hot plate with citrate 
buffer at pH 6 followed by serum-free blocking agent. Slides were subsequently 
blocked with 5% goat serum in PBS and incubated with a human-specific primary 
antibody (See Table 5) overnight at 4°C, followed by incubation with FITC-conjugated 
secondary antibody (See Table 6). Slides were then mounted with VectaShield 
containing DAPI (Vector) to visualise nuclei and imaged by a Leica DM LM 
fluorescence microscope with CoolSnap monochrome camera (UCL GOS Institute of 
Child Health microscopy facility; collaboration with Ms Mahrokh Nohadani).  
2.3.4 Two-photon lifetime imaging 
An upright LSM 510 microscope (Carl Zeiss) with a water-dipping objective (1.0 NA × 
40) was used for the two-photon lifetime imaging of collagen produced by human 
fetal osteoblasts, in collaboration with Dr. Thomas Blacker and Prof. Michael Duchen, 
UCL Department of Cell and Developmental Biology. A 650-nm short-pass dichroic 
and a 460±25 nm emission filters were used. A Chameleon (Coherent) Ti:sapphire 
laser provided two-photon excitation (720 nm for collagen autofluorescence and 920 
nm for second harmonic generation). Fluorescence lifetime measurements were 
recorded with a SPC830 FLIM module (Becker and Hickl). 
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2.4 Micro-computed tomography  
2.4.1 Scan acquisition 
Tibiae were dissected and fixed in 10% neutral buffered formalin for 24 hours, 
subsequently washed with PBS and preserved in 70% ethanol until scanned. Bones 
were scanned with a Bruker Skyscan 1172 micro-CT scanner (by Dr. Michelangelo 
Corcelli, Bone Biology lab, UCL Department of Cell and Developmental Biology), in 
small plastic tubes containing 70% ethanol. Scans were performed using a beam 
energy of 49 KV and a flux 200 μA, a 0.5 mm aluminium filter and an isotropic pixel 
size of 5.06 μm. Each image was acquired with an exposure time of 590 ms, frame 
averaging of 3 and a 0.4-degree rotation step with a total rotation of 180 degrees and 
using medium camera resolution (2000x1048px). Random movement was set to ON 
and flat field correction was applied.  
2.4.2 Reconstruction 
The Skyscan NRecon software (Bruker) was used to reconstruct the scans. The 
following reconstruction settings were applied: ring artifacts reduction was enabled 
and set to 1, smoothing was enabled and set to 1 to reduce background noise and 
beam hardening correction was enabled and set to 25%. 
2.4.3 Analysis 
Skyscan CT Analyser (Bruker) was used to measure the morphometric parameters. 
Figure 8 shows the area of the tibia analysed for the different trabecular and cortical 
parameters. Trabecular bone was analysed taking in consideration a 1 mm thick 
region located 0.25 mm below the end of the tibial growth plate. Cortical thickness 
was measured at 1.75 mm, 2.25 mm and 2.75 mm below the end of the growth plate, 
whereas cortical porosity was assessed in 0.5 mm thick region at 2.25 mm below the 
end of the growth plate. Subchondral parameters were analysed in an area of interest 
of 0.5 mm from the beginning of the growth plate and the thickness of primary 
ossification was calculated manually on Data Viewer as an average of three 
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measurements. The parameters assessed were: percentage bone volume (BV/TV/%), 
trabecular thickness (Tb.Th/mm), trabecular number (Tb.N/mm-1), trabecular 
separation (Tb.Sp/mm), trabecular pattern factor (Tb.Pf/mm-1), cortical thickness 
(Ct.Th/mm) and cortical porosity (Ct.Po/%). 
 
 
 
Figure 8. Diagram showing the sites of micro-CT parameter measurements in mouse tibia. 
Micro-CT morphological parameters, including percentage bone volume (BV/TV/%), 
trabecular thickness (Tb.Th/mm), trabecular number (Tb.N/mm-1), trabecular separation 
(Tb.Sp/mm) and trabecular pattern factor (Tb.Pf/mm-1), were measured for subchondral bone 
in a region of interest (ROI) of 0.5 mm located above the growth plate of mouse tibia. The 
same parameters were measured for trabecular bone in a ROI of 1mm located 0.25mm below 
the growth plate. Cortical thickness (Ct.Th/mm) was assessed in three different locations, 
1.75, 2.25 and 2.75mm below the growth plate. Cortical porosity (Ct.Po/%) was measured in 
a ROI of 0.5mm located 2.25 mm below the growth plate. 
Trabecular	bone	analysis
Cortical	thickness
Subchondral	bone	analysis
Cortical	porosity
Growth	plate
0.5mm
1mm
0.5mm
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2.4.4 BMD and TMD analysis 
Bone mineral density and tissue mineral density measurements were performed by 
calibrating the SkyScan CT Analyser software using standards of known calcium 
hydroxyapatite content as a reference (initial calibration performed by Mr Nick Corps, 
Bruker UK). Two phantoms of 0.25 and 0.75 g/cm3 of calcium hydroxyapatite (Bruker) 
were scanned with the same settings used for the samples and the calibration was 
performed by the Hounsfield unit system. Bone mineral density was measured in the 
trabecular ROI, while tissue mineral density in the cortical ROI (Figure 8). 
 
2.5 Statistics 
Data were expressed as mean ± SEM (standard error of the mean). Data were 
analysed by unpaired two-tailed Student’s t-test or one-way analysis of variance 
(ANOVA) followed by Bonferroni post hoc correction using GraphPad (Version 6, 
GraphPad Sotware Inc.). P< 0.05 was considered significant. Chi-squared with Yates 
correction and to one degree of freedom was used to compare fracture incidence. 
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2.6 Primers 
 
Table 4. List of primers.  
List of primer sequences or product number in case of commercially available products. 
Custom made primers were designed by Dr. Gemma Jones.  
Gene Forward Reverse Product	number
Mouse	osteogenesis	
gene	array - -
QiagenRT2 Profiler	
PAHS-026Z
β-actin
(human)
5’-CTGGAACGGTGAA	
GGTGACA-3’
5’-AAGGGACTTCCTGT	
AACAATGCA-3’
β-actin
(human/mouse)
5’-GCTCCTCCTGAGCG	
CAAGTA-3’
5’-GATGGAGGGGCCG	
GACT-3’
β-actin
(mouse) - -
QiagenQuantitect
QT00095242
Alp1 - - Qiagen	Quantitect	QT00157717	
Cdkn1a - - Qiagen	Quantitect	QT00137053	
GAPDH 5’-AACAGCGACACC	CACTCCTC-3’
5’-CATACCAGGAAAT	
GAGCTTGACAA-3’
Osteocalcin	
(human)
5’-CCTCACACTCCTC	
GCCCTATT-3’
5’-CCCTCCTGCTTGG	
ACACAAA-3’
Osteocalcin	(mouse) - - QiagenQuantitectQT00259406
Osteopontin 5’-GCCGACCAAGGA	AAACTCACTA-3’
5’-CAGAACTTCCAGA	
ATCAGCCTGTT-3’
Osteprotegerin - - QiagenQuantitect	QT00106757
RANKL - - QiagenQuantitectQT00147385
Runx2 - - QiagenQuantitectQT00102193	
Serpine1 - - Qiagen	Quantitect	QT00154756
TNFα	 - - Qiagen	Quantitect	QT00104006
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2.7 Antibodies 
 
 
Table 5. List of primary antibodies. 
 List of primary antibodies used, the host species developed in, dilution used, application and 
product number.  
Antibody Host Application Dilution ProductNumber
CD34-FITC Mouse Flow	cytometry 1:10 BD	Bioscience555-821
CD45-FITC Mouse Flow	cytometry 1:10 BD	Bioscience555-482
CD73-PE Mouse Flow	cytometry 1:10 Miltenyi130-095-182
CD90-APC Mouse Flow	cytometry 1:10 Miltenyi130-095-402
CD105-FITC Mouse Flow	cytometry 1:10 Miltenyi130-098-774
OSTEOPONTIN Mouse Immuno-fluorescence 1:100
Vector
VP-O852
OSTEOPONTIN Mouse Immuno-histochemistry 1:50
Vector												
VP-O852
COLLAGEN I	α2 Goat Western	blot 1:200 Santa	Cruzsc8786
OSTEOCALCIN Rat Western	blot 1:500 Takara								M188
β-ACTIN Mouse Western	blot 1:5000 Abcamab3280
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Table 6. List of secondary antibodies.  
List of secondary antibodies used, the host species developed in, dilution used, application 
and product number. 
  
Antibody Host Application Dilution ProductNumber
Anti-mouse	
HRP Horse Western	blot 1:1000
Cell Signaling
7076
Anti-goat	HRP Donkey Western	blot 1:1000 Santa	Cruzsc2020	
Anti-rat	HRP Rabbit Western	blot 1:1000 Abcamab6734
Anti-mouse	
FITC Goat
Immuno-
fluorescence 1:1000
Santa	Cruz
sc2082
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Chapter 3  
Human AFSCs: characterisation and 
engraftment in the oim model 
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3.1 Introduction and objectives 
Cell therapy is a promising option for the treatment of OI. A number of preclinical 
studies have shown the feasibility and efficacy of MSC transplantation in animal 
models of OI, both prenatally and postnatally (Pereira et al., 1998; Guillot et al., 2008; 
Vanleene et al., 2011; Jones et al., 2014a). Moreover, a small number of children with 
severe OI have been transplanted with adult bone marrow MSCs and fetal liver MSCs 
with encouraging results and without major adverse effects or immune rejection of 
the cells (Horwitz et al., 2001; Götherström et al., 2014).  
One of the main hurdles for the further development of cell therapies for OI is the 
identification of a suitable source of MSCs for transplantation. The optimal cell source 
needs to be easily and ethically accessible. Moreover, since large numbers are 
needed for transplantation, the cells need to have a high proliferative capacity. Fetal 
MSCs have been demonstrated to have faster growth kinetics, reach senescence later 
and have a better differentiation capacity than adult MSCs (Guillot et al., 2008). 
However, cells from fetal tissues are isolated from terminated pregnancies and their 
use is limited due to ethical restrictions. In the past decade, AFSCs have been 
investigated as a potential and ethically available cell source for regenerative 
medicine purposes (De Coppi et al., 2007; Ramachandra et al., 2014).  
The aim of this chapter is to characterise second trimester AFSCs and to assess 
engraftment levels and in vivo differentiation, when transplanted into oim neonatal 
mice.  
More specifically, the first objective of this chapter is the characterisation of second 
trimester AFSCs, according to the MSC-defining criteria set by the International 
Society for Cellular Therapy (Dominici et al., 2006). The second objective is to 
compare the osteogenic potential of AFSCs to the one of fetal liver MSCs, which are 
considered the ‘gold standard’ as a cell source for the treatment of OI. The last 
objective is to measure the engraftment levels and in vivo differentiation of AFSCs 
transplanted into oim mice. 
 
  80 
3.2 Results 
3.2.1 Characterisation and in vitro osteogenic potential of human AFSCs  
Human second trimester AFSCs (n=3) showed plastic adherence and grew in a 
monolayer. Cells exhibited the characteristic fibroblast-like spindle-shaped 
morphology that is typical of MSCs (Figure 9). 
 
Figure 9. Morphology of human AFSCs.   
A) Low and B) high magnification phase contrast images showing cell morphology of 
proliferating, undifferentiated AFSCs at passage 8.  Scale bar: 200 µm. 
 
Similar to other human fetal MSCs, human AFSCs are fetal cells that meet the 
minimum MSC-defining criteria defined by the International Society for Cellular 
Therapy (Dominici et al., 2006). Human AFSCs show above 95% co-expression of the 
MSC markers CD73 (ecto-5’-nucleotidase), CD90 (Thy-1) and CD105 (endoglin) 
(Figure 10A) and lack expression of the hematopoietic progenitor/endothelial marker 
CD34 (hematopoietic progenitor cell antigen CD34) and of hematopoietic marker 
CD45 (protein tyrosine phosphatase, receptor type C) (Figure 10B).  
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Figure 10. Human AFSCs express MSC markers. 
Flow cytometry histograms showing AFSC (n=3, representative results shown) expression of 
MSC markers CD73, CD90 and CD105 (A) and lack of expression of endothelial markers CD34 
and hematopoietic marker CD45 (B). Isotype control in blue. 
 
MSCs are multipotent stem cells that are able to undergo adipogenic, chondrogenic 
and osteogenic differentiation (Dominici et al., 2006). Human AFSCs (n=3) cultured in 
adipogenic medium for 2 weeks differentiated into lipid-producing adipocytes. Lipid 
droplets were visualised by Oil Red O staining (Figure 11).  
Human AFSCs (n=4) were able to differentiate into osteoblasts in vitro. A trabecular 
network of bone formed by human AFSCs was visible after 3 weeks of culture in 
osteogenic medium (Figure 12A and C). Alizarin red staining confirmed calcium 
deposition (Figure 12B).   
 
A 
B 
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Figure 11. In vitro adipogenic 
differentiation of human AFSCs. 
Oil Red O staining showing lipid droplets 
produced by human AFSCs cultured in 
adipogenic medium for 2 weeks. Scale bar: 
100µm.  
 
 
 
Figure 12. In vitro osteogenic differentiation of human AFSCs. 
A) Unstained trabecular network of human AFSCs cultured in static 2D conditions in 
osteogenic medium for 3 weeks and visualised by scanning. B) Alizarin Red staining showing 
calcium deposits. Scale bar: 2mm. C) Trabecular network visualised by phase contrast 
microscopy. Scale bar: 300µm  
A B 
C 
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3.2.2 Comparison of osteogenic potential of human AFSCs and fetal liver MSCs 
Human AFSCs and human fetal liver MSCs derived from first trimester pregnancies 
(n=1) were cultured in monolayers in DMEM supplemented with 10% FBS. Human 
fetal liver MSCs were previously characterised by (Guillot et al., 2008). Both cell 
populations were plastic-adherent, showed similar fibroblast-like morphology and 
grew in a monolayer (Figure 13).  
Figure 13. Morphology of human AFSCs and fetal liver MSCs. 
Phase contrast image showing cell morphology of first trimester human AFSCs (A) and human 
fetal liver MSCs (B). Scale bar: 200µm. 
 
The growth rate of AFSCs and fetal liver MSCs was assessed by seeding cells at low 
density (5,000 cells/cm2) and charting their growth over a period of 18 days, 
throughout which the cell number was counted and the same number of cells re-
seeded every 3 days. AFSCs grew approximately twice as fast as fetal liver MSCs. The 
population doubling time was 63.0 ± 4.5 hours for AFSCs and 127.6 ± 12.8 hours for 
fetal liver MSCs, P<0.01 (Figure 14A). Cumulative population doublings over the 18 
days were 7.2 ± 0.2 for hAFSCs and 3.8 ± 0.3 for fetal liver MSCs, P<0.001 (Figure 14B). 
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Figure 14. Human AFSCs grow faster than human fetal liver MSCs. 
A) Population doubling time of human AFSCs and fetal liver MSCs. B) Cumulative population 
doublings of human AFSCs and fetal liver MSCs measured for a period of 18 days. (n=1 run in 
triplicate) Data represent mean ± SEM * P<0.05, ** P<0.01 and *** P<0.001 (Student’s t-test)  
 
The in vitro osteogenic potential of human AFSCs and fetal liver MSCs was assessed 
by culturing cells for 20 days in osteogenic permissive medium containing ascorbic 
acid, β-glycerophosphate and dexamethasone. Human AFSCs showed extensive bone 
formation characterised by mineralised trabecular structures, whilst human fetal liver 
MSCs did not show osteogenic differentiation (Figure 15A).  
Alizarin red staining confirmed calcium deposition in human AFSCs and lack of 
mineral deposition in human fetal liver MSCs (Figure 15B).  
The in vitro osteogenic differentiation potential of human AFSCs and fetal liver MSCs 
was also investigated by quantitative real-time PCR for expression of the osteogenic 
markers osteopontin and osteocalcin, after 10 days of differentiation. There was no 
significant difference in the expression of the two osteogenic genes, although 
osteocalcin, a marker of late osteogenic differentiation, was expressed at slightly 
higher levels in AFSCs than in fetal liver MSCs (Figure 15C). 
 
A B 
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Figure 15. Human AFSCs have greater in vitro osteogenic potential than fetal liver MSCs. 
A) Unstained osteogenic cultures of human AFSCs and fetal liver MSCs at day 20 in osteogenic 
medium. B) Alizarin Red staining showing calcium deposition. Scale bar: 2 mm. C) 
Quantitative real time PCR of expression of osteogenic genes after 10 days of differentiation. 
(n=1 run in triplicate) Data represent mean ± SEM. Student’s t test. 
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3.2.3 Human AFSCs engraft into the bones of oim mice and differentiate into 
osteoblasts in vivo 
Human AFSCs were transplanted intraperitoneally into neonatal oim mice (106 cells 
per mouse, transplantation and dissection performed by Dr. Jemma Jones). After 8 
weeks, bones were harvested and engraftment was assessed by quantitative real 
time PCR. The level of engraftment was measured by the ratio of the expression of 
human β-actin over the total amount of human and mouse β-actin, as previously 
described (Guillot et al., 2008a; Jones et al., 2014) (See Materials and methods for 
details). Human donor cells were detected in bones of all of the 20 transplanted mice 
analysed. Transplanted human AFSCs preferentially engrafted into the epiphyses of 
the long bones, which is the site of active bone formation. To a lesser extent, donor 
cells also engrafted into the diaphysis and the bone marrow. Engraftment levels in 
the bone epiphysis were 1.8-fold higher than in the diaphysis (350.0 x 10-5 ± 17.9 vs 
195.2 x 10-5 ± 13.5, P<0.0001) and 1.4-fold higher than in the bone marrow (241.3 x 
10-5 ± 15.1, P<0.0001) (Figure 16).  
 
Figure 16. Human AFSCs transplanted into oim mice engraft into the bones. 
Quantitative real time PCR of donor cell engraftment calculated as the 2-ΔΔCt of human specific 
β-actin normalised to human-mouse non-specific β-actin in the femoral epiphysis, diaphysis 
and bone marrow (n=20). Data represent mean ± SEM **** P<0001 (One-way ANOVA 
followed by Bonferroni post hoc test). 
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Engraftment of human AFSCs was also assessed also in the soft tissues of 10 
transplanted oim mice. Cells were not detected in the brain, thymus and spleen of 
any of the animals analysed. There were low levels of cell engraftment observed in 
the liver (18.7 x 10-5 ± 2.1), lungs (94.7 x 10-5 ± 1.6) and kidneys (29.3 x 10-5 ± 2.9), all 
significantly lower than those detected in the bones (P<0.0001) (Figure 17).  
 
 
 
 
 
 
 
Figure 17. Human AFSCs show low level of multi-organ engraftment in oim mice. 
 Quantitative real time PCR of donor cell engraftment calculated as 2-ΔΔCt of human specific β-
actin normalised to human-mouse non-specific β-actin in brain, thymus, spleen, liver, lungs 
and kidneys (n=10), compared to the epiphyses, from figure 14 (n=20). Data represent mean 
± SEM **** P<0001 (One-way ANOVA followed by Bonferroni post hoc test). 
In vivo osteogenic differentiation of transplanted human AFSCs was assessed in 8-
week old transplanted oim tibiae by immunohistochemistry. Differentiated donor 
cells were visualised using a human-specific anti-osteopontin monoclonal antibody. 
Osteopontin is a non-collagenous protein, secreted by osteoblasts, which contributes 
to the formation of the bone ECM. Human osteopontin, absent in non-transplanted 
oim (Figure 18A and D), was localised mainly in the epiphyseal primary ossification 
zone (below the growth plate) (Figure 18C, E and F) and, to a lesser extent, in the 
cortical region of the tibiae (Figure 18B). The osteogenic differentiation of 
transplanted human AFSCs was evidenced also by the detection of the alpha 2 chain 
of collagen type I (COL1A2) in transplanted bones (Figure 19). Oim mice, due to a 
mutation on the COL1A2 gene do not produce the protein (Chipman et al., 1993).  
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Figure 18. Human AFSCs home to the bones of recipient oim mice and express osteopontin 
in vivo. 
Visualisation of human AFSCs in transplanted oim tibiae with immunofluorescent (A-C) and 
immunohistochemical (D-F) staining for human osteopontin. Donor cells are visualised in the 
tibial cortex (B), sub-epiphyseal zone (C) and ossification zone (E-F). An absence of staining 
was observed in non-transplanted oim tibia (A and D). Scale bars: 100µm. 
 
 
 
Figure 19. Human AFSCs transplanted into oim mice restore the production of COL1A2. 
Western blot of COL1A2 in wild-type (wt), oim and oim transplanted with human AFSCs. β-
actin was used as a loading control. 
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3.3 Discussion 
The expression of MSC markers and the ability to differentiate into cells of 
mesodermal lineages confirmed are consistent with AFSCs being MSCs. Fetal liver 
MSCs have been used as cell source for in utero transplantation in fetuses with severe 
OI (Götherström et al., 2014). However, their isolation is challenging and relies on 
termination of pregnancies, which limits their use due to ethical restrictions. 
Moreover, in a previous study which compared the differentiation potential of a 
number of fetal and adult MSCs, fetal liver MSCs showed a lower osteogenic potential 
when cultured in osteogenic permissive media than other fetal MSCs, including fetal 
blood and fetal bone marrow MSCs (Guillot et al., 2008). Data presented in this 
chapter support the previous study and suggest that AFSCs grow faster and have a 
higher in vitro osteogenic potential than fetal liver MSCs. Although the experiments 
described in this thesis were performed using second trimester AFSCs, the 
comparison with fetal liver MSCs was carried out using first trimester AFSCs, in order 
to match the gestational age of the fetal liver MSCs available in the laboratory cell 
bank. Due to a limited number of first trimester samples, the experiments were 
performed on only one sample per cell type and therefore more samples would be 
needed to draw any conclusions.  
When second trimester AFSCs were transplanted into oim mice, cells were detected 
after 8 weeks in all the 20 mice analysed. Levels of engraftment and distribution of 
transplanted cells were in accordance with previous studies using the same method 
of quantification. An estimate of the percentage of engraftment, measured with a 
standard curve generated previously in the laboratory, suggest a low level of 
engraftment, around 7%, in line with previous studies (Guillot et al., 2008a; Vanleene 
et al., 2011; Jones et al., 2014). Transplanted cells preferentially migrated to the 
bones, supporting the hypothesis that MSCs home to sites of fracture (Granero-Moltó 
et al., 2009). Moreover, AFSCs underwent in vivo osteogenic differentiation and 
restored the production of the missing collagen chain, again in agreement with 
previous studies, thus supporting the idea of the amniotic fluid as a promising source 
of stem cells for cell therapy in OI (Guillot et al., 2008a; Jones et al., 2014).  
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Chapter 4  
Therapeutic effects of AFSCs on oim 
bones 
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4.1 Introduction and objectives 
OI is characterised by generalised osteopenia, caused by the inability of osteoblasts 
to fully differentiate and produce normal collagen. Moreover, excessive bone 
resorption, not balanced by new bone formation, leads to loss of bone mass (Forlino 
et al., 2011). Histomorphometric analyses of iliac bone biopsies from children with OI 
revealed that bone loss was primarily caused by a 15-27% reduction in the thickness 
of trabeculae and a 41-57% reduction in the number of trabeculae, compared to age 
matched healthy children (Rauch et al., 2000). Bone loss leads to frequent long bone 
fractures, which strongly impact upon the quality of life of OI patients (Trejo and 
Rauch, 2016). The long bone fracture rate and micro-structural organisation of bones 
are therefore two of the most important parameters to be assessed for the 
evaluation of any therapy for OI.  
Homozygous oim mice resemble the features of severe type III OI, particularly low 
bone mass, skeletal deformities and multiple fractures (Chipman et al., 1993). Oim 
bones are characterised by fewer trabeculae of reduced thickness, decreased cortical 
volume and increased porosity compared to wild-type age-matched mice, thus 
contributing to bone fragility. Moreover, oim bones are less strong and elastic, 
performing worse than controls in biomechanical tests (Bart et al., 2014). 
The aim of the work presented in this chapter is to assess whether transplantation of 
human AFSCs into oim mice ameliorates bone biomechanical properties and bone 
structure.  
The first objective of this chapter is to assess the biomechanical properties of 
transplanted bones, using the three-point bending test. The second objective is the 
investigation of the microstructural properties of the trabecular and cortical portions 
of transplanted tibiae using high–resolution micro computed tomography (micro-CT). 
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4.2 Results 
4.2.1 Transplantation of human AFSCs improves the mechanical properties of oim 
bones 
Eight weeks following the transplantation of human AFSCs, bones were isolated from 
oim mice and assessed for fractures along with their biomechanical properties, by 
other members of the lab. Whilst all the non-transplanted oim mice presented at 
least one long bone fracture, 9/28 transplanted oim mice (32.1%) had long bone 
fractures (Data obtained by Dr. Gemma Jones and Dr. Maximilien Vanleene, Figure 
20). The fracture incidence in humeri was reduced from 34.6% (18/52 bones) in non-
transplanted oim to 10.7% (6/56 bones) in transplanted oim, which corresponds to a 
69% reduction in fracture rate. An 89% reduction was observed in femoral fracture 
incidence, from 32.7% (17/52) in non-transplanted oim to 3.6% (2/56) in transplanted 
mice; and a 79.2% decrease in tibia fractures, from 17.3% (9/52) in non-transplanted 
oim to 3.6% (2/56) in transplanted mice. The overall fracture incidence in long bones, 
calculated as the number of fractured tibia, femur, and humeri over the total number 
of these bones, decreased from 28.2% (44/156 total bones) in non-transplanted oim 
to 5.9% (10/168 total bones) in transplanted oim, which corresponds to an overall 
79% decrease (Data obtained by Dr. Gemma Jones, not shown).  
 
 
 
 
 
Figure 20. Transplantation of human AFSCs decreases the fracture rate in oim bones.  
Graph showing the percentage of mice with any long bone fractures. N=26 for non-
transplanted oim and n=28 for transplanted oim. *** P<0.0001 (Chi-squared test with Yates 
correction). Data obtained by Dr. Gemma Jones. 
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Three-point bending test was used to assess the biomechanical properties of wild-
type, oim and AFSC-transplanted oim femurs (Data obtained by Dr. Maximilien 
Vanleene). All parameters of bone strength were significantly higher in wild-type than 
in oim femurs (P<0.0001 for each parameter). Human AFSC-transplanted femurs 
showed a significant increase in all the parameters considered, indicating that stem 
cell injection increased their overall quality. The total work required to fracture the 
bone was significantly increased by 141% in transplanted oim (Figure 21A), whilst the 
bending stiffness was increased by 64% (Figure 21B). Moreover, the ultimate load 
was increased by 61.8%; and the yield load was increased by 72%. Similarly, work 
from yield to fracture also significantly increased by 3-fold in transplanted oim bones, 
reflecting an increase in bone plasticity following stem cell injection. The ratio of 
plastic on total work to fracture (Rp/tW), which describes bone behaviour by 
assessing plastic deformation, was significantly (2.7-fold) higher in transplanted oim 
bones compared to non-transplanted ones, confirming that transplanted bones were 
stronger and less brittle (Data not shown, obtained by Dr. Maximilien Vanleene).  
 
 
Figure 21. Injection of human AFSCs increased oim bone strength and quality. 
Dot-plot of three-point bending load-deflection curves until fracture. A) total work to fracture, 
B) bending stiffness. Data represent mean ± SEM * P<0.05, **** P<0.0001 (One-way ANOVA 
followed by Bonferroni post hoc test). Data obtained by Dr. Maximilien Vanleene. 
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The improvement of bone mechanical properties correlated with the numbers of 
donor cells engrafted. Human AFSC engraftment in the epiphysis of the oim femur 
was positively correlated with total work to fracture (R2= 0.68, P<0.05, Figure 22A) 
and with bending stiffness (R2= 0.80, P<0.0001, Figure 22B).  
 
 
 
 
 
 
 
Figure 22. Improvement of oim bone mechanical properties positively correlates with 
transplanted cell engraftment. 
Correlation of transplanted human AFSC engraftment against total work to fracture (A, n=7) 
and bending stiffness (B n=13) in femurs. Linear line of best fit given. P<0.05 (A) and P<0001 
(B). 
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4.2.2 Transplantation of human AFSCs improves oim bone structure 
Haematoxylin and eosin staining of histological samples from wild-type, oim and 
transplanted oim mice tibiae (n=3 per group), highlighted some structural differences 
in the epiphyses of wild-type and oim bones. Particularly evident was the absence in 
oim tibiae of the numerous and thick trabeculae, characterised by mineralised tissue, 
present in wild-type mice tibiae (Figure 23A arrows and B). On the other hand, there 
were no visible differences in the organisation of the growth plate. The structure of 
the tissue did not change following transplantation (Figure 23C).  
 
 
 
 
 
 
 
 
 
 
 
Figure 23. H&E staining of the growth plate of transplanted oim tibiae. 
Haematoxylin and eosin staining shows the structure of bone tissue in the growth plate area 
of A) wild type, B) oim and C) transplanted oim tibiae. Arrow indicates mineralised trabecular 
bone. Scale bar: 500µm. 
To better assess the microarchitecture of trabecular and cortical bone, samples were 
analysed by micro-computed tomography (micro-CT) (Scans were performed by Dr. 
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Michelangelo Corcelli). Representative scans of wild-type (n=6), oim (n=6) and 
transplanted oim tibiae (n=9) are shown (Figure 24).  
 
Figure 24. Micro-CT analysis of transplanted oim tibiae. 
Representative micro-CT images of trabecular bone cross-sections at 0.25 mm below the tibial 
growth plate, obtained for 8-week-old wild-type, non-transplanted oim and transplanted oim. 
Scale bar: 300µm 
Trabecular thickness and trabecular number were significantly higher in wild-type 
than in oim bones (0.038 ± 0.001 mm vs. 0.030 ± 0.001 mm, P<0.01; and 3.18 ± 0.15 
mm-1 vs. 1.27 ± 0.19 mm-1, P<0.001, respectively) and were not improved by 
transplantation (0.031 ± 0.001 mm and 1.670 ± 0.22mm-1, respectively) (Figure 25A 
and B). Similarly, trabecular separation, which resulted lower in wild-type than in oim 
tibiae (0.17 ± 0.01 mm vs. 0.256 ± 0.019 mm, P<0.01), was unchanged in transplanted 
oim (0.29 ± 0.03 mm) (Figure 25C). Bone volume/total volume, which was 
significantly higher in wild-type than in oim bones (12.25 ± 0.63% vs. 3.94 ± 0.67%, 
P<0.0001), was slightly increased in transplanted oim (5.22 ± 0.67%) albeit not to a 
significant degree (Figure 25D). Trabecular bone pattern factor, which is a unit of 
measure of trabecular connectivity (Hahn et al., 1992) was significantly lower in wild-
type than in non-transplanted oim mice (27.34 ± 0.94 vs 52.80 ± 2.60, P<0.0001), 
indicating a better architectural trabecular organisation in wild-type mice. The 
trabecular pattern factor was significantly lowered by 19% in transplanted oim mice 
tibiae (42.79 ± 2.88, P<0.05), indicating that stem cell transplantation did not increase 
the production of bone tissue, but rather improved the orientation and connectivity 
of trabeculae (Figure 25E).  
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Figure 25. AFSC transplantation improves trabecular connectivity in oim mice without 
increasing bone volume. 
 Dot plot of micro-CT trabecular morphological parameters, in wild-type (n=6), non-
transplanted oim (n=6) and transplanted oim (n=9) mice: Trabecular thickness (A), Trabecular 
number (B), Trabecular separation (C), Bone volume/total volume (D), Trabecular pattern 
factor (E). Data represent mean ± SEM * P<0.05, *** P<0.001, **** P<0.0001 (One-way 
ANOVA followed by Bonferroni post hoc test). 
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Following calibration with phantoms of known calcium hydroxyapatite (CaHA) 
content, bone mineral density (BMD) and tissue mineral density (TMD) were 
measured in wild-type, oim and transplanted oim tibiae. Both BMD and TMD indicate 
the volumetric density of CaHA in a biological tissue in g/cm3. BMD relates to the 
amount of bone in a mixture of hard and soft tissue and is used to assess mineral 
density in trabecular tissue. TMD, on the other hand, is used to measure mineral 
density in cortical bone and refers to the material density of the bone, without taking 
into account any soft tissue (Bouxsein et al., 2010). BMD was measured in the 
trabecular portion of the tibiae. Wild-type bones had a higher BMD than oim ones 
(0.13 ± 0.01 g/cm3 vs 0.03 ± 0.01 g/cm3, P<0.0001) and this parameter was not 
significantly altered following transplantation with human AFSCs (0.06 ± 0.01 g/cm3) 
(Figure 26A). TMD was measured in the cortical part of the tibiae. Wild-type and oim 
tibiae did not differ in TMD (1.02 ± 0.04 g/cm3 vs 1.02 ± 0.01 g/cm3), however 
transplantation significantly increased the mineral content in the cortex of the bone 
(1.10 ± 0.01 g/cm3, P<0.01) (Figure 26B).  
 
 
Figure 26. AFSC transplantation increased the cortical mineral content of oim tibiae. 
Dot-plot of mineral density measures of wild-type (n=6), oim (n=6) and AFSC-transplanted oim 
tibiae (n=9). A) Bone mineral density measured in the trabecular region. B) Tissue mineral 
density measured in the cortical region. Data represent mean ± SEM ** P<0.01, **** 
P<0.0001 (One-way ANOVA followed by Bonferroni post hoc test). 
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Figure 27. AFSC transplantation did not improve cortical thickness and bone porosity in 
oim tibiae. 
A) Representative micro-CT images of cortical bone cross-sections at 1.75 mm below the 
growth plate, obtained for 8-week-old wild-type, oim and AFSC-transplanted oim. Dot plot of 
micro-CT cortical morphological parameters, in wild-type (n=6), oim (n=6) and transplanted 
oim (n=9) mice. Cortical thickness measured at 1.75 mm (B), 2.25 mm (C) and 2.75 mm (D) 
below the growth plate. Total cortical porosity of the cortex (E). Data represent mean ± SEM 
* P<0.05, **** P<0.0001 (One-way ANOVA followed by Bonferroni post hoc test). 
A 
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Cortical thickness was significantly decreased in oim compared to wild-type bones 
and transplantation did not cause any change. Additionally, porosity was significantly 
increased in oim compared to wild-type bones and this parameter was not improved 
following transplantation of human AFSCs either. Representative micro-CT sections 
of cortical bone are shown in Figure 27A. Cortical thicknesses measured in the three 
different areas along the length of the tibia were 0.082 ± 0.002 mm, 0.089 ± 0.002 
mm and 0.098 ± 0.003 mm in wild-type, 0.052 ± 0.003 mm, 0.059 ± 0.003 mm and 
0.067 ± 0.003 mm in oim and 0.054 ± 0.002 mm, 0.060 ± 0.002 mm and 0.067 ± 0.003 
mm in transplanted oim bones (Figure 27B-D). Cortical porosity was significantly 
higher in oim compared to wild-type tibiae (1.20 ± 0.16 % vs 0.78 ± 0.07%, P<0.05) 
and remained unchanged after transplantation (1.04 ± 0.13%) (Figure 27E). 
MicroCT was also used to quantify the area of primary ossification, which refers to 
the area below the growth plate where cartilage starts to mineralise. Representative 
images of primary ossification in wild-type (n=6), oim (n=6) and transplanted oim 
(n=9) are shown in Figure 28A. Oim tibiae had a much thicker primary ossification 
area (0.29 ± 0.03 mm vs 0.16 ± 0.01 mm, P<0.001), which decreased significantly 
following transplantation with human AFSCs (0.20 ± 0.01 mm, P<0.05) (Figure 28B). 
Subchondral bone is located below the joint cartilage and plays an important role in 
absorbing stress. Its structural properties were evaluated by micro-CT for wild-type 
(n=6), oim (n=6) and oim transplanted with human AFSCs (n=9). All parameters tested 
were worse in oim compared to wild-type bones and were not changed following 
transplantation. In particular, Bvol/Tvol percentage in wild type was 23.88 ± 1.21% 
vs. 13.21 ± 1.56% in oim, P<0.0001, vs. 15.15 ± 0.52% in transplanted oim (Figure 
29A). Trabecular pattern factor in wild-type was -19.00 ± 2.40 mm-1 vs. 11.05 ± 5.69 
mm-1 in oim (P<0.001) vs. 2.63 ± 1.71 mm-1 in transplanted oim (Figure 29B). Similarly, 
trabecular thickness in wild-type was 0.048 ± 0.001 mm vs. 0.038 ± 0.002 mm in oim 
(P<0.01) vs. 0.039 ± 0.001 mm in transplanted oim (Figure 29C) and trabecular 
number in wild-type was 4.95 ± 0.12 mm-1 vs. 3.40 ± 0.24 mm-1 in oim (P<0.01) vs. 
3.85 ± 0.14 mm-1 following transplantation (Figure 29D). 
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Figure 28. AFSC transplantation decreased immature ossification in oim tibiae. 
A) Representative micro-CT images of primary ossification, obtained for 8-week-old wild-type 
(n=6), non-transplanted oim (n=6) and transplanted oim (n=9). B) Dot plot of thickness of the 
primary ossification area of wild-type, oim and transplanted oim. Data represent mean ± SEM 
* P<0.05, *** P<0.001 (One-way ANOVA followed by Bonferroni pots hoc test). 
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Figure 29. Transplantation of human AFSCs did not affect subchondral bone in oim mice. 
Dot plot of subchondral bone micro-CT morphological parameters, in wild-type (n=6), non-
transplanted oim (n=6) and transplanted oim (n=9) mic tibiae. A) bone volume/total volume, 
B) trabecular pattern factor, C) trabecular thickness and D) trabecular number. Data 
represent mean ± SEM ** P<0.01, *** P<0.001 and **** P<0.0001 (One-way ANOVA followed 
by Bonferroni post hoc test). 
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4.3 Discussion 
Despite the overall low level of AFSC engraftment, transplantation caused a 
substantial decrease in fracture rate and improved bone biomechanical properties. 
Moreover, the increase in bone strength and bending stiffness positively correlated 
with the number of cells engrafted in bones. Other studies have also reported 
significant decreases in the number of fractures despite low levels of cellular 
engraftment, possibly due to the paracrine effect of donor stem cells on resident 
defective cells (Guillot et al., 2008a; Vanleene et al., 2011; Jones et al., 2014).   
In this study, the 79% reduction in long bone fracture rate was not accompanied by 
changes in the total volume of bone tissue, the number or the thickness of the 
trabeculae. The only parameter that was significantly improved following 
transplantation was the trabecular pattern factor, an index of trabecular connectivity. 
This parameter is a widely used index of the relative concavity of trabecular bone 
surface. Surface concavity indicates the presence of connected structures, while 
surface convexity relates to isolated and disconnected structures (Hahn et al., 1992). 
This is in contrast with previous work, carried out in the Guillot lab, showing that 
transplantation of human chorionic stem cells into oim mice increased bone volume 
and led to higher ductility of the bones, whilst bone strength and stiffness remained 
unchanged (Jones et al., 2014). This suggests that cells from the placenta and the 
amniotic fluid improve the OI phenotype by different mechanisms.  
One of the main limitations of this and previous preclinical studies for cell therapy in 
OI is the absence of longer time points. The longest follow-up analysis in a mouse 
model transplanted with stem cells was performed at 12 weeks post-transplantation 
and there are no data available on the long-term effects of transplantation (Guillot et 
al., 2008). Clinical data from OI children transplanted with MSCs demonstrated that 
the beneficial effects of stem cell administration, including boosts in growth and 
reduction of fracture number, were limited to the first few months after treatment 
and repeated transplantations were needed (Horwitz et al., 2002; Götherström et al., 
2014). Longer term investigations will therefore be necessary before cell therapy 
approaches in OI are translated into clinical practice. 
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Chapter 5  
Therapeutic effects of AFSCs on the 
bone cells of oim mice 
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5.1 Introduction and objectives 
Data from this study and others show that MSCs, when transplanted into the oim 
model, are able to home to the bones, possibly due to their attraction to 
inflammatory cytokines, and undergo osteogenic differentiation, depositing normal 
type 1 collagen  (Wang et al., 2006; Guillot et al., 2008a; Li et al., 2010a; Jones et al., 
2014). In addition to this direct contribution to tissue repair, an indirect effect of 
MSCs on resident cells, through the release of paracrine factors, has been 
hypothesised as a mechanism of action in MSC-based therapies (Prockop, 2017). 
MSCs have been shown to release a wide variety of molecules, including growth 
factors and anti-inflammatory cytokines (Doorn et al., 2012).  
The oim model is characterised by frequent bone fractures, which lead to the release 
of pro-inflammatory cytokines and, at the cellular level, by impaired osteoblasts that 
are unable to fully differentiate (Li et al., 2010b). Therefore, the paracrine effect of 
MSCs could explain, at least in part, the significant improvement in disease 
phenotype observed here despite the low level of cell engraftment. 
Moreover, a recent study on a mouse model of recessive OI suggested that excessive 
TGF-β signalling contributes to the pathogenesis of OI. The authors show that the 
defective OI extracellular matrix is unable to retain the inactive form of TGF-β. This 
leads to the abnormal release of the active form, which has been linked to the 
inhibition of osteoblast differentiation (Alliston et al., 2001; Grafe et al., 2014). 
The aim of this chapter is to assess whether transplanted human AFSCs exert their in 
vivo therapeutic effect via a paracrine mechanism.  
The objective of this chapter is the investigation of the in vivo effects of AFSC 
transplantation on oim resident cells, in terms of gene expression. In order to 
investigate the indirect contribution of donor cells, the expression of oim endogenous 
genes involved in skeletal development, bone turnover, osteoblast differentiation, 
inflammation and TGF-β signalling was assessed in transplanted and non-
transplanted oim bones. 
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5.2 Results 
5.2.1 Transplantation of human AFSCs stimulates endogenous osteogenesis in oim 
mice  
In order to investigate the potential paracrine effect of transplanted human AFSCs on 
resident oim osteoblasts, the expression levels of a panel of endogenous mouse 
genes involved in skeletal development were assessed. A mouse-specific gene array 
was used to evaluate the endogenous expression of the gene panel in the femoral 
epiphysis of oim (n=2) and AFSC-transplanted oim (n=2). An overall upregulation of 
the genes involved in skeletal development, bone mineral metabolism, and ECM 
development was observed, whilst no changes were found in the expression of genes 
involved in the regulation of the cell cycle. In particular, genes involved in bone 
mineralisation such as ameloblastin (Ambn) and enamelin (Enam) (Stakkestad et al., 
2017), were upregulated by 3.5 and 3.1-fold respectively. Transplanted oim mice also 
showed an 8.4 fold increase in the expression of SRY-Box 9 (Sox9), a gene involved in 
mesenchymal condensation and cartilage development (Bi et al., 2006; Zhang et al., 
2017). Dentin matrix protein 1 (Dmp1) and Phex, genes expressed by osteoblasts 
which govern the mineralisation of bone via the FGFR pathway (Martin et al., 2011; 
Ichikawa et al., 2017), showed an up-regulation of 10.6 and 4.6-fold respectively. 
Human AFSC transplantation also stimulated the production of collagen type I by 
resident cells, as shown by the 5.5-fold upregulation.  
The gene array also revealed an upregulation of bone morphogenetic proteins (Bmp) 
2, 4, 5 and 6 (2.3, 3.4, 3.5 and 4.7-fold respectively) (Figure 30A). BMP proteins are 
part of the TGF-β superfamily and are key regulators of bone and cartilage 
development (Grimaud et al., 2002; Majidinia and Yousefi, 2017). BMP2 in particular 
acts as an osteoinductive agent and is involved in the commitment to the osteogenic 
lineage (Urist, 1965; Nguyen et al., 2017). AFSC-transplantation also caused an 
upregulation of genes involved in ECM formation. Serpinh1, a gene responsible for 
collagen type I folding (Masago et al., 2012), showed a 8.8-fold increase in expression. 
Finally, cartilage oligomeric matrix protein (Comp), gene involved in chondrocyte 
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organisation (Haleem-Smith et al., 2012), was upregulated by 3.9-fold (Figure 30B). 
Transplantation did not influence the expression of endogenous genes involved in 
cell proliferation (Figure 30C). 
 
Figure 30. AFSC transplantation upregulated endogenous genes of oim mice involved in 
osteogenesis. 
Graph to show fold changes in the expression of genes involved in A) osteogenesis, B) ECM 
formation and C) cell proliferation in the femoral epiphysis of human AFSC-transplanted oim 
compared to non-transplanted oim mice (n=2) (2-fold change selected as threshold cut-off). 
A 
B 
C 
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Importantly, an upregulation of genes involved in osteoblast differentiation and 
maturation was observed. Runt-related transcription factor 2 (Runx2), which plays a 
pivotal role in the differentiation of MSCs into osteoblasts (Ducy et al., 1997; Komori 
et al., 1997), showed a 11.3-fold increase in expression following transplantation. 
Moreover, osteocalcin (Bglap), a marker of mature osteoblasts (Ryoo et al., 1997), 
increased its expression of 3-fold (Figure 31).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. AFSC transplantation upregulated endogenous genes of oim mice involved in 
osteoblast differentiation. 
Graph to show fold changes in the expression of genes involved in osteoblast development 
and differentiation in the femoral epiphysis of human AFSC-transplanted oim, compared to 
non-transplanted oim mice (n=2) (2-fold change selected as threshold cut-off). 
 
Gene array analyses also showed that transplantation with human AFSCs decreased 
the expression of genes involved in osteoclast activity. RANK ligand (Tnfsf11, RANKL), 
is produced by pre-osteoblasts and, by binding to its receptor RANK (Tnfrsf11a) on 
osteoclasts, stimulates osteoclast differentiation. OPG (Tnfrsf11b, Osteoprotegerin) 
is instead a decoy receptor for RANKL, produced by differentiated osteoblasts. A high 
RANKL/OPG ratio is therefore present in actively resorbing bones, whereas a low ratio 
indicates that the bone turnover status is shifted toward bone formation 
(Teitelbaum, 2000). 
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RANKL and OPG expression was further assessed by quantitative real-time PCR in oim 
(n=7) and transplanted oim (n=12). RANKL was significantly down-regulated following 
transplantation (P<0.01) (Figure 32A). OPG was slightly up-regulated following 
transplantation, albeit not statistically significant. (Figure 32B).  
 
 
Figure 32. AFSC transplantation lowered the RANKL expression in oim mice. 
Quantitative real time PCR of expression of A) RANK ligand and B) Osteoprotegerin in oim 
(n=7) and human AFSC-transplanted oim (n=12). Data represent mean ± SEM ** P<0.01 
(Student’s t-test).  
 
Osteocalcin expression in wild-type (n=2), oim (n=5) and transplanted oim (n=8) 
femurs was assessed at the protein level by western blot analysis. Oim mice had 
significantly lower levels of osteocalcin compared to wild-type age matched controls 
(Bglap/Actin ratio: 11.76 ± 0.73 in wild-type vs 4.96 ± 1.17 in oim P<0.05). Following 
transplantation, levels of osteocalcin appear to be increased, although not reaching 
significance, due to the high variability between animals (9.51 ± 2.10) (Figure 33). 
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Figure 33. AFSC transplantation increased osteocalcin levels in oim mice. 
A) Western blot analysis of osteocalcin in wild-type (n=2), oim (n=5) and human AFSC-
transplanted oim (n=8) femurs. B) Quantification of western blot after normalisation to β-
actin. Data represent mean ± SEM * P<0.05 (One-way ANOVA followed by Bonferroni post 
hoc test). 
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5.2.2 Transplantation of human AFSCs does not affect the inflammatory status of 
oim bones but downregulates TGF-β signalling 
 
The expression of endogenous genes involved in inflammation was assessed in oim 
(n=7) and transplanted oim (n=12) femurs. Expression levels of TNFα (Figure 34A) and 
NFκB (Figure 34B) did not differ significantly in transplanted oim compared to oim.  
 
Figure 34. AFSC transplantation did not affect endogenous expression of oim mice genes 
involved in inflammation. 
Quantitative real time PCR of expression of A) TNFα and B) NFκB in oim (n=7) and human 
AFSC-transplanted oim (n=12). Data represent mean ± SEM (Student’s t-test). 
 
Increased TGF-β signalling, due to excessive levels of active TGF-β being released 
from the abnormal OI ECM, has recently been linked to the pathogenesis of OI in 
mouse models (Grafe et al., 2014b). In order to investigate the status of TGF-β 
signalling following transplantation, the expression of endogenous plasminogen 
activator inhibitor-1 (Serpine1) and cyclin-dependent kinase inhibitor 1a (Cdkn1a), 
two known TGF-β targets, was assessed by quantitative RT-PCR. Transplantation with 
human AFSCs significantly decreased the expression of Serpine1 (P<0.01) (Figure 
35A).  
The expression of Cdkn1a was slightly reduced in transplanted oim compared to non-
transplanted oim mice, albeit not statistically significant (Figure 35B).  
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Figure 35. Transplantation of human AFSCs decreased TGF-β signalling in oim mice. 
Quantitative real time PCR of expression of TGF-β targets A) Serpine1 and B) Cdkn1a in oim 
(n=7) and human AFSC-transplanted oim (n=12). Data represent mean ± SEM ** P<0.01 
(Student’s t-test). 
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5.3 Discussion 
Data from this study, as well as others, indicate that transplantation of human MSCs 
improves the phenotype of oim mice, partly due to the cell replacement paradigm, in 
which cells differentiate in vivo and replace damaged cells. Nevertheless, the low 
level of engraftment, together with the lack of increase in bone volume following 
transplantation and the up-regulation of endogenous genes involved in bone 
development, suggest that other mechanisms might be involved (Jones et al., 2014). 
Results presented in this chapter, although not conclusive due to the small number 
of samples used for the gene arrays (n=2), are consistent with the paracrine effect 
theory. This theory hypothesises that transplanted cells do not exert their beneficial 
function by directly contributing to the regeneration of the injured tissue, 
differentiating and replacing damaged cells, but rather by secreting soluble factors 
that modulate resident cells (Prockop, 2017). Osteoblasts in the oim model, as well 
as in the Brtl IV model, are unable to fully differentiate and express lower levels of 
osteogenic genes, including Runx2 and type I collagen (Li et al., 2010b; Gioia et al., 
2012). Endogenous gene expression analyses suggest that AFSC transplantation 
promotes the differentiation of oim osteoblasts, possibly by a paracrine effect. 
Moreover, transplanted mice showed a lower expression of RANKL in bones, 
compared to non-transplanted oim mice. This suggests that transplantation 
decreased osteoclastogenesis and led to lower rates of bone turnover. On the other 
hand, the inflammatory status of bones before and after transplantation did not 
change, as shown by the expression of inflammatory genes TNFα and NFκB.  
From these data, a hypothesis for the mechanism of action of transplanted AFSCs has 
been developed and will be the focus of future work in the group (Figure 36). At a 
cellular level, OI in the oim model is manifested through the inability of pre-
osteoblasts to produce the α2 chain of collagen type I, leading to the formation of 
homotrimeric collagen molecules and of a disorganised extracellular matrix. On the 
other hand, oim osteoblasts fail to fully differentiate and remain at a pre-osteoblast 
stage, which has been reported to promote osteoclastogenesis, thus unbalancing 
bone turnover (Martin et al., 2011b; Gioia et al., 2012). More recently, a study 
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showed that an up-regulated TGF-β signalling is present in OI, due to the excessive 
release of TGF-β from the ECM, and further contributes to the inhibition of osteoblast 
differentiation (Grafe et al., 2014).   
Thus, transplantation of human AFSCs may improve the disease phenotype by two 
mechanisms. Firstly, AFSCs differentiate into osteoblasts in vivo and produce the 
missing Col1α2 chain, thus normalising the defective ECM and restoring TGF-β 
sequestration. Moreover, AFSCs may produce trophic factors that stimulate the 
differentiation of osteoblasts. Moreover, mosaic carriers that have a small number of 
healthy osteoblasts producing the correct collagen chains show little or no symptoms, 
suggesting that a chimeric matrix, even with little engraftment, can have therapeutic 
effects (Cabral and Marini, 2004).    
 
Figure 36. Model of mechanism of action of AFSCs in the oim model. 
Oim osteoblasts (blue) produce abnormal collagen type 1 (orange). The defective ECM 
releases excessive levels of TGF-β which inhibits osteoblast differentiation. Pre-osteoblasts 
promote osteoclastogenesis by the release of RANKL (pink). Transplanted AFSC normalise the 
ECM and restoring TGF-β sequestration. On the other hand, paracrine factors produced by 
AFSCs may promote the differentiation of resident oim osteoblasts. 
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Chapter 6  
In vitro investigation of the mechanism 
of action of AFSCs on oim osteoblasts 
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6.1 Introduction and objectives 
In vivo mechanisms that lead to therapeutic benefits in the oim model, following 
transplantation of MSCs, are complex and difficult to study. Donor cells may act in 
different ways, both direct and indirect, and many signalling pathways are thought to 
be involved. In order to better understand the impact of MSCs on resident cells, in 
vitro modelling can be useful, since it allows to isolate events in a controlled 
environment, without the influence of other cell types present in the in vivo setting. 
Moreover, in vitro modelling and co-cultures between relevant cell types have been 
essential in the elucidation of the aetiology of diseases, including OI (Martin et al., 
2011; Gioia et al., 2012).  
The main aim of this chapter is to investigate in vitro the effect of AFSCs on resident 
osteoblasts, in order to better understand the mechanism of action of donor cells. 
The second aim is to establish a protocol for the isolation and differentiation of 
human fetal osteoblasts to be used to model bone formation in vitro. 
The first objective of this chapter is to recapitulate in vitro the effects of human AFSCs 
seen on osteoblasts in vivo. The effect of AFSC-conditioned medium was investigated, 
with AFSCs either in their naïve state or following pre-conditioning with inflammatory 
factors, in order to better mimic the inflammatory environment of OI bones.    
Protocols have been developed for the isolation and differentiation of murine 
osteoblasts, which can be obtained in large numbers and are able to form bone 
efficiently when cultured in osteogenic permissive medium (Orriss et al., 2012). 
Murine osteoblasts, however, have a limited proliferation capacity and are unable to 
differentiate following repeated passaging or freezing.  
There have been a number of attempts to isolate human osteoblasts, both from adult 
and fetal tissues. Adult-derived osteoblasts can be obtained from hip-replacement 
surgical waste, however they are usually derived from older patients and have low 
growth and differentiation ability (D'Ippolito et al., 1999; Gallagher, 2003). More 
recently, fetal tissues have been investigated as a better alternative for the isolation 
of MSCs and pre-osteoblasts (Gothard et al., 2015).  
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The second objective of this chapter is the optimisation of an enzymatic digestion 
protocol for the efficient isolation and differentiation of human fetal osteoblasts, 
derived from calvarial bone tissue obtained from terminated pregnancies.    
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6.2 Results 
6.2.1 Co-culture of human AFSCs and oim osteoblasts 
In order to recapitulate in vitro the effect of human AFSCs on oim osteoblasts, calvaria 
from oim 7-day-old pups were dissected and osteoblasts were isolated. Two different 
methods were used: explant culture and enzymatic digestion with trypsin and 
collagenase, as described in (Orriss et al., 2012). Oim osteoblasts derived by the 
digestion protocol were obtained in higher numbers and faster than by explant 
outgrowth and were therefore used for the co-culture experiments (Figure 37). 
 
 
 
 
 
 
 
 
Figure 37. Isolation of osteoblasts from calvaria of 7-day-old oim mice. 
Oim osteoblasts isolated by A) culturing bone chips explants and B) trypsin-collagenase 
digestion, after 6 days in culture with αMEM. Scale bar: 200 µm. 
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A 
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Oim osteoblasts were cultured for two weeks in osteogenic medium supplemented 
with conditioned medium derived from human second trimester AFSCs (n=3) in a 1:1 
ratio. At the end of the experiment, oim osteoblasts were collected and RNA was 
extracted, to assess the expression of osteogenic markers. Oim osteoblasts cultured 
in osteogenic medium, supplemented with proliferative medium in a 1:1 ratio, were 
used as control (n=3). The gene expression (2-ΔΔCt) of Runx2, Alp1 (alkaline 
phosphatase) and Bglap (osteocalcin) was dramatically decreased in oim osteoblasts 
cultured with AFSC-conditioned medium, compared to controls (Figure 38). This 
reduction was possibly due to the exhaustion of the conditioned medium by human 
AFSCs.   
 
 
Figure 38. AFSC-conditioned medium decreases the expression of osteogenic markers in 
oim osteoblasts in vitro. 
Quantitative real time PCR of expression of A) Runx2, B) Alp1 and C) Bglap in oim osteoblasts 
cultured for 2 weeks in osteogenic αMEM supplemented with human AFSC-conditioned 
medium (50%) (n=3), compared to oim osteoblasts cultured in non-supplemented osteogenic 
medium (n=3). Data represent mean ± SEM * P<0.05 and ** P<0.01 (Student’s t-test). 
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6.2.2 Co-culture of human AFSCs and MG-63 osteoblast-like cells 
Due to the difficulty in maintaining the ability of oim osteoblasts to differentiate after 
repeated passaging, because of senescence, other cell sources were identified to 
further investigate the effect of AFSCs on osteoblasts. The MG-63 human 
osteosarcoma cell line was used as cell source to model the effect of AFSCs in a 
‘human-on-human’ system.  MG-63 cells are osteoblast-like cells, easy to grow 
without reaching senescence, however they are not as physiologically relevant as 
primary cells and exhibit a heterogeneous expression profile of osteogenic markers 
(Pautke et al., 2004). MG-63 cells were cultured for two weeks in osteogenic medium 
supplemented with concentrated (x200) conditioned medium derived from human 
second trimester AFSCs (n=3). MG-63 cells cultured in osteogenic medium were used 
as controls. At the end of the experiment, cells were collected to extract RNA and 
assess the expression of osteogenic markers. The gene expression levels (2-ΔΔCt) of the 
osteogenic markers osteopontin (Opn) and osteocalcin (Bglap) were very low and not 
significantly affected by the AFSC-conditioned medium (Figure 39).   
 
 
Figure 39. Concentrated AFSC-conditioned medium does not affect the expression of 
osteogenic markers in MG-63 osteoblast-like cells. 
Quantitative real time PCR of expression of A) Osteopontin and B) Bglap in MG-63 cells 
cultured for 2 weeks in osteogenic αMEM supplemented with concentrated (x200) human 
AFSC-conditioned medium (n=3), compared to MG-63 cells cultured in non-supplemented 
osteogenic medium (n=3). Data represent mean ± SEM (Student’s t-test). 
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6.2.3 Optimisation of a protocol for the isolation of human fetal osteoblasts from 
calvarial tissue 
In order to achieve a ‘human-on-human’ in vitro model to further investigate the 
effect of AFSCs on osteoblasts, a more physiologically relevant cell source was 
necessary. Calvarial bones were obtained from fetal samples derived from voluntary 
terminations of pregnancy, obtained through a collaboration with the MRC-
Wellcome Trust Human Developmental Biology Resource (HDBR), based at the UCL 
GOS Institute of Child Health. The isolation protocol for osteoblasts used for rodent 
tissues, developed by (Orriss et al., 2012; Taylor et al., 2014) and consisting of 
sequential digestions with 0.25% trypsin-EDTA and 0.2% collagenase type II in Hanks 
balanced salt solution (HBSS), was adapted and optimised for human fetal tissue. A 
detailed protocol can be found in the “Materials and methods” chapter. This work 
was performed with Dr Rachel Sagar. 
Calvarial tissue was dissected, cut in small pieces and subsequently washed 
thoroughly in PBS. In order to optimise the protocol, fragments were then treated 
with different 15-minute trypsin-EDTA incubation cycles, followed by 2 cycles of 1-
hour collagenase incubation. For every cycle, the solution was changed with fresh 
trypsin-EDTA. The highest number of cells retrieved was observed after 1 cycle of 
trypsin-EDTA, although there was no statistical difference in the number of cells 
obtained after 1 to 4 cycles.  Cells obtained were 18.2 x 104 ± 1.8 x 104 after 1 cycle, 
16.0 x 104 ± 1.9 x 104 after 2 cycles, 9.6 x 104 ± 3.6 x 104 after 3 cycles and 13.2 x 104 
± 1.2 x 104 after 4 cycles of trypsin-EDTA (Figure 40A). 
One cycle of trypsin-EDTA was selected and used to then optimise the collagenase 
protocol. Bone fragments were incubated with collagenase solution for 30 minutes, 
1 hour and 2 cycles of 1 hour each. The highest number of cells were isolated after 1 
hour of digestion, however the number of cells did not significantly differ in the three 
conditions. Cells obtained were 7.9 x 104 ± 0.3 x 104 after 30 minutes of collagenase 
incubation, 15.5 x 104 ± 3.6 x 104 after 1 hour and 9 x 104 ± 2.4 x 104 after 2 x 1-hour 
cycles of collagenase digestion (Figure 40B). A protocol consisting of 15 minutes of 
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0.25% trypsin-EDTA followed by 1 hour of 0.2% collagenase type II was selected for 
the isolation of human fetal osteoblasts from the calvaria. 
 
 
Figure 40. Optimisation of a protocol for the isolation of osteoblasts from human fetal 
calvaria. 
Comparison of number of cells isolated from human fetal calvaria (20 pcw) by A) different 
trypsin-EDTA and B) collagenase type II digestion times. Data represent mean ± SEM (One-
way ANOVA followed by Bonferroni post hoc test). 
Following the optimisation of the isolation protocol, different culture conditions were 
tested with the aim of finding the ideal osteogenic differentiation protocol for 
calvaria-derived human fetal osteoblasts. The concentration of β-glycerophosphate 
has been identified as critically important in the osteogenic differentiation of 
osteoblasts. The absence of β-glycerophosphate prevents mineralisation, while 
excessive concentrations cause non-selective widespread deposition of minerals, 
thus impairing cell viability (Orriss et al., 2012). Cells at passage 3 were seeded at high 
density (20,000 cells/cm2) and cultured in DMEM or αMEM supplemented with 0.2 
mM ascorbic acid and 10 nM dexamethasone and 2.5 or 5 mM β-glycerophosphate. 
Human fetal osteoblasts formed dense regularly structured networks after 2 weeks 
when cultured in osteogenic αMEM with 5 mM β-glycerophosphate, to a lesser 
extent in the 2.5 mM condition, and they formed only sparse structures when 
cultured in the DMEM conditions (Figure 41A). Deposition of calcium minerals was 
confirmed by alizarin red staining (Figure 41B). Bone formation was assessed by 
B A 
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quantifying the percentage of mineralised area. When cultured in DMEM, human 
fetal osteoblast bone network covered 10.7 % ± 1.6 in the 2.5 mM and 19.1 % ± 1.0 
in the 5mM β-glycerophosphate condition. When cultured in αMEM, the area 
covered was 38.9 % ± 0.2 in the 2.5 mM and 56.4 % ± 2.0 in the 5mM β-
glycerophosphate condition (Figure 41C).  
Figure 41. Optimisation of culture conditions for the osteogenic differentiation of human 
fetal osteoblasts. 
A) Bone trabecular networks formed by human fetal osteoblasts (20 weeks post conception) 
derived from the calvaria, cultured in different osteogenic conditions for 2 weeks. Scale bar: 
2 mm. B) Alizarin red staining confirming calcium deposition. C) Quantification of the area 
covered by mineralised bone. Data represent mean ± SEM **** P<0.0001 (One-way ANOVA 
followed by Bonferroni post hoc test). 
A 
B 
C 
  124 
Calvaria-derived human fetal osteoblasts, from different gestational ages, cultured in 
αMEM supplemented with 0.2 mM ascorbic acid, 10nM dexamethasone and 5mM β-
glycerophosphate showed dense trabecular bone network formation and magnified 
visualisation through a phase contrast microscope revealed selective mineralisation, 
which left the underlying osteoblast cell layer intact and viable (Figure 42).  
Two photon lifetime imaging (FLIM) analyses were used to confirm the deposition of 
collagen by human fetal osteoblasts cultured in osteogenic medium. Second 
harmonic signal was detected (Figure 43) and two lifetimes of fluorescence decay of 
the autofluorescence were measured: 0.34(+/-0.01) ns and 2.69(+/-0.02) ns. Given 
that the longer lifetime was obtained by 26.6(+/-0.3) % of the signal, the resulting 
mean lifetime was 0.97(+/-0.02) ns. These data are in agreement with those 
corresponding to collagen type I (Shirshin et al., 2017), thus confirming the deposition 
of collagen by human fetal osteoblasts. 
 
 
Figure 42. Human fetal osteoblasts form trabecular bone networks in vitro. 
A) Bone trabecular networks formed by human fetal osteoblasts (13 weeks post conception) 
derived from the calvaria. Unstained osteoblast culture imaged by reflected light scanner. B) 
Phase contrast magnification of trabecular network showing selective mineralisation. Scale 
bar: 2 mm. 
A B 
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Figure 43. Collagen deposited by human fetal osteoblasts visualised by dual-photon 
microscopy. 
Second harmonic generation signal showing collagen type I fibres (arrows) deposited by 
human fetal osteoblasts derived from calvarial tissue (13 weeks post-conception) and 
cultured for 2 weeks in osteogenic medium. Scale bar: 20 µm. In collaboration with Dr Thomas 
Blacker and Prof Michael Duchen, UCL Department of Cell and Developmental Biology. 
 
Human calvaria-derived fetal osteoblasts showed a high expansion potential and 
were able to grow after repeated passages. In order to assess the proliferation rate 
of cells isolated from different gestational ages, osteoblasts derived from samples of 
9, 12 and 16 weeks post-conception (wpc) (n=1 per gestational age) were cultured 
and their growth charted for 5 passages. The growth rate was assessed by seeding 
cells at low density (5,000 cells/cm2) and charting their growth over a period of 18 
days, throughout which the cell number was counted and the same number of cells 
re-seeded every 3 days. Interestingly, cells from older gestational age grew faster 
than cells from younger donors. Specifically, osteoblasts from the 16 wpc sample 
reached 7.3 ± 0.7 population doublings in 18 days, compared to cells from the 12 wpc 
sample which reached 6.7 ± 0.3 population doublings and cells from the 9 wpc sample 
that achieved 4.4 ± 0.2 (P<0.01) However, the cells from 16 weeks sample appeared 
to stop growing around day 15. (Figure 44). 
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Thanks to the samples and the karyotype data kindly provided by the MRC-Wellcome 
Trust Human Developmental Biology Resource (HDBR), a biobank consisting of 24 
human fetal osteoblast lines isolated from the calvaria was built, with sample 
gestational ages ranging from 9 to 21 weeks post-conception (Table 7). 
 
 
 
Figure 44. Human fetal osteoblasts from older gestational ages grow faster than younger 
ones. 
Cumulative population doublings of human fetal osteoblasts isolated from calvaria of 9, 12 
and 16 weeks post conception (wpc), measured for a period of 18 days (n=1 for each 
gestational age, data collected in technical replicates). Data represent mean ± SEM ** P<0.01 
(One-way ANOVA followed by Bonferroni post-hoc test). 
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Table 7. Human fetal osteoblast biobank.  
Human fetal calvarial osteoblasts were isolated from samples of different gestational ages, 
ranging from 9 to 21 weeks post-conception (wpc).   
 
Sample	number Tissue Gestationalage Karyotype
1 Calvaria 9	wpc 46	XX
2 Calvaria 10	wpc 46	XY
3 Calvaria 11	wpc 46	XX
4 Calvaria 12	wpc 46	XX
5 Calvaria 12	wpc 46	XY
6 Calvaria 13	wpc 46	XX
7 Calvaria 13	wpc 46	XY
8 Calvaria 13 wpc 46	XY
9 Calvaria 13	wpc 46	XX
10 Calvaria 13	wpc 46	XY
11 Calvaria 15	wpc 46	XY
12 Calvaria 15	wpc 46	XY
13 Calvaria 15	wpc 46	XX
14 Calvaria 16	wpc 46	XY
15 Calvaria 17	wpc 46	XX
16 Calvaria 17	wpc 46	XX
17 Calvaria 19	wpc 46	XX
18 Calvaria 19	wpc 46	XY
19 Calvaria 20	wpc 46	XX
20 Calvaria 20	wpc 46	XY
21 Calvaria 20	wpc 46	XY
22 Calvaria 20	wpc 46	XY
23 Calvaria 21	wpc 46	XY
24 Calvaria 21	wpc 46	XX
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6.2.4 Co-culture of human AFSCs and human fetal osteoblasts 
The human fetal osteoblasts isolated and banked using the protocol described above 
were then used in a preliminary investigation of the effects of AFSC-conditioned 
medium on osteoblasts, in a ‘human-on-human’ system.  
Human fetal osteoblasts from 13 weeks post conception samples were cultured for 
two weeks in osteogenic medium supplemented with concentrated (x200) 
conditioned medium derived from either naïve or TGF-β- and TNFα- stimulated AFSCs 
(5 ng/ml, 24-hour stimulation). Human fetal osteoblasts cultured in osteogenic 
medium were used as controls. At the end of the experiment, cells were collected to 
extract RNA and assess the expression of osteogenic markers. Interestingly, the level 
of expression of osteopontin (Opn) was significantly reduced after exposure to naïve 
AFSC-conditioned medium, while no changes were seen when AFSCs were stimulated 
with TGF-β and TNFα (Figure 45A). Osteocalcin (Bglap), did not show any changes in 
its expression, which remained very low in all the conditions (Figure 45B). 
 
Figure 45. Concentrated AFSC-conditioned medium does not affect the expression of 
osteogenic markers in human fetal osteblasts. 
Quantitative real time PCR of expression of A) Osteopontin and B) Bglap (osteocalcin) in 
human fetal osteoblasts (13 wpc) cultured for 2 weeks in osteogenic αMEM supplemented 
with concentrated (x200) medium conditioned by naïve AFSCs, TGF- β–stimulated AFSCs and 
TNFα-stimulated AFSCs, compared to human fetal osteoblasts cultured in non-supplemented 
osteogenic αMEM. Data represent mean ± SEM ** P<0.01 (One-way ANOVA followed by 
Bonferroni post hoc test). 
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6.3 Discussion 
These data show that exposing osteoblasts to AFSC-conditioned medium did not 
mimic the therapeutic effects of in vivo stem cell administration in the oim model. 
Moreover, when osteogenic medium was supplemented with conditioned medium 
from naïve AFSCs, the expression of osteopontin in human fetal osteoblasts 
decreased significantly.  
Many reasons could explain this: conditioned medium is not an optimal experimental 
setting, since medium can be exhausted from the conditioning cell type. 
Concentrating conditioned medium and supplementing it to fresh medium is useful 
to avoid exhaustion, however the concentration step is carried out by centrifuging 
medium through filters. Although the smallest pores size was selected to avoid losing 
small cytokines, the filters used had a cut-off of 3 kDa, which cannot ensure the 
retention of small factors. Moreover, optimal in vitro osteogenic differentiation 
protocols involve long-term culture, ranging from 4 weeks for rodent cells to 2 weeks 
for human fetal osteoblasts (Orriss et al., 2012). Long-term culture without passaging 
can cause cell apoptosis and senescence and represents a major risk of 
contamination. More work with different experimental approaches is therefore 
needed to elucidate the paracrine effect of stem cells on osteoblasts in the oim 
model.  
Different mechanisms of actions are most certainly involved and need to be 
investigated to explain the therapeutic effects described in the previous chapters, 
despite the low engraftment of donor cells found. Such mechanisms, that are further 
discussed in the general discussion, include direct contact between AFSCs and target 
resident cells, the effect of chimeric extracellular matrix formed by collagen produced 
in part by AFSCs and the immunomodulatory properties of MSCs.  
The isolation and in vitro differentiation of osteoblasts has been crucial for the study 
of bone development and for the understanding of human bone pathologies. Most in 
vitro studies have been performed with murine osteoblasts, which are easy to isolate 
and maintain but have limited proliferation and differentiation potential and may 
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behave differently than human cells. Human fetal osteoblasts are better alternatives 
to those isolated from adult biopsies, since they have high proliferation and 
differentiation potential (Gothard et al., 2015). The protocol described in this chapter 
is simple and reproducible and yields a high number of osteoblasts, which can be 
useful for the modelling of human bone pathologies and as a platform for drug 
testing.  
  131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7  
General discussion, conclusions and 
future work 
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7.1 Background 
The work presented in this thesis builds on previous studies investigating of the 
potential of cell therapy for OI. Since the first stem cell transplantation in a mouse 
model of OI, in 1998, more than ten preclinical and clinical studies have been 
published, each representing a step forward towards the translation of stem cell 
therapy for OI in clinics (Pereira et al., 1998). 
The first attempts involved the transplantation of murine cells in mouse models of OI 
and focused on proving the feasibility of transplantation, avoiding immune rejection 
and achieving engraftment of donor cells in recipient target tissues (Pereira et al., 
1998; Wang et al., 2006; Li et al., 2007). Those studies paved the way for further 
investigation in a human on human system. At the same time, progress in basic 
research led to the discovery of the immune-privileged properties of MSCs, which 
allow transplanted cells to escape being recognised by host immune cells (Liechty et 
al., 2000). Human stem cells began to be used in preclinical studies of cell therapy for 
OI and the focus became the identification of the most suitable route of 
administration. In preclinical studies different ways were investigated, including 
intra-peritoneal (Jones et al., 2012a; 2014), intra-venous, in utero (Guillot et al., 
2008a; Panaroni et al., 2009; Vanleene et al., 2011) and local administration in bones 
(Li et al., 2010a; Pauley et al., 2014). OI is a collagen type I disorder and it therefore 
involves the entire body, including the skeletal system. Systemic administration 
route, despite achieving lower levels of engraftment in single bones than the intra-
femur injection and causing off-target homing of cells, which especially remain 
trapped in the lungs, allows better distribution of transplanted cells and appears 
therefore to be the best option for cell therapy in OI. 
In the 20 years since the first transplantation of MSCs in children with severe OI, only 
10 patients have received cell therapy for OI, both before and after birth.  Remarkable 
improvements of disease phenotype were observed, although limited in the 6-12 
months after transplantation, thus requiring multiple infusions (Horwitz et al., 1999; 
2002; Le Blanc et al., 2005; Götherström et al., 2014).   
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Clinical translation of cell therapy for OI is now closer than ever, with the first 
registered clinical trial for pre- and post-natal transplantation of allogeneic fetal liver 
MSCs in children with OI underway across Europe at the moment. Results from the 
trial will provide important information on the long-term safety and efficacy of stem 
cell therapy, including the optimal dose and whether it would be better to transplant 
before or after birth (Chitty et al., 2016).  
Despite these impressive scientific, surgical and technological advances, many 
challenges remain to be addressed before stem cell transplantation for OI can be 
routinely implemented in clinics. 
 
7.2 Advantages of using AFSCs for cell therapy 
One of the key issues remains finding the most relevant stem cell type to use. The 
optimal source for cell therapy for OI needs to be accessible without ethical 
restrictions and easy to isolate in large numbers. Moreover, cells need to have a high 
proliferative potential, to be able to sustain extensive expansion in vitro, in the event 
of repeated transplantations, and to facilitate cell survival and proliferation in vivo 
following transplantation. Finally, the optimal cell source needs to meet safety 
criteria, including not being susceptible to attack by the immune system of the host 
and not being able to form tumours after transplantation.  
Fetal MSCs, including those derived from the liver and used clinically in the first in 
utero transplantation in children with severe OI, meet all these criteria (Götherström, 
2016). However, many drawbacks limit the use of fetal liver MSCs: they are obtained 
from terminated pregnancies, are difficult to isolate and are available in small 
numbers, requiring long-term expansion in culture.   
In recent years, more ethical sources of fetal stem cells that meet these criteria have 
been investigated for their potential in the field of regenerative medicine, including 
extraembryonic tissues such as the placenta, the umbilical cord and the amniotic fluid 
(De Coppi et al., 2007; Soncini et al., 2007; Joerger-Messerli et al., 2016; Antoniadou 
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and David, 2016). Human fetal chorionic cells, obtained by either diagnostic chorionic 
sampling or from discarded placentae at birth, have been investigated by Dr. Guillot’s 
lab as a valid alternative for cell therapy in the oim model (Jones et al., 2014a). 
This thesis proposes AFSCs as a cell source for transplantation for the treatment of 
OI. AFSCs have numerous advantageous characteristics that make them promising 
candidates for cell therapy. AFSCs are available throughout pregnancy and can be 
safely isolated during second trimester routine amniocentesis, typically between the 
14th and the 16th week of gestation, during third trimester amnioreduction in the case 
of excessive amniotic fluid or at the end of gestation, during caesarean section. The 
amniotic fluid is therefore a highly accessible source of stem cells, not limited by the 
ethical and legal restrictions that restrain the use of other cell types with potential 
for regenerative medicine, such as embryonic stem cells or fetal cells that rely on 
terminated pregnancies (Loukogeorgakis and De Coppi, 2016). While other extra-
embryonic tissues such as the umbilical cord and the placenta are rich sources of stem 
cells available at birth, AFSCs can be safely isolated also during pregnancy, which 
could allow autologous use for perinatal therapy (Loukogeorgakis and De Coppi, 
2017).   
Other characteristics of AFSCs useful for regenerative medicine purposes are their 
high proliferative potential and broad differentiation capacity, which are however not 
accompanied by the ability to form teratomas in vivo. It has become clear that AFSCs 
show characteristics that are consistent with a broadly multipotent phenotype. Other 
than the three mesodermal lineages, AFSCs are in fact able to differentiate in vitro 
into cells of endothelial, hepatic and neuronal lineages (Roubelakis et al., 2007). In 
contrast to their primitive phenotype, when transplanted in immunocompromised 
mice, AFSCs are unable to form tumours (Moschidou et al., 2012; Loukogeorgakis and 
De Coppi, 2017). 
Due to this advantageous trade-off between proliferation and differentiation 
potential and safety, AFSCs have been investigated in preclinical studies for the 
treatment of a number of pathologies. For example, intravascular injection of rat 
allogeneic AFSCs has been reported to ameliorate heart failure and decrease 
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inflammation in a rat model of pulmonary hypertension (Castellani et al., 2013). 
Therapeutic effects were also obtained following intraperitoneal administration of 
AFSCs in a rat model of necrotizing enterocolitis and in a mouse model of muscular 
dystrophy (Zani et al., 2014; Loukogeorgakis and De Coppi, 2017).  
 
7.3 AFSCs are promising candidates for the treatment of OI 
The study carried out for this thesis represents the first investigation of the 
therapeutic effects of human amniotic fluid stem cells in a mouse model of OI.  
Transplanted AFSCs migrated preferentially to the oim mice bones where they were 
detected, through estimating the levels of human mRNA, eight weeks after injection. 
Histological analyses showed donor cells localised preferentially at sites of active 
bone formation and differentiated in vivo into functional osteoblasts, able to produce 
collagen type I and osteopontin. The relatively low level of engraftment and 
differentiation was in line with previous studies which used both murine and human 
MSCs, that estimated 2-10% engraftment in the oim model. The ability of donor 
AFSCs to contribute to the ECM formation through production of the Col1a2 chain, 
which is missing in the oim model, are consistent with data from other groups using 
different types of MSCs, supporting MSCs as a suitable source of cells for bone 
regenerative medicine of bone disorders (Li et al., 2007; Guillot et al., 2008a; Panaroni 
et al., 2009; Vanleene et al., 2011; Jones et al., 2014).   
AFSC transplantation led to a 79% decrease in the number of fractures, compared to 
non-transplanted oim mice. The ability of human fetal MSCs to reduce fractures in 
the long bones has been reported previously by other studies. Reductions of fracture 
numbers, following transplantation with human fetal blood and placental MSCs, 
ranged between 66% to 84%, which is in line with the findings of this study (Guillot 
et al., 2008a; Vanleene et al., 2011; Jones et al., 2014).  
In the oim model, bone fragility is caused by the simultaneous reduction of bone 
quantity and quality. In order to assess the therapeutic effects of transplantation, 
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analyses of the biomechanical properties of bones and of their structural organisation 
are therefore essential (Chipman et al., 1993; Shapiro et al., 2009). 
Three-point bending analyses showed that transplantation of AFSCs significantly 
increased the biomechanical qualities of oim femurs. In particular the stiffness of 
bones and the work needed to reach the breaking point, which are dramatically 
reduced in oim femurs compared to wild type, were significantly increased after AFSC 
transplantation. These data demonstrate that transplantation of AFSCs increases the 
strength of oim bones. In previous studies using other sources of fetal MSCs, 
transplantation failed to impact long bone strength and stiffness, despite reducing 
fracture rate. Transplantation of fetal blood MSCs led to an 84% reduction of fracture 
numbers, but was not concomitant with changes in the biomechanical properties 
measured in femurs, which remained the same as non-transplanted oim bones 
(Vanleene et al., 2011). Conversely, transplantation with placenta-derived chorionic 
MSCs, which reduced the overall number of long-bone fractures by 66%, caused a 
significant decrease in bone stiffness. The fewer fractures observed following 
transplantation were explained by the increased ductility of bones, possibly because 
of the production of normal collagen that normalises the ECM. This theory was 
supported also by the increase of the maximum deflection before fracture achieved 
in transplanted bones compared to oim bones. Moreover, bone strength remained 
unchanged (Jones et al., 2014). 
In this study, AFSC engraftment levels were positively correlated with increase in 
bone strength and stiffness, suggesting that, at least in part, donor cells directly 
contributed to the improvement of biomechanical properties. Interestingly, placental 
stem cell engraftment level was inversely correlated with bone stiffness, supporting 
the theory that placental cells may ameliorate bone quality by impacting on bone 
ductility rather than stiffness (Jones et al., 2014).  
Micro-structural analyses by micro-CT showed that AFSC transplantation did not have 
any effects on cortical or trabecular bone volume, trabecular number and thickness 
and on total porosity. The only parameter that was significantly improved following 
transplantation was the level of connectivity of the trabeculae, which was estimated 
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by measuring the trabecular pattern factor (Hahn et al., 1992). In this study, the 
increase of bone strength was therefore attributed to the structural organisation of 
trabecular bone. In the case of fetal blood MSC transplantation, bone volume and 
trabecular parameters analysed by micro-CT remained also unchanged despite 
transplantation and the connectivity of trabeculae was not assessed. On the other 
hand, placental cell administration significantly increased tibial bone volume, while 
other trabecular and cortical parameters analysed remain similar to those measured 
in non-transplanted oim bones (Jones et al., 2014).  
Taken together, the data presented in this thesis and the studies carried out by other 
authors suggest that distinct cell sources, although similar in their phenotype and 
characteristics, as is the case of placental and amniotic fluid MSCs, may improve the 
quality of oim bones through very different mechanisms.  
The disease phenotype of OI is in part caused by the impaired maturation of 
osteoblasts, which are unable to fully differentiate, thus leading to increased 
osteoclastogenesis and bone turnover that is shifted towards bone resorption 
(Kalajzic et al., 2002; Martin et al., 2011; Gioia et al., 2012). Recently, osteoblast 
differentiation impairment has been linked to the formation of a disorganised ECM, 
which fails to bind proteoglycans such as decorin that are responsible for the 
sequestration of excessive TGF-β (Grafe et al., 2014b). TGF-β is a strong inhibitor of 
osteoblast and an stimulator of osteoclast activity when present at excessive levels 
(Hattersley and Chambers, 1991; Alliston et al., 2001). 
Transplantation of AFSCs appears to improve the differentiation of oim osteoblasts, 
as shown by the higher expression of genes involved in mouse skeletal development, 
ECM formation and osteoblast activity. These data appear to support the theory that 
increased osteoblast differentiation leads to normalisation of bone remodelling, as 
shown by the decrease in RANKL expression. Gene array data are however not 
conclusive as they only derived from two oim and two transplanted samples. In a 
similar trend, the aforementioned study using placental stem cells showed an 
increase in the expression of genes involved in endochondral and intramembranous 
ossification. In particular, genes involved in hypertrophic chondrocytes 
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differentiation were upregulated following placental chorionic MSC transplantation 
(Jones et al., 2014).  
 
7.4 Mechanism of action 
In the context of developing a stem cells therapy for clinical translation, the 
understanding of the mechanism of action of donor cells and of their fate following 
transplantation is of major importance. Different mechanisms of action can be 
speculated for the explanation of the therapeutic effects observed in the oim model 
following transplantation of AFSCs.  
Engraftment data from this thesis show that AFSCs migrated towards the bones, 
homed there and differentiated into osteoblasts in vivo. Moreover, the improvement 
of bone mechanical properties such as stiffness and total work to fracture positively 
correlated with the number of cells engrafted. These data support the classic theory 
of cell therapy, which postulates that donor cells exert anabolic functions by 
differentiating and replacing defective cells, thus directly contributing to new 
“healthy” bone formation by participating in the generation of chimeric ECM (Spees 
et al., 2016).  This theory builds on studies investigating the phenomenon of naturally 
occurring mosaicism in OI families. OI mosaic carriers show little or no symptoms 
despite having a high proportion of mutated cells, ranging from 40% to 75% of the 
total number of osteoblasts (Dalgleish, 1998; Cabral and Marini, 2004) . Those data 
suggested that defective collagen can be incorporated at a high percentage in the 
ECM without causing major impairment to bone quality and strength and that there 
might be a threshold level of mutant collagen that needs to be reached in order to 
exhibit any OI skeletal symptoms. It is therefore possible that a small number of 
normal cells, able to produce the missing collagen chain, would be enough to 
normalise the quality of the defective matrix observed in the oim model (Gerson, 
1999). 
However, the percentage of engraftment reported by this as well as other studies in 
the oim model does not appear to reach significant levels and durations sufficient to 
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entirely justify the therapeutic effects seen in terms of tissue regeneration. The 
donor-resident chimerism levels of the matrix described in these studies seem 
unlikely to be enough to directly sustain the improvements in bone quality and 
quantity described by these studies. It appears more likely that they are a 
consequence of the migratory and plasticity properties of human fetal MSCs, which 
are able to undergo efficient osteogenic differentiation when homed to a permissive 
environment. This is in line with a growing trend in regenerative medicine that 
postulates that other mechanisms might take part and need to be considered to 
explain the therapeutic effects observed in cell therapy studies, despite low level of 
cell survival and proliferation (Spees et al., 2016).  
Recently, the interest of the stem cell community has shifted towards the 
investigation of the paracrine effects that MSCs exert after being transplanted in a 
damaged or inflamed tissue. This is exemplified by the developmental origin and 
physiological functions of MSCs, which act as stromal support cells to sustain the 
hematopoietic and endothelial niches during development (Sacchetti et al., 2007; 
Crisan et al., 2008). Transcriptome and proteome analyses have demonstrated that 
MSCs produce a wide variety of trophic factors, including anti-inflammatory and 
immune-modulatory cytokines and growth factors, known for promoting cell survival 
and having angiogenetic properties (Silva et al., 2003; Caplan and Dennis, 2006; 
Phinney et al., 2006). It has been reported that conditioned medium derived from 
MSC cultures can act as replacement to cell product administration in preclinical 
studies for heart infarction and acute kidney injury (Bi et al., 2007; Iso et al., 2007; 
Spees et al., 2016). 
An alternative hypothesis to explain the findings presented in this thesis is therefore 
that the anabolic therapeutic effects of AFSC transplantation were mediated by the 
release of growth factors that promoted the osteogenic differentiation of the 
defective oim pre-osteoblasts, rather than by the direct differentiation of AFSCs. This 
theory is supported by the gene array data that show a general upregulation of 
endogenous genes involved in the skeletal development and resident osteoblast 
differentiation. AFSCs are known to produce anti-inflammatory cytokines as well, 
particularly in response to an inflammatory environment such as the one observed in 
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OI due to the damaged tissues and bone fractures. It is therefore possible that the 
therapeutic effects observed are due to the dampening of the inflammation following 
transplantation. The gene expression analyses of two key inflammatory factors TNFα 
and NFKB, however, did not show any decrease in the inflammatory status of AFSC-
transplanted oim compared to non-transplanted mice, suggesting that this pathway 
might not be relevant in this case. It is however important to note that these two 
genes are also known for having other functions and they might not be the most 
relevant markers to assess tissue inflammatory status. Also priming AFSCs with 
inflammatory factors such as TGF-β and TNFα did not lead to any changes in the 
maturation of osteoblasts that were cultured in conditioned medium derived from 
primed-AFSCs cultures. However, these observations were limited to few genes and 
more studies focused on investigating the influence that AFSC-derived products have 
on the inflammatory status in OI are needed to better understand the mechanism of 
action of AFSC-based cell therapies.  
A third possible explanation builds on recent work showing that an excessive TGF-β 
signalling, due to reduced TGF-β sequestration within the defective OI ECM, is 
involved in the pathogenesis of OI (Grafe et al., 2014b). Abnormal collagen 
production and assembly have been shown to prevent proper retention of cytokines 
and proteoglycans within the bone matrix, causing a defective niche for the 
recruitment and differentiation of MSCs into osteoblasts (Kalajzic et al., 2002; Li et 
al., 2010b) It is therefore possible that AFSCs exert their beneficial effects in the oim 
model by contributing to the ECM structure. The production of a chimeric matrix of 
better quality compared to the defective oim ECM could be better able to sequester 
TGF-β and other factors, contributing to the maintenance of their physiological levels. 
Data collected for this thesis seem to support this hypothesis, since decreased gene 
expression levels of the TGF-β target Serpine1 were observed in AFSC-transplanted 
mice compared to non-transplanted ones. Excessive TGF-β signalling has been shown 
to stimulate osteoclast activity and to prevent the differentiation of osteoblast, 
therefore reducing its levels might contribute to the improved oim pre-osteoblast 
differentiation observed following transplantation ( Hattersley and Chambers, 1991; 
Erlebacher and Derynck, 1996; Alliston et al., 2001). 
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7.5 Limitations  
The data described in this thesis represent a preliminary proof of concept for the use 
of amniotic fluid as a source of fetal MSCs for cell therapy in OI. This study however 
has some limitations that need to be addressed before the potential translation of 
AFSC-based therapy into clinical practice. 
The most important limitation of this study is the small number of animals used for 
the in vivo experiments.  The significance of some of the statistical analyses may have 
been limited by the modest number of sample used in this study. In particular, a post 
hoc power analysis on the micro-CT data showed that, based on the mean and effect 
size observed in the study (d=0.79), an n of 42 animals would be required to reach 
statistical power at 0.80 level. 
Another important limitation is the lack of information on the long-term effects of 
AFSC transplantation. In this study, mice were culled and analysed at 8 weeks of age. 
Other preclinical studies using human fetal MSCs involved longer-term analyses, 
however never exceeding the 12 weeks, mainly due to regulations for the use of 
animals on research (Guillot et al., 2008a).  
The only long-term data derived from the few clinical transplantations. Ten children 
affected by severe OI were transplanted with bone marrow MSCs and fetal liver MSCs 
(Horwitz et al., 2002; Le Blanc et al., 2005; Götherström et al., 2014). In all cases some 
therapeutic effects including boost in growth and reduction of fracture rate were 
seen, but was limited to the first months or year after surgery, leading to repeated 
transplantations. Moreover, in most cases the effects of MSC administration were 
confounded by the concomitant pharmacological treatment with bisphosphonates, 
making it difficult to discern the effects of the individual therapies. Longer-term 
studies with proper mutation-matched controls are needed not only to confirm the 
effectiveness of the therapy but also its safety, since the absence of in vivo teratomas 
formation was only investigated for a short time. It is however reassuring that no 
major adverse effects and no tumours were detected in children transplanted with 
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fetal MSCs, which suggests that the primitive phenotype of these cells does not pose 
a threat in terms of safety.   
Another important issue that was not investigated in this study is the fate of those 
transplanted cells that remain trapped into the lungs, following systemic 
transplantation. It has been speculated that those cells, that are retained within the 
vasculature of the lungs due to their relative size, are able to influence distant tissues 
by secreting trophic factors, such as growth factors and cytokines, in the circulation. 
No preclinical studies of cell therapy for OI to date have investigated whether 
transplanted cells proliferate and differentiate in the lungs. It is however reassuring 
that fetal cell transplantation in children was well tolerated and no ectopic tissue 
formation was detected during follow up visits. This suggests that transplanted cells 
that are retained in the lungs do not proliferate excessively but rather undergo 
apoptosis or differentiate.  
Finally, the exact mechanism of action of transplanted cells is also still largely 
unknown. While it is widely accepted that MSCs used in cell therapy may exert, at 
least in part, their therapeutic effects in a paracrine manner, through the secretion 
of numerous trophic factors and cytokines, little is known about the exact 
composition of the MSC “secretome” and especially of the portion which could be 
beneficial to the treatment of OI (Caplan and Dennis, 2006; Dimmeler et al., 2014).  
Moreover, in this study, conditioned medium containing factors secreted by AFSCs 
was unable to reproduce the effects seen in the in vivo experiments, both when AFSCs 
were in their naïve state and when they were stimulated with TNFa and TGF-β. More 
studies on the paracrine effect of AFSCs are needed and particularly important would 
be the understanding of the exact signalling pathways impacted by the trophic factors 
released.     
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7.6 Future of cell therapy for OI 
The current knowledge in terms of basic biology and technical progress is expanding 
quickly, opening new exciting scenarios in the field of cell therapy.  
The further study and characterisation of the factors produced by fetal MSCs that 
contribute to ameliorating the OI disease phenotype could in the future allow the 
administration of purified factors as a pharmacological therapy. This strategy would 
allow researchers to mimic the beneficial effects seen after administration of stem 
cells, while avoiding any concerns related to the transplantation of whole cells and its 
long-term effects, including the possibility of immune response or ectopic tissue 
formation. Moreover, the administration of growth factors or cytokines is far less 
technically challenging than the processing and infusion of stem cells. This could 
facilitate the implementation of more frequent administrations, to keep the 
therapeutic effects constant and avoid the boosts of growth alternated with periods 
of growth decline seen in children transplanted with fetal MSCs (Horwitz et al., 2001; 
2002; Le Blanc et al., 2005; Götherström et al., 2014). Moreover, MSCs used in cell-
based therapies are considered by international regulatory bodies as “Advanced 
therapy medicinal products” and need to comply to strict Good Manufacturing 
Practice standards to ensure quality and safety of the product (Hanna et al., 2016).  
More recently, the study of extracellular vesicles that are produced by MSCs and 
contain a variety of growth factors and cytokines has sparked interest for the 
potential application in regenerative medicine. The idea of a self-contained targeted 
delivery of trophic factors is appealing in the context of cell-free therapy for OI. It is 
thought that extracellular vesicles are unable to trigger any immune response and 
would facilitate the tight control of the dose and half-life of factors administered. The 
translation of extracellular vesicle therapies seems however to be far from 
implementation in clinical practice, mainly due to the difficulties on standardising the 
product and the high costs. Moreover, the European Medicinal Agency and the Food 
and Drug Administration have not yet classified the pharmaceutical category to which 
extracellular vesicles used for clinical applications might belong (Lener et al., 2015; 
Crivelli et al., 2017).   
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MSCs used so far in clinical cases of children with severe OI were transplanted in an 
allogeneic setting. They included adult bone marrow MSCs, which were obtained by 
HLA-matched siblings, and fetal liver MSCs, which were isolated by terminated 
pregnancies and were not HLA-matched (Horwitz et al., 1999; 2002; Le Blanc et al., 
2005; Götherström et al., 2014). AFSCs can be isolated during pregnancy and at 
delivery, making it possible to use cells also in an autologous manner. It would be 
therefore possible to isolate AFSCs from an OI pregnancy and then genetically correct 
them and transplant them either in utero or postnatally ruling out any possibilities of 
immune recognition (Loukogeorgakis and De Coppi, 2016; 2017).  
On the other hand, in line with the allogeneic use of MSCs that has been already 
investigated in the few cases to date of clinical transplantations in OI, biobanks of 
AFSCs would need to be built within GMP laboratories, to ensure adequate number 
of cells from the same donor in case of repeated transplantations needed. Moreover, 
with the advancement of scientific and technological knowledge, genome editing of 
cells could become a useful tool to gene-correct cells.  
In terms of the best route of administration, it has recently become evident that in 
utero infusions, despite posing technical challenges, have many advantages over 
post-natal transplantation. Transplanting stem cells before birth could prevent in 
utero fractures and skeletal deformities that are often seen in the most severe cases 
of OI (Tonni et al., 2016). Moreover, studies have shown that developing tissues are 
more permissive to stem cell homing and support their survival and proliferation 
(Ramachandra et al., 2014). Lastly, smaller number of cells would be needed to 
transplant a fetus than a child, and this could shorten the time necessary to expand 
the number of cells needed, avoiding at the same time the pitfalls of culturing cells 
for long periods of time, which risks changing their phenotype and limits their 
proliferation and differentiation ability (Kim and Park, 2017).  
The first clinical trial for cell therapy in OI, BOOSTB4, will in the upcoming years 
compare the outcomes of prenatal and postnatal fetal MSC transplantation in 
children with severe OI, including also for the first time a control group. The results 
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of the clinical trial will likely delineate the future of cell therapy strategies for OI, in 
terms of dose, timing and route of administration (Chitty et al., 2016).  
 
7.7 Human fetal osteoblasts project  
A side project of this thesis was the establishment of a protocol for the isolation and 
differentiation of human fetal osteoblasts.  This project was initially started because 
of the difficulty in differentiating rodent osteoblasts, which require culturing cells in 
osteogenic permissive medium for up to four weeks. Moreover, there is a need to 
find a physiologically relevant cell type for the investigation of bone development and 
for the modelling of human bone, which could be useful for drug testing or to model 
bone diseases. Currently, most laboratories studying bone physiology and disease use 
rodent cells or human cell lines, such as the osteosarcoma cell lines MG-63 and Saos-
2, which are however very different in their behaviour compared with human primary 
osteoblasts (Pautke et al., 2004). Human primary osteoblasts can be isolated by 
biopsies taken during orthopaedic surgery, however adult osteoblasts have very 
limited proliferation capacity and are not able to efficiently form bone in vitro 
(D'Ippolito et al., 1999; Gallagher, 2003). Fetal bones have been therefore 
investigated as a source of cells for the in vitro modelling of human bone (Gothard et 
al., 2015). 
The protocol described in this thesis represents a promising source of human 
osteoblasts, that can be isolated from surgical waste from terminations of 
pregnancies. The protocol allows the isolation and expansion of a large number of 
cells, that do not lose their high proliferative capacity and differentiation potential 
even after repeated passaging and freezing-thawing cycles.  
Thanks to the collaboration with the HDBR, a small biobank of fetal osteoblasts from 
different gestational ages, ranging from 9 to 21 weeks post conception has been 
developed and will keep expanding, with the aim of getting enough samples in 
triplicate for all gestational ages available. Possible applications that will be explored 
in the future include the further investigation of their in vitro bone differentiation 
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ability and how it changes across the different gestational ages. Moreover, a 
complete characterisation will be carried out, to fully assess the pattern of expression 
of osteogenic genes during fetal development. 
In line with the interests of the laboratory for the study of OI, surgical waste from 
termination of OI pregnancies could be obtained and compared with age-matched 
samples from the cell bank. This will possibly contribute to the better understanding 
of the pathogenesis of OI, which is thought to start early in fetal skeletal development 
and could help identifying the best time for in utero transplantation of stem cells, in 
order to maximise the therapeutic outcomes.  
Moreover, human fetal osteoblast cultures can be used to model human bone in the 
search for new drug treatments for skeletal disorders or in the study of potential bone 
side effects of other therapies, thus allowing the reduction of animals used and the 
related costs. The protocol presented in this thesis allows the robust differentiation 
of human fetal osteoblasts in vitro and offers an endpoint, bone formation, that is 
easily quantified. 
 
7.8 Conclusions 
In conclusion, work carried out for this thesis proposes AFSCs as a promising source 
of MSCs for cell therapy of OI. This work demonstrated that AFSCs transplanted into 
oim neonates led to therapeutic benefits and ameliorated the disease phenotype. 
Limited data from this study suggest that, beyond their potential as a source of 
replacement for defective OI osteoblasts, AFSCs may also mediate paracrine effects 
to stimulate endogenous osteoblast differentiation in the oim model. However, AFSC-
conditioned medium was unable to replicate in vitro the effects seen in vivo. Larger 
studies are needed to further investigate the long-term safety and efficacy of these 
cells, as well as their mechanism of action, before the potential translation of AFSC-
based therapies into clinical practice. 
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AFSC     Amniotic fluid stem cell  
ALP     Alkaline phosphatase 
ANOVA   Analysis of variance 
BCA    Bicinchoninic acid 
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BMP     Bone morphogenetic protein 
Brtl IV    Brittle mouse IV 
BSA    Bovine serum albumin 
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DMEM    Dulbecco’s modified eagle medium 
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DNA     Deoxyribonucleic acid 
dNTP    Deoxy nucleotide triphosphate 
ECM     Extracellular matrix 
EDTA    Ethylenediaminetetraacetic acid 
FBS    Fetal bovine serum  
FDA    Food and Drug Administration 
FLIM    Two photon lifetime imaging 
GADPH   Glyceraldehyde-3-Phosphate Dehydrogenase 
GFP    Green fluorescent protein 
GVHD    Graft versus host disease 
HBSS    Hank’s balanced salt solution 
HDBR    Human Developmental Biology Resource 
HLA    Human leukocyte antigen 
HRP    Horseradish peroxidase 
HSC    Hematopoietic stem cell 
IFN γ    Interferon γ 
iPSC    Induced pluripotent stem cell 
IU    International unit 
kDa    Kilo Dalton 
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M-CSF     Macrophage colony-forming factor 
Micro-CT   Micro computed tomography   
mRNA     Messenger ribonucleic acid   
MSC     Mesenchymal stem cell 
NIH    National Institutes of Health 
OI    Osteogenesis imperfecta 
Oim    Osteogenesis imperfecta murine 
OPG     Osteoprotegerin 
OPN    Osteopontin 
PBS    Phosphate buffered saline 
PCR    Polymerase chain reaction 
qPCR/RT-PCR   Quantitative/real time PCR 
PFA    Paraformaldehyde 
RANK    Receptor Activator of Nuclear Factor κ B 
RANKL    RANK ligand 
RNA     Ribonucleic acid 
RNAse    Ribonucleasae 
RUNX2    Runt-related transcription factor 2 
SDF-1    Stromal cell-derived factor 1 
SDS    Sodium dodecyl sulfate 
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SEM    Standard error of the mean 
TGF beta    Transforming growth factor b 
TMD    Tissue mineral density 
TNFα    Tumour necrosis factor α 
Wpc    Weeks post conception 
WT    Wild-type 
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